Study Title: 
Sponsor: 
INDNumber: 
EudraCT Number: 
Clinical Trials.gov 
Identifier: 
Indication: 
Protocol ID: ~ GILEAU 
CLINICAL STUDY PROTOCOL 
A Phase 3b Randomized, Open-label , Controlled Study of the 
Efficacy, Safety and Tolerability of 12 Weeks of 
Ledipasvir /Sofosbuvir (LDV/SOF) Treatment for HIV/HCV 
Co-infected Subjects who Switch to 
Elvitegravir /Cobicistat/Emtr icitabine/Tenofovir Alafenam ide 
(E/C/F IT AF) or Emtricitabine/Ri lpi[INVESTIGATOR_12979]/Tenofovir Alafenamide 
(F/R/TAF) prior to LDV/SOF HCV Treatment, the HIV/HCV 
Co-STARs study (Co-infection treatment with Single Tablet Antiviral 
Regimens) 
[COMPANY_009] Sciences, Inc. 
[ADDRESS_763739] 
Foster City, CA [ZIP_CODE] 
123098 
2014-004545 -27 
TBD 
HIV-1 Infection 
GS-US-366-1992 
[COMPANY_009] Clinical Name: [CONTACT_580888]: Telephone: 
Fax: 
[COMPANY_009] Co-Medical Name: 
[CONTACT_580889]: Telephone: 
Mobile: 
[COMPANY_009] Co-Medical Name: 
[CONTACT_580889]: Telephone: 
Mobile: 
Protocol Version/Date: Original: Richard Haubrich , MD 
[COMPANY_003] 
[COMPANY_003] 
Thai N~en-Clemy , MD 
[COMPANY_003] [COMPANY_003] 
18 December 2015 
CONFIDENTIALITY STATEMENT 
The infonnation contained in this document , particulm·ly 1mpublished data, is the prope1iy or 
under conti"ol of [COMPANY_009] Sciences, Inc., and is provided to you in confidence as an investigator , 
potential investigator, or consultant , for review by [CONTACT_10825], your staff, and an applicable Institutional 
Review Board or Independent Ethics Committee. The info1mation is only to be used by [CONTACT_580875]. 
You will not disclose any of the infmmation to others without written authorization from 
[COMPANY_009] Sciences, Inc., except to the extent necessa1y to obtain infonned consent from those 
persons to whom the dmg may be administe red. 
FTC/RPV/TAF
Protocol GS -US-366-[ADDRESS_763740] OF IN- TEXT FIGURES ...................................................................................................................................... 5
PROTOCOL SYNOPSIS .............................................................................................................................................. 6
GLOSSARY OF ABBREVIATI ONS AND DEFINITION O F TERMS.................................................................... 13
1.INTRODUCTION .............................................................................................................................................. 17
1.1.Background ............................................................................................................................................ 17
1.2.Tenofovir Alafenamide (TAF, GS -7340)............................................................................................... 19
1.2.1. General Information ............................................................................................................. 19
1.2.2. Clinical Trials of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir 
Alafenamide (E/C/F/TAF, Genvoya®)................................................................................. 19
1.2.3. Clinical Tr ials of Emtricitabine/Rilpi[INVESTIGATOR_12979]/Tenofovir Alafenamide 
(F/R/TAF) Fixed Dose Combination ................................................................................... 21
1.3.Ledipasvir/Sofosbuvir (LDV/SOF, Harvoni®) Fixed Dose Combination .............................................. 22
1.3.1. General Information ............................................................................................................. 22
1.3.2. Clinical Trials of Ledipasvir/Sofosbuvir (LDV/SOF, Harvoni®) Relevant 
to the Proposed Study ........................................................................................................... 22
1.4.Rationale for This Study ........................................................................................................................ 27
1.5.Risk/Benefit Assessment for the Study .................................................................................................. [ADDRESS_763741] Selection ............................................................................................ 34
4.2.Inclusion Criteria .................................................................................................................................... 34
4.3.Exclusion Criteria ................................................................................................................................... 37
5.INVESTIGATIONAL MEDI CINAL PRODUCTS........................................................................................... 40
5.1.Randomization ....................................................................................................................................... 40
5.2.Description and Handling of E/C/F/TAF, F/R/TAF, and LDV/SOF ..................................................... 40
5.2.1. Formulation.......................................................................................................................... 40
5.2.2. Packaging and Labeling ....................................................................................................... 41
5.2.3. Storage and Handling ........................................................................................................... 42
5.3.Dosage and Administration of E/C/F/ TAF, F/R/TAF, and LDV/SOF ................................................... [ADDRESS_763742] (IMP) ................................................................. [ADDRESS_763743] Enrollment and Treatment Assignment ..................................................................................... 49
6.2.Pretreatment Assessments ...................................................................................................................... 49
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page3 18 December [ZIP_CODE].2.1. Screening Visit ..................................................................................................................... 49
6.2.2. Day 1 Assessments ............................................................................................................... 51
6.3.Randomization ....................................................................................................................................... 53
6.4.Treatment Assessments .......................................................................................................................... 53
6.4.1. HIV and HCV Treatment Visits (Weeks 4, 6, 8, 12, 16, and 20) ......................................... [ADDRESS_763744] -HCV Treatment Assessments (Post -HCV 
Treatment Weeks 4 and 12) ................................................................................................. [ADDRESS_763745]-treatment Assessments ................................................................................................................... 58
6.5.1. Early Study Drug Discontinuation (ESDD) Visit ................................................................. 58
6.5.2. 30-Day Follow-Up Visit....................................................................................................... 60
6.6.Assessments for Premature Discontinuation from Study ....................................................................... 61
6.7.Criteria for Discontinuation of Study Treatment .................................................................................... 61
6.8.Other Assessments ................................................................................................................................. 62
6.8.1. Blood and Urine Storage ...................................................................................................... 62
6.8.2. Bone Safety and Inflammation ............................................................................................. 62
6.8.3. Markers of Platelet Function and Coagulation ..................................................................... 62
6.8.4. Markers of Renal Tubular Function ..................................................................................... 62
6.9.HIV Virologic Failure ............................................................................................................................ 63
6.9.1. Management of HIV Virologic Rebound ............................................................................. 63
6.9.2. Subjects with ≥ 400 copi[INVESTIGATOR_014]/mL of HIV -[ADDRESS_763746] .................................................................................................. 77
8.2.Analysis Conventions ............................................................................................................................. 77
8.2.1. Analysis Sets ........................................................................................................................ 77
FTC/RPV/TAF
Protocol GS -US-366-[ADDRESS_763747] (IRB)/Independent Ethics Committee (IEC) 
Review and Approval ........................................................................................................... [ADDRESS_763748] Accountability and Return ............................................. 84
9.1.8. Inspections ............................................................................................................................ 84
9.1.9. Protocol Compliance ............................................................................................................ 84
9.2.Sponsor Responsibilities ........................................................................................................................ 84
9.2.1. Protocol Modifications ......................................................................................................... 84
9.2.2. Study Report and Publications ............................................................................................. 85
9.3.Joint Investigator/Sponsor Responsibilities ........................................................................................... 85
9.3.1. Payment Reporting ............................................................................................................... 85
9.3.2. Access to Information for Monitoring .................................................................................. 85
9.3.3. Access to Information for Auditing or Inspections .............................................................. 86
9.3.4. Study Discontinuation .......................................................................................................... 86
10.REFERENCES ................................................................................................................................................... 87
11.APPENDICES .................................................................................................................................................... 91
Appendix 1.Investigator Signature [CONTACT_3490] .................................................................................................... 92
Appendix 2.Study Procedures Table .......................................................................................................... 93
Appendix 3.Management of Clinical and Laboratory Adverse Events (HIV ARV Agents only) ..............96
Appendix 4.GSI Grading Scale for Severity of Adverse Events and Laboratory Abno rmalities............... 97
Appendix 5.Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements ................................................................................................. 120
Appendix 6.CDC Classification Systems, AIDS -Indicator Con ditions................................................... 123
FTC/RPV/TAF
Protocol GS -US-366-[ADDRESS_763749] OF IN -TEXT TABLES
Table1-1. Combined Analysis from Phase III ION Studies .................................................................... 24
Table1-2. Study 1: F/R/TAF and LDV/SOF ........................................................................................... 25
Table1-3. Study 2: E/C/F/TAF and LDV/SOF PK Parameter ................................................................ 26
Table4-1. Allowable ARV Agents of Pre- Existing HIV Regimen ......................................................... 34
Table4-2. Disallowed Agentsa................................................................................................................ 38
Table5-1. Prior and Concomitant Medications –E/C/F/TAF + LDV/SOF ............................................ 43
Table5-2. Prior and Concomitant Medications –F/R/TAF + LDV/SOF ................................................ [ADDRESS_763750] OF IN -TEXT FIGURES
Figure3-1.Study Schema ......................................................................................................................... 32
Figure6-1.HIV Virologic Rebound Schema ............................................................................................ 65
FTC/RPV/TAF
Protocol GS -US-366-[ADDRESS_763751].
Foster City ,CA [ZIP_CODE]
StudyTitle: A Phase 3b Randomized, Open- label, Controlled Study  of the 
Efficacy, Safety and Tolerability  of 12 Weeks of 
Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV 
Co-infected Subjects who Switch to  
Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Alafenamide 
(E/C/F/TAF) or Emtricitabine/Rilpi[INVESTIGATOR_12979]/Tenofovir Alafenamide 
(F/R/TAF) prior to LDV/SOF HCV Treatment , the 
HIV/HCV 
Co-STARs study  (Co-infection treatment with Single Tablet Antiviral 
Regimens )
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:[PHONE_12051]-004545-27
TBD
Study Centers 
Planned:Approximately  50centers in North America
Objectives: The primary  objective of this study  is as follows:
To evaluate ef ficacy of LDV/SOF as measured b y the proportion 
of subjects achieving HCV RNA below the lower limit of 
quantification (LLOQ) [ADDRESS_763752] dose of LDV/SOF 
(sustained virologic response [SVR12] ).
The secondary  objectives of this study  are:
To determine the proportion of subjects achieving HCV RNA 
below LLOQ [ADDRESS_763753] dose of LDV/SOF ( SVR4);
To evaluate maintenance of HIV -1 RNA suppression after 
switching to E/C/F/TAF or F/R/ TAF 24 weeks from the start of 
the F/TAF -based regimen ; 
To evaluate the safet y and tolerability  of switching to E/C/F/TAF 
or F/R/TAF from the current antiretroviral (ARV)therapy in 
virologicall y-suppressed, HIV -1/HCV co -infected subjects;
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page7 18 December 2015To evaluate the safety and tolerability  of12 weeks of treatment 
for HCV with LDV/ SOF in virologicall y-suppressed, HIV -1/HCV 
co-infected subjects who switched to E/C/F/TAF or F/R/TAF.
Study Design: Randomized, multicenter, open- label, 2-part study in adult male and 
female subjects with HIV who are co -infected with chronic genot ype 
(GT) 1HCVinfection.  Subjects will have one of the following: 
1)no cirrhosis and no prior HCV treatment (treatment- naïve); 
2) no cirrhosis and have received HCV treatment only  with 
interferon (IFN) +/-ribavirin (RBV) or IFN + RBV + an HCV 
protease inhibitor (PI) (treatment- experienced); or 
3)compensated cirrhosis and be naïve to HCV therap y
(treatment -naïve).  
Subjects will be on stable ARV therap y for 6 months prior to 
screening and with HIV RNA < 50 copi[INVESTIGATOR_014]/mL.
Part 1:Approximately  240 subjects will be randomized 1:1 to switch 
from stable ARV therapy to one of the following treatments.  
Randomization will be stratified b y race (black vs. non -black).
Treatment Group 1: Switchfrom 2 nucleoside /nucleotide
reverse transcriptase inhibitor (NRTI) plus a third ARVagent to 
E/C/F/TAF fixed dose combination (FDC) (n = 120 ) 
Treatment Group 2: Switchfrom [ADDRESS_763754] ARV
agent to F/R/TAF FDC (n = 120) 
All subjects will receive [ADDRESS_763755] an 
assessment of safet y, tolerability and HIV -1 RNA values at the 
conclusion of 8 weeks. Plasma samples collected at Week 6 
(laboratory visit only ) will be included in assessing virologic 
suppression of HIV -1 RNA at Week 8. Subjects who toleratethe 
switchto E/C/F/TAF FDC or F/R/TAF FDC and maintain virologic 
suppression of HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL will continue to 
Part2.HIV treatmentwill be continued until their SVR12 
assessment .
Part 2:After 8 weeks on the randomized E/C/F/TAF FDC or 
F/R/TAF FDC treatment, subjects will continue their HIV treatment
and initiate12 weeks of LDV/SOF HCV therapy .  
LDV/SOF FDC tablet once daily for 12 weeks
After LDV/SOF therap y, subjects will continue their HIV treatment
and be followed for safety  and efficacy  for an additional 12weeks to 
determine the HCV SVR12 endpoint and HIV safety  and efficacy  
endpoints.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page8 18 December 2015Number of Subjects 
Planned:240 subjects (approximately  120 subjects randomized to each of 
E/C/F/TAF FDC or F/R/TAF FDC ).
Target Population: Chronic GT [ADDRESS_763756] cirrhosis 
and are HCV treatment -naïve or treatment -experienced with IFN +/-
RBV +/-PI.  Compensated cirrhotic subjects must be treatment- naïve. 
Subjects are on a stable HIV regimen with 2 NRTI  + 3rdagent with 
suppressed HIV RNA.
Duration of 
Treatment:Part 1:Subjects will be randomized toreceive E/C/F/TAF or 
F/R/TAF for 8 weeks. 
Part 2:Subjects will receive 12 weeks of LDV/SOF and continue 
their randomized F/TAF-based regimen for 12 weeks after 
completion of LDV/SOF (total approximately  24 weeks in Part 2
).
Diagnosis and Main 
Eligibility  Criteria:HIV/HCV co -infected adult subjects who meet the following criteria 
will be given the option to participate in the study:
Chronic GT1
, HCV infected, male and non -
pregnant/non- lactating female subjects, without cirrhosis, 
treatment -naïve or treatment -
experienced with IFN +/-RBV +/-
HCV PI.  Compensated cirrhotic subjects must be HCV 
treatment -naïve. No prior treatments with NS5A and NS5B or any  
HCV direct acting antivirals ,except boceprevir, telaprevir and 
simeprevir ,in combination with IFN and RBV.
Currently  on the first or second ARV regimen (2 NRT I + a third 
agent) without change for 6 months prior to screening. 
Documented plasma HIV -1 RNA levels < 50copi[INVESTIGATOR_014]/mL  (or 
undetectable HIV -1 RNA level according to the local assay  being 
used if the limit of detection is ≥ 50 copi[INVESTIGATOR_014]/mL ) for ≥ 6months 
preceding the Screening visit. After reaching HIV -1 RNA 
<50copi[INVESTIGATOR_014]/mL, single values (“blips”) of HIV -1 RNA 
≥ 50copi[INVESTIGATOR_014]/mL  followed by  [CONTACT_580876]. 
Plasma HIV-1 RNAlevel<50 copi[INVESTIGATOR_014]/mL  at the Screening visit.
Have no documented resistance to an y of the HIV study agents at 
any time in the past, including but not limited to the reverse 
transcriptase resistance mutations K65R, K70E, K101E/P, 
E138A/G/K/R/Q, V179L, Y181C/I /V, M184V/I, Y188L , H221Y, 
F227C, M230I /L, the combination of K103N+L100I , or 3or more 
thymidine analog associated mutations (TAMs) that include 
M41L or L210W (TAMs are M41L, D67N, K70R, L 210W, 
T215Y/F, K219Q/E/N/R) .
No history  of HIV virologic failure.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page9 18 December 2015No evidence of Hepatitis B infection.
Estimated glomerular filtration rate (eGFR)≥ 30 mL/minas
estimated by  [CONTACT_3158]- Gault formula.
Study Procedures/
Frequency :Screening assessments will be completed within [ADDRESS_763757] collection 
(if available; HIV DNA archive genot ype if no historical HIV 
genotype available), height, weight, vital signs, 12 -lead 
electrocardiogram (ECG), screening procedure rel ated adverse events 
(AEs), concomitant medications (CM), safety  laboratory  tests 
(including hematology , chemistry , and coagulation), HCV and HIV 
RNA, serology  (HIV, HCV, HBV), HCV genot ypi[INVESTIGATOR_007], assessment of 
the absence of cirrhosis, serum β -hCG (females of child bearing 
potential only ), IL28B genoty pi[INVESTIGATOR_007], and urinalysis.
On treatment assessment:
Part 1:F/TAF-based ARV regimen switch: 
Day 1 and Weeks 4, 6 (lab only )
,and 8 
Part 2:LDV/SOF therapy  and follow -up
First dose of LDV/SOF at Week 8, then Weeks 12, 16,and 
20(4, 8,and 12 we eks after HCV start) and post LD V/SOF 
follow up at 4 and 12 weeks posttreatment (SVR 4 and 12).
On treatment assessments will include AEs, CMs, study  drug dosing 
adherence (including pi[INVESTIGATOR_692]), phy sical examination, weight, vital 
signs, safety  laboratory  tests, HCV and HIV RNA, urine pregnancy  
tests (females of child bearing potential only ).
Fasting lipid profile measurements and fasting glucose will be 
performed at Day  1, Weeks 8, [ADDRESS_763758]-HCV Treatment 
Week12. Lipi[INVESTIGATOR_580845] (TC), high density  and 
low density  lipoproteins (HDL, LDL), non- HDL cholesterol, 
triglycerides (TG) and cholesterol ratios.  
Post treatment assessments will include AEs and CMs collected 
through [ADDRESS_763759] dose of HIVstudy drug, HCV and HIV 
RNA, safet y laboratory  tests (including hematology  and chemistry ), 
and urine pregnancy tests (females of childbearing potential only ).
Plasma samples for viral HIV RNA will be collected at Day 1 and 
every visit thereafter (except HCV RNA at Week 4). S tored samples 
for HCV RNA sequencing/phenot ypi[INVESTIGATOR_580846]/RPV/TAF 
Protocol GS-US-366-[ADDRESS_763760], Dose, 
and Mode of 
Administration : 
Reference Therapy, 
Dose, and Mode of 
Administration : 
Criteria for 
Evaluation: 
Safety: 
Efficacy: 
CONFIDENTIAL Final 
Original 
genotypi[INVESTIGATOR_007]/phenotypi[INVESTIGATOR_384734] 1 and evety visit 
thereafter. Blood will be collected at Screening for analysis ofHIV 
proviral DNA genotype, as needed. 
Calculated creatinine clearance , hematology , serum chemistly, and 
urinalysis tests will be perf01med at all visits. 
Health Related Quality of Life (HRQoL) Surveys will be conducted 
at Day 1, Week 8, 20, and Post-HCV Treatment Week 12 visits. 
[COMPANY_003] 
Phannacokinetic (PK) blood samples will be collected at specified 
time points pre-and/or postdose at post-Day 1 visits. 
Elvitegravir 150 mg/cobicistat 150 mg/emtt·icitabine 200 mg/ 
tenofovir alafenamide 10 mg (E/C/F/TAF) FDC administered once 
daily with food. 
Emtl'icitabine 200 mg/rilpi[INVESTIGATOR_12979] 25 mg/tenofovir al afenamide 25 mg 
(FIR/TAF) FDC administered once daily with food. 
Ledipasvir 90 mg/sofosbuvir 400 mg (LDV/SOF) FDC administered 
once daily with or without food. 
None. 
Adverse events will be collected at all visits. Clinicallaborat01y tests 
will be perf01med at all visits. 
The safety and tolerability of the treatment regimens will be assessed 
with adverse event and clinicallaboratOI J,: tests (includin selected 
evaluations of renal ftmction and [COMPANY_003] 
Efficacy will be evaluated using scheduled assessments ofHCV RNA 
perf01med using COBAS® Ampliprep I COBAS® TaqMan® HCV 
Quantitative Test, v2.0 and COBAS® TaqMan® HIV RNA Test, v2.0. 
Primmy endpoint 
• HCV RNA< lower limit of quantification (LLOQ) 12 weeks after 
completion ofLDV/SOF treatlnent (SVR12) 
Page 10 18 December 2015 
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page11 18 December 2015Secondary endpoints
Efficacy:
HCV RNA < LL OQ 4 weeks after completion of LDV/SOF 
treatment ( SVR4)
HIV-1RNA ≥ 50 copi[INVESTIGATOR_014]/mL  (virologic failure) 24 weeks after 
start of the F/TAF -based regi men using modified FDA snapshot 
algorithm
Safety:
Grades 1 through 4 adverse events after switch ingto E/C/F/TAF 
or F/R/TAF throughout the study  and during coadministration 
with LDV/SOF treatment.
Pharmacokinetics: Samples collected for potential population PK assessment .
Health Related 
Questionnaires:Health related questionnaires will be administered, including the 
Adherence Visual Analogue Scale (VAS), HIV Treatment 
Satisfaction (HIVTSQ) , Medical Outcome Study  Short Form -36 
(SF-36), Functional Assessment of Chronic I llness Therapy -Fatigue 
scale (FACIT-
F), chronic liver disease questionnaire( CLDQ-HCV) 
and work productivity  and activity  impairment questionnaire (WPAI).
Statistical Methods: This is a two part, randomized (for HIV therap y) multicenter study  to 
evaluate the efficacy  and safet y of switching to a F/TAF -based 
regimen in HCV co- infected subjects on a current suppressive ARV 
regimen.  
The primary  efficacy endpoint is SVR12 (HCV RNA < LLOQ 
12weeks post HCV treatment) in the HCV Full Analy sis Set. The 
primary analysis will use a two-sided exact one -sample binomial test
at the 0.[ADDRESS_763761] 95% confidence interval (CI).    
Secondary  efficacy analyses will evaluate the proportion of subjects 
with HCV RNA < LLOQ at [ADDRESS_763762] coadministration of 
LDV/SOF treatment.  Assessment of HIV -
1RNA ≥ 50copi[INVESTIGATOR_014]/mL  
(virologic failure) will be done at 
24 weeks after start of the 
F/TAF-based regimen using modified FDA snapshot algorithm. 
Safety analyses will evaluate adverse events (clinical and laboratory ) 
during switch to F/TAF -based regimen and during coadministration 
with LDV/SOF treatment. Additional safet y analyses will evaluate 
theproportion of subjects who discontinued from study treatment 
(HIV or HCV) for an AE.
Additional endpoints to be studied will include the effect of therap y 
on health- related quality  of life.
FTC/RPV/TAF
Protocol GS -US-366-[ADDRESS_763763] 94% of subjects achieve HCV SVR12, the 
95% CIaround the SVR12 rate will be ± 3.2% using exact methods.
The assumed SVR12 rate will have at least 85 % power to be greater 
than 6 percentage points from a performance goal of 88% b y using a 
two-sided exact one- sample binomial test at significance level of 
0.05.
This study  will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page13 18 December 2015GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
C degrees Celsius
F degrees Fahrenheit
3TC lamivudine
AASLD/IDSA American Association for The Study of Liver Diseases/Infectious Diseases Society of 
America
ABC abacavir
AE adverse event
AIDS acquired immunodeficiency syndrome
ALT (SGPT) alanine aminotransferase
APTT activated partial thromboplastin time
ART antiretroviral therapy
ARV antiretroviral
AST (SGOT) aspartate aminotransferase
APRI AST: platelet ratio index
ATR Atripla®
ATV atazanavir
AUC area under the concentration vs. time curve
AUCinf area under the concentration verses time curve extrapolated to infinite time, calculated as 
AUC0-last+ (Clast/z)
AUClast area under the concentration curve verses time curve from time zero to the last 
quantifiable concentration
AZT zidovudine
BMD bone mineral density
Clast last observed quantifiable plasma concentration of drug
Cmax maximum observed plasma concentration of drug
Ctau observed drug concentration at the end of the dosing interval
Cx minimum observed quantifiable plasma concentration x hours after the last dose of drug
CBC complete blood count
CFR Code of Federal Regulations
CI confidence interval
CK creatinine kinase
CLcr creatinine clearance 
CLDQ-HCV chronic liver disease questionnaire
CM concomitant medications
CMH Cochran-Mantel-Haenszel
COBI cobicistat, C
CRO Contract Research Organization
CSR clinical study report
DAA direct acting antiviral(s)
DDI drug-drug interaction
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page14 18 December 2015DF disoproxil fumarate
dL deciliter
DNA deoxyribonucleic acid
DP diphosphate
DRV darunavir
DSPH Drug Safety and Public Health
DTG dolutegravir, Tivicay®
ECG electrocardiogram
eCRF electronic case report forms(s)
EDC electronic data capture
EFV efavirenz, Sustiva®
eGFR estimated glomerular filtration rate
eGFRcg estimated glomerular filtration rate, Cockcroft -Gault
ESA erythropoiesis -stimulating agents
eSAE electronic serious adverse event
ESDD Early Study Drug Discontinuation
ETR etravirine
EVG elvitegravir, E
EU European Union
E/C/F/TAF Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide, Genvoya®
FACIT-F functional assessment of chronic illness therapy -fatigue scale
FAS full analysis set
FDA (U.S.) Food and Drug Administration
FDC fixed dose combination
FTC emtricitabine, F
FTC/RPV/TAF emtricitabine/rilpi[INVESTIGATOR_12979]/tenofovir alafenamide  
FTC/RPV/TDF emtricitabine/rilpi[INVESTIGATOR_12979]/tenofovir disoproxil fumarate  
FTC/TAF emtricitabine/tenofovir alafenamide
FTC/TDF emtricitabine/tenofovir disoproxil fumarate  
g gram(s)
GCP Good Clinical Practice (Guidelines)
GCSF granulocyte colony stimulating factor
GLSM/GMR geometric least squares mean ratio
GGT gamma glutamyl transferase
GSI [COMPANY_009] Sciences, Inc.
GT genotype
h hour(s)
HAART highly active antiretroviral therapy
HBV hepatitis B virus
HBsAg hepatitis B surface antigen
HCC Hepatocellular carcinoma
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page15 18 December 2015HCV hepatitis C virus
HDL high density lipoprotein
HDPE high-density polyethylene
HIV-1 human immunodeficiency virus type 1
HIV-2 human immunodeficiency virus type 2
HIVTSQc HIV Treatment Satisfaction Questionnaire – Change version
HIVTSQs HIV Treatment Satisfaction Questionnaire – Status version
HLGT high-level group term
HLT high-level term
HRQoL Health Related Quality of Life
IB investigator’s brochure
ICH International Conference on Harmonisation
IFN interferon
IEC Independent Ethics Committee
IMP investigational medicinal product
INR International Normalized Ratio
INSTI integrase strand transfer inhibitor
IRB Institutional Review Board
IUD intrauterine device
IWRS Interactive Web Response System 
kg kilogram
kPa kilopascal
KS Kaposi's sarcoma
LDL low density lipoprotein
LDV/SOF ledipasvir/sofosbuvir, Harvoni®
LLN lower limit of the normal range
LLOQ lower limit of quantification
LLT lower–level term
LPV lopi[INVESTIGATOR_580847]
m2square meter
mm3cubic millimeter(s)
g microgram
m micrometer
ng nanogram
NNRTI non-nucleoside reverse transcriptase inhibitor
NRTI nucleoside reverse transcriptase inhibitor
NVP nevirapi[INVESTIGATOR_050], Viramune ®
FTC/RPV/TAF
Protocol GS -US-366-[ADDRESS_763764]-exposure prophylaxis
PI [INVESTIGATOR_580848], Isentress®
RBV ribavirin
RNA ribonucleic acid
RT reverse transcriptase
RTV ritonavir
RPV rilpi[INVESTIGATOR_12979], R , Edurant®
SAE serious adverse event
SADR serious adverse drug reactions
SF-36 medical outcome study short form -36
sGPVI soluble glycoprotein VI
SOC system organ class
SOF sofosbuvir, Sovaldi®
SOP standard operation procedure
STB Stribild®
STR Single Tablet Regimen
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction
SVR sustained virologic response
Tlast time (observed time point) of C last
Tmax time (observed time point) of C max
TAF  tenofovir alafenamide 
TAF fumarate tenofovir alafenamide fumarate
TAM thymidine analog associated mutations
TDF tenofovir disoproxil fumarate , Viread®
TFV tenofovir
TPO thrombopoietin 
TVD Truvada®
ULN upper limit of the normal range
US [LOCATION_002]
VAS visual analogue scale
VR virologic rebound
wt Weight
WPAI work productivity and activity impairment questionnaire
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page17 18 December [ZIP_CODE]. INTRODUCTION
1.1. Background
HIV Infection
Human Immunodeficiency  Virus type 1 (HIV-1)infection is a life -threatening and serious 
disease that is of major public health interest around the world. There are 35 million people 
worldwide and approximately  1.1 million people in the US living with HIV -1 {Campsmith et al 
2010}, {World Health Organigation (WHO) 2011 }. Within Western and Central Europe, it is 
estimated that there are over 900,000
individuals living with HIV and 131,000 new infections in 
2012{The Joint United Nations Programme on HIV/AIDS (UNAIDS) 2012
}.
If left untreated or suboptimally  treated, HIV infection is characterized by  [CONTACT_580877], the subsequent occurrence of opportunistic infections and malign ancies, 
ultimately  resulting in death. Therapeutic strategies for the treatment of HIV -[ADDRESS_763765] been 
significantl y advanced by [CONTACT_580878]  (HAART); 
theintroduction of HAART was associated with a dramatic decrease in acquired immune 
deficiency  syndrome (AIDS) -related morbidity  and mortality  {Palella et al 1998 }, {Mocroft et al 
1998}, {Sterne et al 2005 }. 
The primary  goals of ARV therap y for HIV -[ADDRESS_763766] emtricita bine/tenofovir DF (FTC/TDF) as a preferred nucleos(t)ide 
reverse transcriptase inhibitor NRTI /NtRTI backbone in combination with either 
cobicistat -boosted elvitegravir [EVG/COBI] administered as EVG/COBI/FTC/TDF, raltegravir, 
dolutegravir or darunavir/ritonavir as an initial ARV regimen {Department for Health and 
Human Services (DHHS) 2015}. Although HAART has dramatically  improved the prognosis of 
patients infected with HIV -1, eradication of the virus is not possible with currentl y available 
therapi[INVESTIGATOR_014]. Long- term viral suppression and prevention of drug resistance are goals of successful 
therapy. In regimens of comparable efficacy, the total pi[INVESTIGATOR_13551], dosing frequency, and 
concerns about safety  and si
de effects are generally the most significant obstacles to achieving 
high adherence {Stone VE 2002 }, {Chesney  2000}, {Department for Health and Human 
Services (DHHS) 2015 }.
Tenofovir disoproxil fumarate (TDF) is a preferred NRTI  among recommended regimens for 
treatment -naïve HIV -positive patients, but is associated with nephrotoxicity  and reduced bone 
mineral density (BMD){Panel on Antiretroviral Guidelines for Adults and Adolescents 2012 }. 
Lifelong antiretroviral treatment and the increasing comorbidities being recognized and treated 
in HIV-positive patients creates an urgent need to improve the safet y profile of regimens that 
most effectivel y suppress HIV replication. Tenofovir alafenamide (TAF) is novel oral prodrug of 
tenofovir (TFV), a nucleotide analog that inhibits HIV
-1 reverse transcription. [COMPANY_009] has 
coformulated TAF with the integrase strand transfer inhibitor elvitegravir (EVG), cobicistat 
(COBI), and emtricitabine (FTC) into a fixed-dose combination (FDC). Compared to TDF, the 
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page18 18 December 2015use of TAF in the E/C/F/TAF FDC provides enhanced l ymphatic delivery  of tenofovir, resulting 
in higher intracellular levels of the active phosphory lated moiety  tenofovir -diphosphate, and 
lower systemic circulating levels of tenofovir. These features translate into an improved 
tolerability  and safety profile, especially with respect to renal and bone safety {Sax et al 2015 }.
HCV and HIV/HCV Co -Infection
Hepatitis C virus (HCV) infection is a global health challenge with an estimated 150 million 
individuals infected worldwide {Gay  et al 2011}. Currently  there are 6 major HCV genot ypes 
recognized {
Nakano et al 2012}. Genoty pes 1, 2, and 3 are common throughout North America 
and Europe and when combined account for approximately  75% of the chronic HCV infections 
globally. Genotype4, which is common in the Middle East and Africa, accounts for 
approximately  20% of the global HCV population. Genoty pes [ADDRESS_763767] Asia ,respectivel y {Lavanchy 2011}.
In the [LOCATION_002] (US), approximately  2.[ADDRESS_763768] chronic HCV infection 
{Denniston et al 2014 }and HCV infection causes over 15,000 deaths each y ear {Ly et al 2012 }, 
although under -reporting of HCV infection on death certificates may  contribute to as much as a 
5-fold underestimation of the actual number of deaths {Mahajan et al 2014 }. Of the HCV related 
deaths that are reported, almost three quarters occurred in the bab y
-boomer generation with a 
median age of death of 57 y ears, which is approximately  20 years less than the average lifespan 
{Smith et al 2012 }. Successful treatment of chronic HCV infection reduces the need for liver 
transplant, the incidence of hepatocellular carcinoma ( HCC)and overall mortality  {Backus et al 
2011}
. Thus, the public health benefit of safe and effective HCV treatment regimens is high. 
HIV-infected patients are frequentlyco-infected with HCV because of the shared routes of 
infection. HIV/H CV co-
infection is estimated to occur in one quarter of HIV -infected persons in 
Europe, Australia, and the [LOCATION_002], {Thomas 2008}, and in a study from the Veterans 
Affairs Medical Center in Atlanta, Ge orgia, HCV infection occurred as many as 33% of the 
patients with HIV infection {Staples et al 1999 }
. The use of antiretroviral therap y(ART) has 
markedly reduced opportunistic infections and HIV -infected persons are living longer. 
However, liver dise ase has emerged as the main cause of morbidity  and mortality  in theHIV 
positive patient 
{Salmon-Ceron et al 2005 }, and the development of end stage liver disease 
seems to beunrelated to the CD4 count and the immune virological status of the patient 
{Salmon-Ceron et al 2005 }. In twometa-analyses published 8 y ears apart, co -infected patients 
were 5 to 6 times more likely  todevelop deco mpensated liver failure and 1.5 to 2 times more 
likely to develop histological cirrhosis {Graham et al 2001}, {Deng et al 2009}. I n the latter 
analysis, the risk of death in the co- infected patients was nearly4 times greater compared with 
that in mono -infected individuals {Myers et al 2008 }. As might be expected, hospi[INVESTIGATOR_580849] -infected patient have increased {Laguno et al 2004 }. Furthermore, 
the previous gold standard therap y for the treatment of HCV infection, pegylated nterferon alfa 
(PEG
-IFN) plus ribavirin (RBV), appears to be less effective in patients with co-infection than in 
patients with HCV mono
-infection {Torriani et al 2004}, {Carrat et al 2004 }. 
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page19 18 December 2015The development of Sovaldi®(sofosbuvir, SOF), a nucleotide analog HCV NS5B poly merase 
inhibitor, represents a major advance in the treatment of HCV as SOF -based regimens are shorter 
in duration, better to lerated and result in higher sustained virologic response ( SVR)rates than 
prior therapi[INVESTIGATOR_014]. SOF in combination with ribavirin ( RBV)pegylated interferon ( PEG-IFN)for 
varying durations was approved in the US and Canada in December 2013 for the treatment of 
genotype 1, 2, 3 and 4 HCV infection and was granted marketing authorization by  [CONTACT_580879]  2014 for the treatment of genot ypes 1-6 HCV infection {[COMPANY_009] Sciences 
Inc 2013}, {[COMPANY_009] Sciences Canada Inc. 2013}, { [COMPANY_009] Sciences Limited 2014} . LDV/SOF is the first 
IFN-free regimen with high SVR rates following 8 -24weeks of treatment across treatment -naïve 
and treatment -experienced pat ients, including patients who failed to achieve SVR with PEG + 
RBV NS3/4A protease inhibitors, irrespective of cirrhosis {[COMPANY_009] Sciences Inc. 2014 }.
1.2. Tenofovir Alafenamide (TAF, GS -7340)
1.2.1. General Information
Tenofovir alafenamide (GS- 7340, TAF, or L-Alanine, N-[(S
)-[[(1R)-2-(6-amino-9H -purin-9-yl)-
1-methylethoxy]methyl]/phenoxy phosphiny l]-, 1-methylethyl ester) is a second generation oral 
prodrug of TFV, a nucleotide analog that inhibits HIV- 1 reverse transcription. TFV is 
metabolized intracellularly  to the active metabolite, TFV -DP, a competitive inhibitor of HIV -1 
reverse transcriptase (RT) that terminates the elongation of the viral DNA chain. In the 
development of TAF, three forms of the drug substance have been used in various studies: 
GS-7340, synonym for GS-7340 as the free base; GS -
7340-02, synonym for TAF monofumarate 
(1:1)molar ratio of TAF to fumaric acid ; and GS-7340-03 as the hemifumarate (2:1) molar ratio 
of TAF to fumaric acid . GS-7340-
03, also known as TAF fumarate, is considered comparable 
based on ph ysical/chemical properties to GS-7340-
[ADDRESS_763769] as the free b ase, TAF (GS -7340), in blood and biological 
fluids.
For further information on the preclinical pharmacology  and toxicology  of TAF, refer to the 
current Investigator’s Brochure (IB) .
1.2.2. Clinical Trials of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir 
Alafenamide (E/C/F/TAF , Genvoya®)
Elvitegravir, an HIV -1 integrase strand transfer inhibitor (INSTI), cobicistat, a CYP3A inhibitor, 
and emtricitabine and tenofovir alafenamide (TAF), both HIV
-1 nucleoside analog reverse 
transcriptase inhibitors (NRTI s) are co-formulated into a single- tablet regimen, E/C/F/TAF , or 
Genvoya®. E/C/F/TAF is indicated as a complete regimen for the treatment of HIV -[ADDRESS_763770] the current antiretroviral regimen in those who are virologicall y suppressed 
(HIV-1 RNA less than 50 copi[INVESTIGATOR_269487]) on a stable antiretroviral regimen for at least 6 months 
with no history  of treatment failure and no known substitutions associated with resistance to the 
individual components of the regimen .  E/C/F/TAF is not recommended in patients with 
estimated creatinine clearance below 30 mL  per minute. The efficacy  and safet y of E/C/F/TAF 
continue to be evaluated in a broad clinical development program. Available data from key  
studies are described in the most current version of the E/C/F/TAF IB. The details of the key  
clinical studies are provided below .
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page20 18 December 2015Study GS-US-292-0102, a Phase 2, randomized, double -blind, double -dummy, multicenter, 
active-controlled study  evaluate the safet y and efficacy of the novel tenofovir prodrug, 
tenofovir alafenamide (TAF), as part of a single-tablet regimen  for the initial treatment of 
HIV
-1 infection. Antiretroviral naive adults with HIV -1 RNA ≥ 5000 copi[INVESTIGATOR_580850] a CD4 count ≥50 cells per microliter were randomized 2:1 to receive an STR of 
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 
elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF), plus plac ebo 
for 48 weeks. Patients on both E/C/F/TAF (n = 112) and E/C/F/TDF (n = 58) had high rates 
of virologic suppression (< 50 HIV copi[INVESTIGATOR_580851]) at Week 24 (86.6%; 89.7%) and at 
week 48 (88.4%; 87.9%), and had similar improvements in CD4 at W eek 48 (177; 204), 
respectivel y. Both treatments were well tolerated, and most adverse events were self -limiting 
and of mild to moderate severity. Compared with patients on E/C/F/TDF, patients on 
E/C/F/TAF had smaller reductions in e stimated creatinine clearance ( -5.5 vs. -10.1mL/min, 
p= 0.041), significantl y less renal tubular proteinuria, and smaller changes in bone mineral 
density for hip (-0.62% vs. - 2.39%, p < 0.001) and spi[INVESTIGATOR_050] ( -1.00% vs. - 3.37%, p <0.001). 
Patients on E/C/F/TAF had higher increases in tota l cholesterol, low density  lipoprotein, and 
high-density lipoprotein, but the total cholesterol/high -density lipoprotein ratio was 
unchanged for both. Treatment -naive patients given the STR that contained either TAF or 
TDF achieved a high rate of virologic success. Compared with those receiving TDF, patients 
on E/C/F/TAF experienced significantly  smaller changes in estimated creatinine clearance, 
renal tubular proteinuria, and bone mineral density.  The efficacy  data from this Phase 2 
study supported the Ph ase 3 studies and provided initial evidence of durable efficacy ; 87.5% 
of subjects who received E/C/F/TAF achieved and maintained HIV -1 RNA < 50copi[INVESTIGATOR_014]/mL 
through Week 96 (M = F).
GS-US-292 -0104 and G S-US-292 -0111, two Phase 3, randomized double -blind, 
double-dummy, multicenter, active -controlled studies which evaluated the efficacy  and 
safety of two single -tablet regimens, E/C/F/TAF vs E/C/F/TDF. Key  inclusion criteria were 
estimated creatinine clearance of at least 50 mL per min and genoty pic sensitivity  to study 
drugs. The main outcomes were the proportion of patients with plasma HIV -1 RNA less than 
50copi[INVESTIGATOR_580852] W eek 48 as defined b y the US Food and Drug Adminstration (FDA) 
snapshot algorithm (pre -specified noninferiorit y margin of 12%) and pre -specified renal and 
bone endpoints at 48 weeks. Secondary  endpoints are at Week 96 and 144.  1733 patients 
(866E/C/F/TAF and 867 E/C/F/TDF). E/C/F/TAF was non- inferior to E/C/F/TDF, with 92% 
of (800/866) patients in the TAF group and 90% of (784/867) patients in the TDF group 
having plasma HIV -1 RNA less than 50 copi[INVESTIGATOR_269487] (adjusted difference 2.0%, 95% CI –
0.7 to 4.7). Patients given E/C/F/TAF had significantly  smaller mean serum creatinine 
increases than those given E/C/F/TDF (0.08 vs 0.12 mg/dL ; p <0.001), significantly  less 
proteinuria (median % change –3 vs 20; p <
0.001), and a significantl y smaller decrease in 
bone mineral densit y at spi[INVESTIGATOR_050] (mean % change –1.30 vs –
2.86; p <0.001) and hip ( –0.66 vs –
2.95; p <0.001) at 48 weeks. At 96 weeks, 86.6% in the E/C/F/TAF arm and 85.2% in the 
E/C/F/TDF arm had HIV -1 RNA < 50 c/mL (difference 1.5%; 95%CI [- 1.8%, 4.8%]). With 
E/C/F/TAF, decreases in lumbar spi[INVESTIGATOR_580853] y and proteinuria were 
significantl y less and creatinine increase s were significantly  smaller. These longer -term data 
support the use of E/C/F/TAF as a safe, well
-tolerated and durable regimen for initial HIV -1 
treatment.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page21 18 December 2015Study GS-US-292-0109 is a Phase 3, randomized, active controlled, multicenter, open -label, 
non-inferiority trial evaluating efficacy, safet y, and tolerability of switching to E/C/F/TAF 
versus continuing a TDF- containing regimen (ie,  Atripla, Stribild, or COBI -or RTV-boosted 
ATV with FTC/TDF). Key  inclusion criteria included virological suppression (HI V-1 RNA 
<50 copi[INVESTIGATOR_269487]) for at least 6 months on Atripla, Stribild, or COBI -or RTV-boosted 
ATV with FTC/TDF and an estimated creatinine clearance of at least [ADDRESS_763771] one dose of study
 drug 
who had undetectable viral load (HIV -1 RNA < 50 copi[INVESTIGATOR_269487]) at W eek 48.  959 patients 
were randoml y assigned to E/C/F/TAF and 477 continued Atripla, Stribild, or COBI -or 
RTV-boosted ATV with FTC/TDF. Viral suppression at Week 48 was noted in 97% 
(932/959) patients switched to E/C/F/TAF and 93% (444/477) of patients who continued a 
TDF-containing regimen (adjusted difference 4.1%, 95% CI 1.6–6.7), with virological failure 
noted in ten and six patients, respectivel y. The number of adver se events was similar between 
the two groups, but study drug-related adverse events were more common in the tenofovir 
alafenamide group (204 patients [21%] vs 76 [16%]). Hip and spi[INVESTIGATOR_580854] E/C/F/TAF 
group compared with those in the TDF -
containing regimen group.
GS-US-292-0112, is a Phase 3, single- arm, open -label study  which evaluate the efficacy  and 
safety of E/C/F/TAF in virologicall y suppressed, HIV -infected subjects with estimated 
creatinine clearance 30 -69 mL/min over 144 weeks. The primary  endpoint was the change 
from baseline in glomerular filtration rate estimated using various formula. A total of 
242virologicall y suppressed patients enrolled and switch tre atment to E/C/F/TAF.  Subject 
baseline characteristics are mean age 58 years, 18% 
black, 39% h ypertension, 14% diabetes. 
Through Week 48, no significant change in estimated CrCl was observed. Two patients 
(0.8%) discontinued study  drug for decreased creati nine clearance, neither had evidence of 
renal tubulopath y and both had uncontrolled h ypertension. Subjects had significant 
improvements in proteinuria, albuminuria, and tubular proteinuria (p <0.001 for all). Hip and 
spi[INVESTIGATOR_580855] 48 (mean percent 
change +1.47 and +2.29, respectivel y, p<
0.05). 92% (222 patients) maintained HIV- 1 RNA 
<50 copi[INVESTIGATOR_014]/mL at Week 48. The findings of this study  support the use of E/C/F/TAF in 
patients with renal impairmen t down to an eGFR CGof 30 mL/min .
1.2.3. Clinical Trials of Emtricitabine/Rilpi[INVESTIGATOR_12979]/Tenofovir Alafenamide 
(F/R/TAF ) Fixed Dose Combination
The details of the key  clinical studies are provided below .Please refer to the IB for additional 
information on the FTC/RPV/TAF FDC.
GS-US-366-[ADDRESS_763772], 6-sequence, crossover 
study to determine the bioequivalence of FTC and TAF, administered as E/C/F/TAF FDC 
tablet or as FTC/RPV/TAF FDC tablet, and the bioequivalence of RPV a dministered as RPV 
single tablet or as FTC/RPV/TAF FDC tablet. The FTC and TAF components of the 
FTC/RPV/TAF (200/25/25 mg) FDC were found to be bioequivalent to the E/C/F/TAF 
(150/150/200/10 mg) FDC. The RPV component of the FTC/RPV/TAF (200/25/25 mg) FDC
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page22 18 December 2015was found to be bioequivalent to RPV 25 mg tablet (Edurant®). FTC, RPV, and TAF 
administered as FTC/RPV/TAF (200/25/25 mg) FDC, RPV (25 mg), and E/C/F/TAF 
(150/150/200/10 mg) FDC were generall y safe and well -tolerated in healthy volunteers;
GS-US-366-[ADDRESS_763773] of high -calorie, high -fat food, on the PK of a single -
dose FTC/RPV/TAF FDC tablet.  
Overall TAF exposure (AUC last) increased b y approximately  45% and 54%, FTC exposure 
(AUCinf) decreased b y approximately  9% and 12%, and RPV exposure (AUC inf) increased b y 
approximately  13% and 75% (moderate
-fat and high- calorie, high- fat conditions,
respectivel y) when the RPV/FTC/TAF FDC tablet (200/25/25 mg) was administered under 
fed compared with fasted conditions;
1.3. Ledipasvir/Sofosbuvir(LDV/SOF , Harvoni®) Fixed Dose Combination
1.3.1. General Information
Ledipasvir/ sofosbuvir fixed -dose combination (LDV/SOF FDC, or Harvoni®)combines two 
HCV specific DAA agents into a single tablet for the treatment of chronic HCV infection. 
Sofosbuvir is a nucleotide analog that is a potent and selective inhibitor of NS5B -directed HCV 
replication , irrespective of HCV genotype.Ledipasvir is a novel HCV NS5A inhibitor that has 
demonstrated potent anti- HCV activity  against genoty pes 1and 4 HCV infection. 
Please refer to the Investigator’s Brochure (IB) for additional information on the LDV/SOF
FDC,and the individual c omponents, including:
In Vitro Anti -Hepatitis C Virus Activity
Nonclinical Pharmacokinetics and In Vitro Metabolism
Nonclinical Pharmacology and Toxicology
1.3.2. Clinical Trials of Ledipasvir/Sofosbuvir (LDV/SOF ,Harvoni®)Relevant to 
the Proposed S tudy 
Study GS-US-337-0102 (ION -1) was a Phase 3, multicenter, randomized, open -label stud y 
designed to investigate the efficacy and safet y of LDV/SOF FDC + RBV for 12 and 
24weeks.  Subjects were HCV treatment -naive with chronic genot ype 1 HCV infection. 
ION
-1 was based on data from phase2 studies, which demonstrated high SVR rates in 
subjects with HCV genoty pe 1 infection. Subjects wererandomized 1:1:1:1 to receive 
LDV/SOF once dail y for 12 weeks, LDV/SOF + RBV for 12 weeks, LDV/SOF for 
24weeks, or LDV/SOF + RBVfor 24 weeks. The primary  end point was SVR12.
Baseline characteristics of the 865 
randomized and treated subjects included 16% with 
cirrhosis, 12% black, and 67% with HCV genoty pe 1a infection. The rates of SVR12were 
99% (95% confidence interval [CI ], 96 to 100) in the group that received 12 weeks of 
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page23 18 December 2015LDV/SOF; 97% (95% CI, 94 to 99) in the group that received 12 weeks of LDV/SOF plus 
ribavirin; 98% (95% CI, 95 to 99) in the group that received 24 weeks of LDV/SOF; and 
99% (95% CI, 97 to 100) in the group that received 24 weeks of LDV/SOF plus ribavirin. No 
subjectin either 12 -week group discontinued LDV/SOF owing to an adverse event. The most 
common adverse events were fatigue, headache, insomnia, and nausea. The study  
demonstrated that once- daily LDV/SOF+/-RBVfor 12 or 24 weeks was highl y effective in 
previously  untreated patients with HCV genot ype 1 infection.
Study GS-US-337-0109 (ION -2) was a phase 3, randomized, open -label study  ofHCV 
genotype 1 subjects with prior virologic failure of peg-interferon and ribavirin +/-an HCV
protease inhibitor. Subjects were randomized to i) LDV/SOF for 12 weeks, ii) LDV/SOF + 
RBVfor 12 weeks, iii) LDV/SOF for 24 weeks, or iv) LDV/SOF + RBV for 24weeks. The 
primary end point was SVR12. Baseline characteristics of the [ADDRESS_763774] included: 20% with cirrhosis and 79% with HCV genoty pe 1a infection. SVR12 rates 
were: 94% (95% confidence interval [CI ], 87 to 97) for12 weeks of LDV/SOF; 96% (95% 
CI, 91 to 99) for12 weeks of LDV/SOF + RBV; 99% (95% CI, 95 to 100) for24 weeks of 
LDV/SOF; and 99% (95% CI , 95 to 100) for24 weeks of LDV/SOF + RBV. No patient 
discontinued treatment owing to an adverse event. The most common adverse events were 
fatigue, headache, and nausea.  The study demonstrated that treatment with dailyLDV/SOF 
resulted in high rates of SVR12 in HCV -infected subjects who had not had a sustained 
virologic response to prior interferon based treatment.
Study GS-US-337-0108 (ION -3) was a phase 3, open-label stud y, which randomly  assigned 
647 previously  untreated subjectswith HCV genotype 1 infection without cirrhosis to receive 
LDV/SOF +/-RBV for 8 weeks or LDV/SOF for 12 weeks. The primary  end point was 
SVR12
. The rate of sustained virologic response was 94% (95% confidence interval [CI ], 
90to 97) with 8 weeks of L DV/SOF, 93% (95% CI, 89 to 96) with 8 weeks of LDV/SOF + 
RBV, and 95% (95% CI, 92 to 98) with 12 weeks of LDV/SOF. As compared with the 
SVR12 rate in the group that received 8 weeks of LDV/SOF, the rate in the 12 -week group 
was 1 percentage point higher (97.5% CI, −4 to 6) and the rate in the group that received 
8weeks of LDV/SOF + RBV was 1 percentage point lower (95% CI, −6 to 4)demonstrating 
noninferiority  of the 8-week LDV/SOF regimen (noninferiority  margin of 12 %). Adverse 
events were more common in the group that received ribavirin than in the other two groups. 
No patient who received 8 weeks of onl y LDV/SOF discontinued treatment owing to adverse 
events.  Overall, previously  untreated subjects treated with 8 weeks of LDV/SOF achieved 
high ratesof SVR.No additional benefit was associated with the inclusion of riba virinin the 
regimen or with extension of the duration of treatment to 12 weeks .
GS-US-
337-0115 (ION -4) was a multicenter, single -arm, open-label study  that enrolled 
HIV/HCV (genot ype 1 or 4) coinfected subjects to receive 12 weeks of LDV/SOF. Subjects 
were stable on antiretroviral regimen sof F/TDF with EFV, RPV or RAL . The primary  end 
point was SVR12
. Of the 335 patients enrolled, 34% were black, 55% had been previousl y 
treated for HCV, and 20% had cirrhosis. Overall, 322 patients (96%) had SVR12(95% 
confidence interval [CI ], 93 to 98), including rates of 96% (95% CI, 93 to 98) in patients with 
HCV genoty pe 1a, 96% (95% CI , 89 to 99) in those with HCV genot ype 1b, and 100% (95% 
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page24 18 December 2015CI, 63 to 100) in those with HCV genot ype 4. Rates of sustained virologic resp onse were 
similar regardless of previous treatment or the presence of cirrhosis. Of the [ADDRESS_763775] common adverse events were 
headache (25%), fatigue (21%), and diarrhea (11%). No subejctdiscontinued treatment 
because of adverse events.  The study  concluded that L DV/SOF for 12 weeks provided high 
rates of sustained virologic response in patients coinfecte d with HIV -1 and HCV genoty pe1 
or 4.
Combined Analy ses of LDV/SOF Data {Bhagani et al 2015}
A combined anal ysis compared the safet y and efficacy of the single tablet regimen of LDV/SOF 
in HCV genot ype (GT) 1 patients co -infected with HIV -1 in the Phase III ION-4 study with 
HCV mono-infected GT1 patients in the Phase III ION 1- 3 studies. 
In the ION-4 study, 327 GT1 HCV/HIV co -infected patients (126 treatment- naïve, non- cirrhotic, 
134 treatment -experienced, non- cirrhotic, 20 treatment -naïve, cirrhotic, 
47treatment -experienced cirrhotic) received LDV/SOF for 12 weeks. In the ION1- 3 studies, 
538 GT1 HCV mono -infected patients (395 treatment- naïve, non- cirrhotic, 
87treatment -experienced, non
-cirrhotic, 34 treatment -naïve, cirrhotic, 22 treatment -experienced 
cirrhotic) received LDV/SOF for 12 weeks. The pooled anal ysis assessed safet y and sustai ned 
virologic response at week 12 (SVR12).
Overall, 865 patients were treated with 12 weeks. In ION 1-3, the majority  of patients were male 
(329, 61%), non- black (449, 83%), and treatment -naïve (430, 80%) while56 (10%) patients had 
cirrhosis. In ION -4, the majority  of patients were male (276, 82%), non- black (220, 66%), and 
treatment -experienced (185, 55%). Sixty -seven (67)(20%) patients had cirrhosis. SVR12 and 
relapse data are reported in the table. Treatment was well tolerated in both mono -infected and
co-infected patients. Most common adverse events (> 10% reported in an y arm) were fatigue, 
headache, diarrhea, and nausea. Onl y two patients discontinued treatment due to an adverse 
event.  The investigators concluded that the once daily , single tablet re gimen of LDV/SOF for 
12 weeks provided high rates of SVR regardless of presence of HIV infection and wasa safe, 
well-tolerated option for patients with both HCV mono- infection and HIV/HCV co -infection.
Table1-
1. Combined Analysis from Phase III ION Studies
Study ION 1 ION 2 ION 3
ION 1-3 Combined ION 4
N (GT 1) 213 109 216 538 327
SVR12 (%) 99 94 96 97 96
Relapse rates (%) <1 6 1 2 3
Discontinuation rates (%) 0 0 1 <1 0
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page25 18 December 2015LDV/SOF Drug Interactions with E/C/F/TAF and F/R/TAF {Custodio et al 2015 }
Use of anti-HCV agents such as LDV, a P -glycoprotein (P -gp) and BCRP inhibitor, with HI V 
ARV such as TAF, a P -gp and BCRP substrate, may  be complicated by [CONTACT_9934] -drug interactions 
(DDIs). Two Phase 1 studies evaluated DDIs between TAF- based regimens F/R/TAF or 
E/C/F/TAF and the fixed -dose combination anti
-HCV regimen of LDV/SOF. In two 
multiple-dose, randomized, crossover studies, healthy  volunteers received R/F/TAF ( Study1)or 
E/C/F/TAF( Study 2)
,alone or in combination with L DV/SOF, dail y with food for 11 [Study1] 
or 10[Study 2] days. Plasma concentrations of RPV, EVG, COBI, FTC, TAF, TFV (TAF 
metabolite), LDV, SOF ,and GS-331007 ( predominant circulating metabolite of SOF) were 
analyzed and PK parameters calculated via noncompartmental anal ysis. Geometri c least squares 
mean ratio (GMR; combination vs. alone) and 90% confidence intervals (CI ) for analy tes' 
AUCtau, Cmaxand Ctauwere estimated b y linear mixed effect modeling and compared to lack of 
PK alteration bounds (70 -143% except RPV: 80 -125%). Safet y was assessed throughout the 
studies.
Forty (40) of 42 subjects (Study  1) and 30/30 subjects (Study  2) completed the study. Treatments 
were generally  well tolerated .
The GMR and 90% CI for all anal ytes’ PK parameters are:
Table1-2. Study 1: F/R/TAF and LDV/SOF
PK Param eterMean (%CV)
%GLSM Ratio 
(90% CI)FTC/RPV/TAF
(TreatmentB)
(N=42)LDV/SOF+ FTC/RPV/TAF 
(TreatmentC)
(N=42)
FTC
AUCtau(h*ng/mL) 10,764.1(14.3) 10,805.1(15.3) 100.29 (98.43,102.19)
Cmax (ng/mL) 1707.6 (20.2) 1650.3 (17.6) 97.02 (92.72,101.53)
Ctau(ng/mL) 87.9 (28.2) 88.7 (25.1) 101.59 (98.47,104.81)
RPV
AUCtau(h*ng/mL) 3040.1(27.3) 2857.6(25.6) 94.59 (91.20,98.10)
Cmax(ng/mL) 203.3 (25.4) 197.1 (28.3) 96.65 (91.73,101.84)
Ctau(ng/mL) 109.1 (31.6) 100.0 (26.0) 93.33 (89.38,97.45)
TAF
AUClast(h*ng/mL) 277.2 (37.5) 362.3 (34.4) 132.39 (124.99,140.22)
Cmax(ng/mL) 200.0 (43.5) 204.5 (45.7) 103.12 (93.58,113.63)
TFV
AUCtau(h*ng/mL) 268.4 (22.6) 467.2 (21.0) 174.72 (168.78,180.86)
Cmax(ng/mL) 15.8 (21.7) 25.4 (20.0) 161.50 (155.60,167.62)
Ctau(ng/mL) 9.0 (24.8) 16.7 (22.0) 184.86 (177.57,192.46)
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page26 18 December 2015PK Param eterMean (%CV)
%GLSM Ratio 
(90% CI)LDV/SOF
(TreatmentA)
(N=41)LDV/SOF+ FTC/RPV/TAF 
(TreatmentC)
(N=42)
SOF
AUCtau(h*ng/mL) 2909.4 (32.8) 3068.9 (30.5) 104.69 (100.51,109.04)
Cmax (ng/mL) 1469.5 (35.4) 1390.6 (32.3) 95.99 (88.80,103.76)
GS-331007
AUCtau(h*ng/mL) 11,766.4 (12.8) 12,883.3 (16.1) 107.98 (106.20,109.79)
Cmax(ng/mL) 884.4 (13.7) 960.4 (14.8) 108.09 (105.05,111.20)
Ctau(ng/mL) 339.8 (16.4) 378.1 (18.9) 109.92 (107.46,112.44)
LDV
AUCtau(h*ng/mL) 11,590.4 (40.3) 11,944.8 (42.7) 101.53 (97.36, 105.88)
Cmax(ng/mL) 647.4 (35.8) 658.4 (37.7) 100.62 (96.76, 104.63)
Ctau(ng/mL) 419.7 (45.9) 434.3 (47.4) 102.40 (98.02, 106.99)
Table1-3. Study 2: E/C/F/TAF and LDV/SOF PK Parameter
Mean (%CV)
%GLSM Ratio 
(90% CI)E/C/F/TAF
(N = 30)LDV/SOF + E/C/F/TAF
(N = 30)
EVG
AUCtau(h*ng/mL) 26,888.6 (22.74) 29,750.7 (23.26) 110.62 (102.40, 119.50)
Cmax (ng/mL) 2184.3 (23.29) 2155.3 (27.49) 97.85 (89.57, 106.91)
Ctau(ng/mL) 513.3 (40.06) 731.3 (35.57) 145.70 (127.99, 165.86)
COBI
AUCtau(h*ng/mL) 11,354.2 (36.34) 17,046.0 (30.36) 153.17 (144.87, 161.95)
Cmax(ng/mL) 1381.4 (25.98) 1668.0 (17.14) 123.35 (115.35, 131.91)
Ctau(ng/mL) 56.1 (99.59) 175.2 (90.42) 325.08 (287.62, 367.43)
FTC
AUCtau(h*ng/mL) 12,035.7 (15.39) 11,622.9 (15.53) 96.59 (93.22, 100.08)
Cmax(ng/mL) 1777.0 (18.40) 1840.3 (22.12) 103.04 (95.93, 110.67)
Ctau(ng/mL) 103.5 (26.84) 98.5 (27.24) 95.02 (90.82, 99.42)
TAF
AUClast(h*ng/mL) 238.6 (45.87) 194.8 (29.21) 85.67 (77.63, 94.54)
Cmax(ng/mL) 165.9 (50.79) 148.2 (48.24) 90.45 (73.41, 111.45)
TFV
AUCtau (h*ng/mL) 314.8 (18.68) 396.8 (15.90) 126.61 (122.55, 130.81)
Cmax (ng/mL) 17.8 (20.43) 20.7 (16.14) 116.85 (111.71, 122.23)
Ctau(ng/mL) 11.7 (20.05) 15.5 (16.62) 132.89 (127.74, 138.25)
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page27 18 December 2015PK Param eterMean (%CV)
%GLSM Ratio 
(90% CI)LDV/SOF FDC
(N = 30)LDV/SOF + E/C/F/TAF
(N = 30)
LDV
AUCtau(h*ng/mL) 12,657.2 (36.26) 22,939.3 (35.71) 178.99 (163.62, 195.81)
Cmax (ng/mL) 684.2 (32.25) 1136.0 (32.14) 164.74 (152.60, 177.86)
Ctau(ng/mL) 459.2 (40.34) 896.1 (37.74) 193.16 (173.91, 214.55)
SOF
AUCtau(h*ng/mL) 2336.2 (37.40) 3308.4 (24.84) 146.53 (135.44, 158.53)
Cmax(ng/mL) 1220.3 (37.87) 1573.2 (34.88) 128.48 (112.51, 146.72)
GS-331007
AUCtau(h*ng/mL) 12,611.4 (20.91) 18,739.0 (22.60) 148.15 (143.54, 152.91)
Cmax(ng/mL) 950.9 (18.74) 1228.7 (18.57) 129.36 (123.92, 135.04)
Ctau(ng/mL) 358.7 (24.66) 599.5 (27.40) 165.96 (159.61, 172.57)
GLSM and 90% CI s for all anal ytes were contained within the prespecified bounds except : 
i)TFV when RPV/FTC/TAF was administered with L DV/SOF; ii)COBI, when E/C/F/TAF was 
coadministered with LDV/SO F;and iii) LDV, GS-331007and SOFand EVG when a dministered 
with E/C/F/TAF.
Despi[INVESTIGATOR_580856] R/F/TAF + LDV/SOF, t he mean 
TFV AUC tauis ~ 5 times lower than TFV from TDF, and within the range of TFV that did not 
lead to renal AEs or bone loss (E/C/F/TAF Phase 3). There is no association between higher 
COBI exposure and incidence of AEs, renal function parameters (E/C/F/TAF Phase 2/3 data). 
Higher plasma exposures of LDV, SOF and GS -331007 in the presence of E/C/F/TAF are not 
considered to be clinically important based on the established exposure -safety analyses for 
LDV/SOF. Thus, F/R/TAF or E/C/F/TAF may  be coadministe red with LDV/SOF without dose 
modification.
1.4. Rationale for This Study
Currently , LDV/SOF is approved by  [CONTACT_580880]1- infected 
HCV mono and HIV co -infected patients. This Phase 3 open- label study  is designed to extend 
this datato examine the efficacy  and safety of LDV/SOF treatment regimen for chronic genot ype 
1 HCV infection in HIV -infected patients who are receiving HIV therap y with E/C/F/TAF or 
F/R/TAF. Current guidelines for treatment of HCV in HIV co
-infected patients emph asize the 
added need to treat co -infected patients due to higher rates of liver disease progression even if 
the HIV infection is treated with antiretroviral agents. The complex drug interactions that can 
occur between HIV ARV and HCV DAA further the need f or safe, simple regimens that cure 
HCV in HIV -infected subjects without threatening the underl ying HIV suppression. Current 
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page28 18 December 2015IDSA/AASLD guidelines recommend that “ Antiretroviral drug switches may  be performed to 
allow compatibility  of DAAs, with the goal of maintaining HIV suppression without 
compromising future options. ” {HCV Guidelines 2015 }Prior HIV treatment history , underlying 
HIV drug resistance and tolerability  of regimens needs to be considered. 
LDV/SOF has been used successfull y to treat HIV/HCV co -infected patients and the cure rates 
are 96%, comparable to HCV mono -infected patients {Naggie et al 2015 },which has led to a 
recent update to the LDV/SOF package insert that now includes HIV/ HCV co-infection in the 
list of indications {[COMPANY_009] Sciences Inc 2015 }. However, few ARV regimens were evaluated in 
clinical studies of HCV treatment of HIV co -infected subjects.  Only  RAL, EFV and RPV were 
used in the ION -4 study with FTC/TDF as the dual NRTI  component of the regimen. In the 
presence of a boosting agent, such as RTV or COBI(which increase plasma TFV 
concentrations) , further increases inplasma TFV concentrations are noted when coadministered 
with LDV/SOF + TDF.  Guidelin es recommend avoiding RTV or COBI-boosted ARV regimens 
with TDF when treating HCV in HIV- infected patients
,mainly due to lack of data.  The 
availability  of TAF-based regimens will obviate the problem of excessive TFV concentrations 
due to the 91% lower pl asma TFV levels when TAF is used in place of TDF.  The PK drug 
interaction studies (GS-US-366-1689 and Study 2) further justify  the ability to use LDV/SOF in 
HIV-
infected patients who are receiving TAF- based regimens (including COBI) .
Drug-drug interactions of LDV/SOFcoadministered with E /C/F/TAF and F /R/TAF were 
evaluated in healthy  volunteers; the studies found no significant interactions and concluded that 
LDV/SOF and TAF -regimens can be coadministered without dose modification. The duration of 
the health y volunteer drug -interaction studies were 10 and 11 day s. Although, the US package 
insert for Genvo ya®(E/C/F/TAF) suggests there should be no clinically  significant drug 
interaction with LDV/SOF, there is no study to datethathas evaluated the safe ty or efficacy of 
LDV/SOF administered with E/C/F/TAF or F/R/TAF for treatment of HCV in suppressed, HIV
co-infected population. Careful assessment of safety /tolerability  of LDV/SOF with TAF 
regimens for 12 weeks is needed to ensure that the safet y data, noted in healthy  volunteers PK 
studies,
isreplicated during 12 weeks of co administration in HIV/HCV co -infected subjects. The 
goal of this stud y is to evaluate E/C/F/TAF FDC or F/R/TAF FDC with LDV/SOF by 
[CONTACT_580881] y (SVR 12 week s after completion of LDV/SOF) and 
safety and tolerability of co administration of dual STRs .
1.5. Risk/Benefit Assessment for the Study
The risk/benefitfor this study  is acceptable due to the following considerations: i) treatment of 
HCV is indicated and important in all HIV co -infected patients due to accelerated progression of 
liver disease; ii) 12 weeks of LDV/SOF provides high HCV SVR rates in HIV/HCV co -infected 
subjects; iii) changing ARV regimens is an accepted stra tegy for management of patients prior to 
initiation of HCV therapy (AASLD/ IDSA Guidelines); iv) changing to E/C/F/TAF from other 
ART has been shown to be safe, effective and have superior treatment outcome than maintaining 
a current suppressive regimen {Mills et al 2015}; v) F/R/TAF is bioequivalent to approved HIV 
regimens and achieves plasma concentrations of FTC, RPV and TAF that have proven to be safe, 
well tolerated and effective in maintaining virologic suppression in HIV- infected patients .
Thus, 
for individual subjects there is benefit to treating their HCV and for all co -infected patients, 
finding safe, tolerable, efficacious and simple regimens will be a major advance in treatment.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page29 18 December [ZIP_CODE].6. Compliance
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page30 18 December [ZIP_CODE]. OBJECTIVES
The primary  objective of this study  is:
To evaluate ef ficacy of LDV/SOF as measured b ythe proportion of subjects achieving HCV
RNA below the lower limit of quantification (LLOQ) [ADDRESS_763776] dose of 
LDV/SOF ( SVR 12).
The secondary  objectives of this study  are:
To determine the proportion of subjects achieving HCV RNA below LLOQ [ADDRESS_763777] dose of LDV/SOF ( SVR 4);
To evaluate maintenance of HIV -1 RNA suppression after switching to E/C/F/TAF or 
F/R/TAF 24 weeks from the start of the F/TAF- based regimen ;
To evaluate the safet y and tolerability  of switching to E/C/F/TAF or F/R/TAF from the 
current ARV therap y in virologicall y-suppressed, HIV -1/HCV co-infected subjects;
To evaluate the safety and tolerability  of12 weeks of treatment for HCV with L DV/SOF in 
virologicall y-suppressed, HIV -1/HCV co-infected subjects who switched to E/C/F/TAF or 
F
/R/TAF.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page31 18 December [ZIP_CODE]. STUDY DESIGN
3.1. Endpoints
The primary  endpoint of this study  is:
The primary  efficacy endpoint is SVR12 (HCV RNA < LLOQ 12 weeks after completion of 
LDV/SOF treatment )
The secondary  endpoints of this study  are:
SVR4 (HCV RNA < LLOQ 4 weeks after completion of LDV/SOF treatment );
The proportion of subjects with HI V-1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL  (virologic failure) 24 weeks 
after start of the F/TAF -based regimen using modified FDA snapshot algorithm ;
Grades 1 through 4 adverse events aft er switching to E/C/F/TAF or F/R/TAF throughout the 
studyand during coadministration with LDV/SOF treatment .
3.2. Study Design
This protocol describes a randomized, multicenter, open- label, 2-part study to evaluate the 
efficacy, safety, and tolerability of switching to E/C/F/TAF FDC or F/R/TAF FDC HIV 
treatments and adding LDV/SOF HCV treatment for 12 weeks in adult male and female subjects 
with HIV who are co -
infected with chronic GT 1 HCVinfection.
3.3. Study Treatments
Subjects will participate in 2 parts of the study. In Part 1, subjects will be randomized in a 1:1 
ratio to one of the following 2 HIV treatment groups:
Part 1:Approximately  240 subjects will be randomized 1:1 to switch from stable ARV therapy 
to one of the following treatments.  Randomization will be stratified by  [CONTACT_545] (black vs. non-
black) at screening.
Treatment Group 1:Switchfrom [ADDRESS_763778] ARVagent to E/C/F/TAF FDC 
(n=120)
Treatment Group 2: Switchfrom [ADDRESS_763779] ARVagent to F/R/TAF FDC 
(n=120)
Subjects maintaini ng HIV-1 RNA < 50 copi[INVESTIGATOR_014]/mL and tolerating E/C/F/TAF or F/R/TAF 
through Part 1 will continue to Part 2 where they will receive the HCV treatment.  Subjects with 
confirmed virologic failure or who discontinue the HIV study  drugs due to toxicity  in Part1 will 
be discontinued from the study .
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page32 18 December 2015Part 2:After 8 weeks on the randomized E/C/F/TAF FDC or F/R/TAF FDC treatment, subjects 
willmaintain their HIV treatment and willinitiate12 weeks of LDV/SOF HCV treatment .  
At the end of their LDV/SOF HCV treatment, subjects will continue to maintain their HIV 
treatment and be followed for safety  and efficacy  for an additional [ADDRESS_763780] -HCV 
Treatment Week 12. The HCV treatment duration is 12 weeks. Screening assessm ents will be 
completed within 42 days of the Day  1 
visit.
All subjects will complete the following stud y visits: Screening, Day1, Weeks 4, 6(laboratory  
visit only), 8(start of HCV treatment) , 12, 16, and 20 (end of HCV treatment), and post-HCV 
treatment visits [ADDRESS_763781] LDV/SOF dose. 
Subjects who complete the study  through the last study  visit at the Post-HCVTreatment
Week12 visit
willbe required to return to the clinic 30 days after the completion of the study  
treatment for a 30- Day Follow-Up visit.
Figure3-1. Study Schema
aFollowing the Day 1 visit, subjects will return for study visits at Weeks 4, 6 (laboratory visit only), 
8, 12, 16, 20, and 
Post-
HCV Treatment [ADDRESS_763782] LDV/SOF dose.
bPart 1: subjects are randomized to either E/C/F/TAF FDC or F/R/TAF FDC on Day 1 and maintain HIV treatment to the 
Week 8 visit.
cPart 2: At Week 8, once HIV -1RNA suppression (< 50 copi[INVESTIGATOR_014]/mL) is confirmed (based on the Week 6 HIV -1 RNA value) , 
subjects will start on LDV/SOF FDC for 12 weeks (until Week 20) while maintaining their HIV treatment. At Week 20, 
LDV/SOF FDC will be discontinued while continuing HIV treatment . Subjects will continue in the study for another 
12weeks to determine SVR4 ([ADDRESS_763783]-HCV treatment) and SVR12 ([ADDRESS_763784]-HCV treatment).
dSubjects who complete the study through the Post-HCV Treatment Week 12 visit will be required to return to the clin ic 
30days after the completion of the study treatment for a 30-Day Follow -Up Visit. 
e At the Day 1 visit, subjects will switch to either E/C/F/TAF FDC or F/R/TAF FDC and continue on HIV treatment until the 
last study visit at the Post-HCV Treatment Week 12visit.

FTC/RPV/TAF 
Protocol GS-US-366-1992 
[COMPANY_009] Sciences, Inc. 
3.5. Samples for Optional Exploratory Assessments 
PO 
CONFIDENTIAL Page 33 Final 
Original 
18 December 2015 
FTC/RPV/TAF
Protocol GS -US-366-[ADDRESS_763785] Selection
Approximately  240 subjects with HI V-1 who are coinfected with chronic HCV infection and 
who meet the eligibility  criteria will be enrolled. In order to manage the total study  enrollment, 
[COMPANY_009]Sciences, Inc., at its sole discretion, may suspend screening and/or enrollment at any site 
or study-wide at an y time.
4.2. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study.
1)The ability  to understand and sign a written informed consent form, which must be obtained 
prior to initiat ion of any  study procedures .
2)Age ≥ 18 years.
3)Currently  on the first or second ARV regimen (2 NRTI  + a third agent, see Table4-1) 
without change for 6 months prior to s creening. D ocumented plasma HIV -1 RNA levels 
<
50copi[INVESTIGATOR_014]/mL (or undetectable HIV -1 RNA level according to the local assay  being used if 
the limit of detection is ≥ 50 copi[INVESTIGATOR_014]/mL ) for ≥ 6 months preceding the Screening visit. After 
reaching HIV -1 RNA < 50 copi[INVESTIGATOR_014]/mL , single values (“blips”) of HIV -1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL  
followed b y resuppression areallowed.
Table4-1. Allowable ARV Agents of Pre -Existing HIV Regimen
Antiretroviral Class Agents
Boosted PI[INVESTIGATOR_580857]+COBI (or ATV/COBI FDC), darunavir ( DRV)+COBI (or DRV/COBI FDC) , 
DRV+RTV, lopi[INVESTIGATOR_054] (LPV)+RTV, ATV+RTV
NNRTI EFV, etravirine ( ETR), nevirapi[INVESTIGATOR_050] ( NVP), RPV
NRTI FTC, TDF, abacavir (ABC), lamivudine (3TC), zidovudine ( AZT)
INSTI dolutegravir ( DTG), RAL, EVG/COBI or EVG+RTV
4)No history  of HIV virologic failure
5)If the current regimen is a PI /r, the previous regimen cannot contain an NNRTI  or INSTI
6)Plasma HIV -1 RNA level < 50 copi[INVESTIGATOR_014]/mL  at the Screening visit.
7)Have no documented resistance to an y of the HIV study agents at any  time in the past, 
including but not li mited to the reverse transcriptase resistance mutations K65R, K70E, 
K101E/P, E138A/G/K/R/Q, V179L, Y181C/I /V, M184V/I , Y188L, H221Y, F227C, 
M230I/L, the combination of K103N+L100 I, or 3 or more TAMs that include M41L  or 
L210W (TAMs are M41L, D67N, K70R, L2 10W, T215Y/F, K219Q/E/N/R) .
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page35 18 December [ZIP_CODE])Chronic HCV infection (≥ 6 months) documented by  [CONTACT_229037] .
9)HCV genoty pe [ADDRESS_763786] from study  participation.
10)Classification as one of the following criteria:
a)Without cirrhosis and noprior HCV treatment ( treatment -naïve,definedas having never 
been exposed to approved or investigational HCV-specific direct-acting antiviral agents 
or prior treatment of HCV with IFNand RBV)
b)Without cirrhosis and have received HCV treatment only  with IFN +/-RBV +/- HCV PI 
(treatment -experienced , defined as prior treatment failure to a regimen containing IFN
either with or without RBV that was complete d at least [ADDRESS_763787]’s medical records must include sufficient detail of prior treatment experience for 
categorization, as either:
i.Non-Responder: Subject did not achieve undetectable HCV RNA levels while on 
treatment, or 
ii.Relapse/Breakthrough: Subject achiev ed undetectable HCV RNA levels during 
treatment or within 4 weeks of the end of treatment but did not achieve SVR , or
iii.HCV Treatment -Intolerant: Subjects who discontinued HCV treatment of a regimen 
containing IFN(either with or without RBV )due to toxicity   
c)Compensated cirrhosis and no prior HCV treatment (treatment -naïve)
11)Cirrhosis Determination 
a)Presence of c irrhosis is defined as any  one of the following :
i.FibroTest®score > 0.[ADDRESS_763788]:platelet ratio index (APRI ) >2 during 
screening
ii.Fibroscan with a result of > 12.5 kPa 
iii.Liver biopsy  showing cirrhosis (eg, Metavir score = 4 or Ishak score 
≥5)
b) Absence of cirrhosis is defined as an y one of the following:
i.FibroTest®score ≤ 0.48 AND APRI ≤ 1 performed during screening 
ii.Fibroscan with a result of ≤ 12.5 kPa within ≤ [ADDRESS_763789]®/APRIusing the above criteria, a liver biops y or fibroscan is required. 
Liver biopsy  results will supersede Fibrotest®/APRI or fibroscan results and be considered 
definitive.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page36 18 December 201512)Liver imaging within 6 months of Day  1 is required in cirrhotic subjectsonly to exclude 
hepatocellular carcinoma (HCC)
13)HCV RNA 104IU/mL attheScreening visit
14)Normal ECG (or if abnormal, determined b y the Investigator to be not clinically significant)
15)Adequate renal function: estimated GFR ≥ 30 mL/min according to the Cockcroft -Gault 
formula 
(eGFR CG) for creatinine clearance {Cockcroft et al 1976 }:
Male: (140–age in years) ×(wt in kg) CLcr(mL/min)
72 ×(serum creatinine in mg/dL)
Female: (140–age in years) ×(wt in kg) ×0.85 CLcr(mL/min)
72 ×(serum creatinine in mg/dL)
16)Hepatic transaminases (AST and ALT) ≤ 5 ×upper limit of normal (ULN)
17)Total bilirubin ≤ 1.5 mg/dL , or normal direct bilirubin (sub jects with documented 
Gilbert’s syndrome or with atazanavir -associated hy perbilirubinemia may  have total bilirubin 
up to 5×ULN)
18)Adequate hematologic function:
Absolute neutrophil count ≥ 1,000/mm3
Platelets ≥50,000/mm3
Hemoglobin ≥ 8.5 g/dL
19)Albumin 3.0 g/dL
20)INR ≤ 1.[ADDRESS_763790] has known hemophilia or is stable on an anticoagulant 
regimen affecting INR
21)A female subject is eligible to enter the study  if it is confirmed that she is:
a)Not pregnant or nursing
b)
Of non-childbearing potential (ie , women who have had a h ysterectomy, have had both 
ovaries removed or medically  documented ovarian failure, or are postmenopausa l women 
≥ 54years of age with cessation [ for 12months]of previousl y occurring menses), or
c)Of childbearing potential and agrees to utilize protocol- specified contraceptive method s
or be non- heterosexually  active or practice sexual abstinence from scree ning throughout 
the duration of study  treatment and for [ADDRESS_763791] study  drug dose (see 
Appendix 5for definitions and protocol -acceptable contraceptive methods)
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page37 18 December 201522)Male subjects must agree to utilize a protocol-approved method of contraceptio n (as 
defined in Appendix 5) during heterosexual intercourse or be non -heterosexually  active, or 
practice sexual abstinence from first dose throughout the study  period and for [ADDRESS_763792] study drug dose .
23)Male subjects must agree to refrain from sperm donation from first dose until at least 
30days after the last study  drug dose.
4.3. Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study .
1)A new AIDS -
defining condition diagnosed within the30 day s prior to the S creeningvisit
(exceptCD4+cell count and/or percentage criteria) (refer to Appendix 6
)
2) PriorHCVtreatments with NS5A and NS5B or any  HCV directl y acting antivirals except 
boceprevir, telaprevir and simeprevir in combination with IFN +/-RBV.
3) Chronic liver disease of a non- HCV etiology  (e.g., hemochromatosis, Wilson’s disease, 
alfa-1 antitrypsin deficiency, cholangitis).
4)History or current decompensation of liver disease ; varices at low risk of bleeding are 
allowed.
5)Positive 
Hepatitis B surface antigen (HBsAg) or Hepatitis B virus ( HBV)DNA
6)Chronic use of s ystemically administe red immunosuppressive ag ents (eg,prednisone 
equivalent > 10 mg/day).
7) Females who are breastfeeding
8)Positive serum pregnancy test 
9)Have an implanted defibrillator or pacemaker
10)Current alcohol or substance use judged b y the Investigator to potentiall y interfere with 
subject study  
compliance
11)A history of malignancy  within the past 5 y ears (prior to screening) or ongoing malignancy  
other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non -invasive 
cutaneous squamous carcinoma. Subjects with cutaneous KS are e ligible, but must not have 
received an y systemic therapy  for KS within [ADDRESS_763793] not be 
anticipated to require s ystemic therap y during the study.
12)Active, serious infections (other than HIV -
1and HCV infections) requiring parenteral 
antibiotic or antifungal therap y within 42days prior to Day  1
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page38 18 December 201513)Gastrointestinal disorder or post-operative condition that could interfere with the absorption 
of the study  drugs
14)Solid organ transplantation
15)Significant pulmonary  diseaseor significant cardiac disease
16)Any other clinical condition or prior therapy  that, in the opi[INVESTIGATOR_2511] I nvestigator, would 
make the subject unsuitable for the stud y or unable to comply with dosing requirements
17)Participation in any  other clinical trial (including observational trials) without prior approval 
from the sponsor is prohibited while participating in this trial
18)Known hy persensitivity  to thestudy drugs, themetabolites, or formulation excipi[INVESTIGATOR_841] s
19)Subjects receiving ongoing therap y with any of the medications in Table4-
2, including drugs 
not to be used due to the potential for interaction with HIV study drugs (COBI,EVG, FTC, 
RPV, or TAF. ForCOBI, EVG, FTC, or R
PV,refer to the individual agents’ Prescribing 
Information; for TAF, refer to the E/C/F/TAF FDC or F/R/TAF F DC Investigator’s 
Brochures) or HCV study  drugs (LDV or SOF); or subjects with any  known allergies to the 
excipi[INVESTIGATOR_22880] E/C/F/TAF ,F/R/TAF, or LDV/SOF tablets.
Table4-2. Disallowed Agentsa
Drug Class Agents Disallowedb
Acid Reducing AgentsProton pump inhibitors, such as Esomeprazole, Lansoprazole, 
Omeprazole, Pantoprazole, R abeprazole
Alpha Adrenergic Receptor Antagonist s Alfuzosin
Antiarrythmics Amiodaron ed, Quinadine
AnticonvulsantscPhenobarbital, Phenytoin, Carbamazepi[INVESTIGATOR_050], Oxcarbazepi[INVESTIGATOR_580858], Rifapentine, Rifabutin
Calcium Channel Blockers Bepridil
Corticosteroids: Systemic Dexamethasone (more than a single dose)
Ergot DerivativesErgotamine, Ergonovine
Dihydroergotamine
Methylergonovine
Ergometrine
GI Motility Agents Cisapride
Herbal/Natural Supplem entsc St. John’s Wort, Echinacea, Milk thistle (ie, silymarin), Chinese herb 
sho-saiko-to (or Xiao -Shai-Hu-Tang)
HMG-CoA Reductase Inhibitors Simvastatin, Lovastatin , Rosuvastatine
Inhaled Beta Agonist Salmeterol
Neuroleptics Pi[INVESTIGATOR_580859]/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page39 18 December 2015Drug Class Agents Disallowedb
Phosphodiesterase -5 Inhibitors Sildenafil (for PAH)
Sedatives/Hypnotics Orally administered Midazolam, T riazolam
a.Disallowed agents are inclusive of all HIV and HCV study drugs (E/C/F/TAF, F/R/TAF, and LDV/SOF).
b.Administration of any of the following medications must be discontinued at least 42 days prior to the Day 1 visit and for the 
duration of the study , with the exception of amiodarone (see footnote d).
c.May result in a decrease in the concentrations of all HIV and HCV study drugs .
d.May result in symptomatic bradycardia. Mechanism is currently unknown. The use of amiodarone is prohibited from 
60days prior to the Day 1 visit and for the duration of the study .
e.Use with LDV/SOFmay result in an increase in the concentration of rosuvastatin, which is associated with increased risk of 
myopathy including rhabdomyolysis .
FTC/RPV/TAF
Protocol GS -US-366-[ADDRESS_763794] using the Interactive Web 
Response Sy stem (IWRS). The subject number assignment and randomization may  be performed 
up to [ADDRESS_763795] eligibility  has been confirmed.
Subjects will be randomized in a 1:1 ratio to one of the following two treatment arms: 
Treatment Arm 1: Switch from [ADDRESS_763796] ARV agent to E/C/F/TAF FDC (n = 120)
Treatment Arm 2:Switch from [ADDRESS_763797] ARV agent to F/R/TAF FDC (n = 120)
Randomization will be stratified b y race (black vs. non -black).
The IWRS will assign study  drug bottle numbers to be dispensed to the subject at each study  
visit, for all HIV and HCV study  drugs. All Day1assessments and procedures must be 
completed prior to the administration of the first dose of 
HIV study drug. Initiation of 
treatment with the HIV study drug must take place within 24 hours after the Day 1visit.
5.2.
Description and Handling of E/C/F/TAF, F /R/TAF, and LDV /SOF
5.2.1. Formulation
[IP_ADDRESS]. E/C/F/TAF , Genvoya®
E/C/F/TAF tablets are capsule -shaped, film -coated green tablets debossed with “GSI” on one 
side of the tablet an d “510” on the other side . Each E/C/F/TAF tablet contains 150 mg of EVG, 
150 mg of COBI, 200 mg of FTC, and 10 mg of TAF (as 11.2 mg of TAF fumarate).
Inaddition to the active ingredients, the tablets contain silicon dioxide, croscarmellose sodium, 
hydroxypropyl cellulose, lactose monohy drate, magnesium stearate, microcry stalline cellulose, 
and sodium laury l sulfate as inactive ingredients and are film -coated with indigo carmine 
aluminum lake, poly ethylene glycol, polyvin yl alcohol, talc, titanium dioxide, and yellow iron 
oxide.
[IP_ADDRESS]. F/R/TAF 
F/R/TAF tablets are capsule -shaped, film -coated gray  tabletsdebossed with “GSI” on one side 
and “255” on the other side. Each F/R/TAF tablet contains 200 mg of FTC, 25mg of RPV(as 
27.5 mg RPV 
hydrochloride ), and 25mg of TAF(as 28 mg of TAF fumarate)
. 
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page41 18 December 2015In addition to the active ingredients, the tablets contain lactose monohy drate,microcrystalline 
cellulose, polysorbate, povidone, croscarmellose sodium and magnesium stearate. The tablet
cores are film -coated with poly vinyl alcohol, titanium dioxide, poly ethylene glycol, talc, and 
black iron oxide .
[IP_ADDRESS]. LDV/SOF , Harvoni®
LDV/SOFtablets are orange, diamond- shaped, film -coated tablets debossed with “GSI” on one 
side and “7985” on the other side . Each LDV/SOF FDC tablet contains 90mg of LDV and 
400mg of SOF.
In addition to the active ingredients, the tablets containlactose monohy drate, copovidone, 
microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, 
polyvinyl alcohol, titanium dioxide, talc, poly ethylene glycol, and FD&C yellow # 6 /sunset 
yellow FCF aluminium lake.
5.2.2. Packaging and Labeling
Study drug(s) to be distributed to centers in the US and other participating countries shall be 
labeled to meet applicable requirements of the [LOCATION_002] Food and Drug Administration 
(FDA)and/or other local regulations.
[IP_ADDRESS]. E/C/F/TAF, Genvoya®
E/C/F/TAF tablets are packaged in white, high density  polyethylene (HDPE) bottles.  Each bottle 
contains [ADDRESS_763798] of Genvo ya®may 
also be used for the study .
[IP_ADDRESS]. F/R/TAF
F/R/TAF tablets are packaged in white, high density  polyethylene (HDPE) bottles.  Each bottle 
contains 30 tablets, silica gel desiccant, and poly ester packing material. Each bottle is enclosed 
with a white, continuous thread, child -resistant poly propylene screw cap with an 
induction- sealed,andaluminum- faced liner.
[IP_ADDRESS]. LDV/SOF , Harvoni®
LDV/SOF tablets are packaged in white, high density  polyethylene (HDPE) bottles. Each bottle 
contains [ADDRESS_763799] of Harvoni®may 
also be used for the study .
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page42 18 December [ZIP_CODE].2.3. Storage and Handling
E/C/F/TAF, F/R/TAF, and L DV/SOF tablets should be stored at controlled room temperature of 
25 °C (77 °F); excursions are permitted between 15 °C and 30 °C (59 °F and 86 °F). Storage 
conditions are specified on the label. Until dispensed to the subjects, all bottles of study  drug 
should be stored in a securely  locked area, accessible only  to authori zed site personnel.
To ensure the stability and proper identification, study drugs should not be stored in a container 
other than the container in which they  were supplied. Consideration should be given to handling, 
preparation, and disposal through measur es that minimize drug contact [CONTACT_10850] . 
Appropriate precautions should be followed b y avoidingdirect eye contact [CONTACT_279383].
Commercial product of Genvo ya®and Harvoni®may be used for the study . Further information 
regarding storage a nd handling are available in the Prescribing Information for commercial 
products.
5.3. Dosage and Administration o f E/C/F/TAF, F/R/TAF, and LDV/SOF
E/C/F/TAF FDC, F/R/TAF FDC, and LDV/SOF FDC tabletswill be provided by  
[CONTACT_433811].
The two HIV stud y treatments will be administered orall y, oncedaily with food at approximately  
the same time each day :
Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 2 00 mg/tenofovir alafenamide 10 mg 
(E/C/F/TAF) FDC
Emtricitabine 200 mg/rilpi[INVESTIGATOR_12979] 25 mg/tenofovir alafenamide 25 mg(F/R/TAF)FDC
HCV study  treatment (ledipasvir 90 mg/sofosbuvir 400mg[LDV/SOF] FDC)is to be 
administered orally, once daily  with or without food at approximately  the same time each day .
For a missed dose of E/C/F/TAF FDC, F/R/TAF FDC, and/or LDV/SOF FDC tablet, subjects 
should be instructed to take the missed dose of study drug as soon as possible during the same 
day.  Subjects should be cautioned never to double the next dose with a missed dose of study  
drugunder any circumstances.
5.4. Prior and Concomitant Medications
The use of medications for the treatment of HIV and HCV , other than the study  treatments 
(ie,E/C/F/TAF, F/R/TAF, or LDV/SOF) is prohibited .
Should subjects have a need to initiate treatment with any excluded concomitant medication, the 
[COMPANY_009] Medical Monitor must be consulted prior to initiation of the new medication. In instances 
where an excluded medication is initiated prior to discussion with the Medical Monitor, the 
Investigator must notify  [COMPANY_009] as soon as he/she is aware of the use of the excluded medication .
FTC/RPV/TAF
Protocol GS -US-366-[ADDRESS_763800] dose of study  drug need to be recorded in the source documents 
and electronic case report form(s) (eCRFs).
Medications listed in Table5-1(E/C/F/TAF + LDV/SOF ) and Table5-2(F/R/TAF + LDV/SOF ) 
and use of herbal/natural supplements are excluded or should be used with caution while subjects 
are participating in the st udy due to potential drug -drug interactions.
Table5-
1. Prior and Concomitant Medications – E/C/F/TAF + LDV/SOF
Drug Class Agents Disallowed UseWith Caution
Acid Reducing Agents
AntacidsaElvitegravir plasma concentrations are low er with 
antacids due to local complexation in the GI tract 
and not to changes in gastric pH. It is recommended 
to separate study drug and antacid administration by 
[CONTACT_2669] [ADDRESS_763801] sAlfuzosin
AnalgesicsTramadol, Propoxyphene: 
Concentrations may increase with study drug(s); 
clinical monitoring is recommended.
Antiarrhythmics Amiodaronec, QuinadineFlecainide Quinidine, Propafe none, Systemic 
Lidocaine, Mexiletine, Disopyramide: 
Concentrations may increase with study drug(s) 
resulting in a potential for cardiac arrhythmias; 
clinical and ECG monitoring is recommended.
AntibacterialsConcentrations of clarithrom ycin and/or cobicistat 
may be altered when clarithromycin is 
coadministered w ith study drug (s). 
Patients with CL crgreater than or equal to 
60mL/min: 
No dose adjustment of clarithromycin is required. 
Patients with CL crbetween 30 mL/min and 
60mL/min: 
The dose of clarithromycin should be reduced by 
50%. 
Concentrations of telithromycin and/or cobicistat 
may be increased when telithromycis in 
coadministered w ith study drug. Clinical monitoring 
is recommended upon coadministration with study 
drug. 
AnticoagulantsWarfarin: Concentrations may increase or decrease 
with study drug(s); appropriate INR 
(International Normalized Ratio) monitoring 
isrecommended.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page44 18 December 2015Drug Class Agents Disallowed UseWith Caution
AnticonvulsantsbPhenobarbital, Phenytoin, 
Carbamazepi[INVESTIGATOR_050], 
Oxcarbazepi[INVESTIGATOR_580860], Divalproex, Lamotrigine: 
Concentrations may increase with study drug(s); 
clinical monitoring is recommended.
AntidepressantsSelective serotonin reuptake inhibitors (SSRIs): 
Adose reduction may be required for most drugs of 
this class with the exception of sertral ine.
Tricyclics:
Concentrations may increase or decrease w ith study 
drug(s). Concentration monitoring is recommended 
to ensure adequate clinical response.
Trazodone:
Concomitant use with CYP3A inhibitors results in 
increased concentrations and adverse events; dose 
reduction should be considered.
AntifungalsKetoconazole and Itraconazole:
Concomitant use with study drug may result in an 
increase in concentrations. Daily dose of 
ketoconazole and itraconazole should be restricted 
to 200 mg. Subjects receiving ketoconazole or 
itraconazole should be monitored for adequate 
clinical response.
Voriconazole:
Concomitant use with study drug may result in an 
increasein concentrations. Clinical monitoring may 
be needed.
AntigoutDose reductions of colchicine may be required. 
Study drug (s)should not be coadministered w ith 
colchicine in patients with renal or hepatic 
impairment.
AntihistaminesConcentrations of astemizole and terfenadine may 
be increased when coadministered with cobicistat. 
Clinical monitorin g is recommended when these 
agents are coadministered with study drug (s).
Antimycobacterialsb Rifampin, Rifapentine, 
Rifabutin
β-BlockersMetoprolol, Timolol:
Clinical and ECG monitoring of subjects is 
recommended. A dose decrease may be needed.
Calcium Channel Blockers BepridilFelodipi[INVESTIGATOR_050], Nifedipi[INVESTIGATOR_050], Nicardipi[INVESTIGATOR_050], Verapamil, 
Diltiazem, Amlodipi[INVESTIGATOR_050]:
Concentrations may increase with study drug(s). 
Clinical and ECG monito ring of subjects 
isrecommended
Cardiac Medications Digoxind
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page45 18 December 2015Drug Class Agents Disallowed UseWith Caution
Corticosteroids: Inhaled/NasalConcomitant use of inhaled fluticasone and study 
drug(s) may increase plasma concentrations of 
fluticasone. Use is not recommended unless the 
potential benefit to the subject outweighs the risks 
of corticosteroid side effect s. Alternatives should be 
considered, particularly for long -term use.
Corticosteroids: SystemicSystemic dexamethasone, a CYP3A inducer, may 
significantly decrease elvitegravir and cobicistat 
plasmaconcentrations , which may result in loss of 
therapeutic effect and development of resistance . 
Alternative corticosteroids should be considered.
Use of Prednisone as a steroid burst ( ≤1 week of use)
should be monitored appropriately.
Endothelin Receptor AntagonistsBosentan:
Coadministration may lead to decreased elvitegravir 
exposures and loss of therapeutic effect and 
development of resistance. Alternative endothelin 
receptor antagonists may be considered.
Ergot DerivativesErgotamine, Ergonovine
Dihydroergotamine
Methylergonovine
Ergometrine
GI Motility Agents Cisapride
Herbal/Natural SupplementsbSt. John’s Wort, 
Echinacea, Milk thistle 
(ie, silymarin), Chinese 
herb sho- saiko-to (or 
Xiao-Shai-Hu-Tang)
HMG-CoA Reductase 
InhibitorsSimvastatin, Lovastatin , 
RosuvastatineAtorvastatin:
Concentrations may increase with study drug(s). 
Start with the lowest dose; gradual increase in dose 
may be tailored to clinical response. Careful 
monitoring for signs and symptoms of muscle 
weakness or myopathy, including rhabdomyolysis.
Immunosuppressan tsCyclosporine, Rapamycin, Sirolimus, Tacrolimus: 
Concentrations may increase with s tudy drug(s).
Therapeutic monitoring should be considered.
Inhaled Beta Agonist Salmeterol
Neuroleptics Pi[INVESTIGATOR_580861], Risperidone, Thioridazine: 
A dose decrease may be needed.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page46 18 December 2015Drug Class Agents Disallowed UseWith Caution
Opi[INVESTIGATOR_580862]:
Methadone exposures are unaffected upon 
coadministration wit h elvitegravir and cobicistat. 
No dose adjustment of methadone is required upon 
coadministration with study drug(s).
Meperidine (Pethi dine):
Dosage increase and long -term use are not 
recommended due to increased levels of metabolite 
normeperidine, which has analgesic and 
CNSstimulant (eg, seizures) activities.
Buprenorphine:
Concentrations of buprenorphine and 
norbuprenorphine are modestly increased and 
concentrations of naloxone are modestly decreased 
when coadministered with elvitegravir and cobicistat, 
with no effect on opi[INVESTIGATOR_580863].
Theconcentration changes are not considered 
clinically relevant and no dose adjustment of 
buprenorphine/ naloxone is required upon
coadministration with study drug(s).
Phosphodiesterase -5 Inhibitors Sildenafil (for PAH)Pulmonary Arterial Hypertension :
Tadalafil:
Caution should be exercised, including 
consideration of dose reduction, when 
coadministered for treatment of pulmonary arterial 
hypertension.
Erectile Dysfunction :
Sildenafil, Vardenafil, Tadalafil:
It is recommended that a single dose of Sildenafil 
no more than 25 mg in 48 hours, Vardenafil no 
more than 2.5 mg in 72 hours, or Tadalafil no more 
than 10mg in 72 hours be coadministered.
Sedatives/HypnoticsOrally administered 
Midazolam, TriazolamBuspi[INVESTIGATOR_5331], Clorazepate, Diazepam, E stazolam, 
Flurazepam, Zolpi[INVESTIGATOR_6730]:
A dose decrease may be needed for these drugs. 
Clinical monitoring is recommended.
aIt is recommended to separate antacid and LDV/SOF administration by 4 hours. H2-receptor antagonists may be 
administered simultaneously with or staggered from LDV/SOF at a dose that does not exceed doses comparable to 
famotidine 40 mg twice daily.  Proton-pu mp inhibitor doses comparable to omeprazole 20 mg can be administered 
simultaneously with study drugs . Proton-pump inhibitors should not be ta ken before study drugs . 
bMay result in a decrease in the concentrations of study drug s.
cMay result in symptomatic bradycardia. Mechanism is currently unknown. The use of amiodarone is prohibited from 
60days prior to Day 1 through the end of treatment
d Coadministration of E/C/F/TAF or LDV/SOF with digoxin may increase the concentration of digoxin. Caution is warranted 
and therapeutic concentration monitoring of digoxin is recommended when coadministered with E/C/F/TAF or LDV/SOF. 
eUse with study drug may result in an increase in the concentration of rosuvastatin, which is associated with increased risk o f 
myopathy inclu ding rhabdomyolysis
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page47 18 December 2015Table5-2. Prior and Concomitant Medications – F/R/TAF + LDV/SOF
Drug Class Agents Disallowed Use With Caution
Acid Reducing AgentsaProton pump inhibitors, such as 
Esomeprazole, Lansoprazole, 
Omeprazole, Pantoprazole, 
RabeprazoleH2-Receptor Antagonists, Antacids
Cimetidine, Famotidine, Nizatidine, 
Ranitidine
Coadministration of H2 -receptor antagonists 
(H2RA) may cause significant decreases in 
RPV plasma concentrations (increase in 
gastric pH). H2RAs should only be 
administered at least [ADDRESS_763802] 4hours after F/R/TAF
Alkaline antacids: antacids (eg, 
aluminum or magnesium 
hydroxide, calcium carbonate)Antacids should be used with caution as 
coadministration may cause significant 
decreases in RPV plasma concentrations 
(increase in gastric pH). Antacids should 
only be administered either at least [ADDRESS_763803] 4 hours after F/R/TAF.
Antiarrhythmics Amiodaronec, Quinidine
Anticonvulsantsb Carbamazepi[INVESTIGATOR_050], Oxcarbazepi[INVESTIGATOR_050], 
Phenobarbital, Phenytoin
AntifungalsFluconazole, Itraconazole, Ketoconazole, 
Posaconazole, Voriconazole: may increase 
concentration of RPV.
AntimycobacterialsbRifapentine, Rifabutin, Rifampin
Cardiac Medications Digoxind
Corticosteroids: SystemicDexamethasone (more than a 
single dose)
Herbal/Natural SupplementsbSt. John’s Wort, Echinacea, Milk 
thistle (ie, silymarin), Chinese 
herb Sho-Saiko-To (or 
Xiao-Shai-Hu-Tang)
HMG-CoA Reductase InhibitorseRosuvastatin
Narcotic analgesicsMethadone
Clinical monitoring is recommended as 
methadone maintenance therapy may need 
to be adjusted in some patients upon 
coadministration with RPV
aIt is recommended to separate antacid and LDV/SOF administration by 4 hours. H2-receptor antagonists may be 
administered simultaneously with or staggered from LDV/SOF at a dose that does not exceed doses comparable to 
famotidine 40 mg twice daily .  Proton-pump inhibitor doses comparable to omeprazole 20 mg can be administe red 
simultaneously with study drugs . Proton-pump inhibitors should not be ta ken before study drugs . 
bMay result in a decrease in the concentrations of study drug s.
cMay result in symptomatic bradycardia. Mechanism is currently unknown. The use of amiodarone is prohibited from 
60days prior to Day 1 through the end of treatment
d Coadministration of F/R/TAF or LDV/SOF with digoxin may increase the concentration of digoxin. Caution is warranted 
and therapeutic concentration monitoring of digoxin is recommended w hen co-administered with F/R/TAF or LDV/SOF . 
eUse with study drug may result in an increase in the concentration of rosuvastatin, which is associated with increased risk o f 
myopathy including rhabdomyolysis.
FTC/RPV/TAF
Protocol GS -US-366-[ADDRESS_763804] (IMP)
The investigator is responsible for ensuring adequate accountability  of all used and unused IMP. 
This includes acknowledgement of receipt of each shipment of I MP (quantity  and condition). All 
used and unused IMP dispensed to subjects must be ret urned to the site.
IMPaccountability  records will be provided by [CONTACT_10869] (or equivalent documentation 
maintained by  [CONTACT_3452])to:
Record the date received and quantity  of IMP bottles
Record the date, subject number, subject initials, the IMP bottlenumber dispensed
Record the date, quantity of used and unused IMPreturned, along with the initials of the 
person recording the information.
5.5.1. I nvestigational M edicinal P roduct Return or Disposal
IMP return and disposal will be performed as outlined in Section 9.1.7.
FTC/RPV/TAF
Protocol GS -US-366-[ADDRESS_763805] research organization (CRO).
6.1. Subject Enrollment and Treatment Assignment
It is the responsibility ofthe Investigator to ensure that each subject is eligible for the study  
before enrollment. Please refer to Section 5.1for details about randomization and treatment 
assignment.
6.2. Pretreatment Assessments
6.2.1. Screening Visit
Subjects will be screened withi n 42 days prior to the Day  1 visit 
todetermine eligibility  for 
participation in the study . The following assessments will be completed and documented at 
screening:
Obtain written informed consent
Determine eligibility  including cirrhosis determination ( see Section 4.2fordetails)
If the presence of cirrhosis is determined, then appropriate diagnostic imaging (CT or 
Ultrasound) should be performed within 6 months of Day  1 to exclude the presence of 
hepatocellular carcinoma 
Obtain medical history , including: 
History of HIV-1 disease-related events and prior medications within 30days of the 
Screening visit.
Collection of historical HIV genot ype, if available
If HCV treatment -experienced, record the duration of the prior treatment and the ty pe of 
IFN+/-RBV+HCV PI [INVESTIGATOR_537613] . Record whether the subject had a Non-R esponse 
or Relapse/Breakthrough during prior treatment or was Treatment Intolerant .
■Non-Response: Subject did not achieve undetectable HCV RNA while on treatment. 
■ Relapse/Breakthrough: Subject achieved un detectable HCV RNA during treatment or 
within 4 weeks of the end of treatment, but did not achieve SVR
■Treatment Intolerant: Subject discontinued HCV treatment of a regimen containing 
IFNeither with or without RBV due to 
toxicity
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page50 18 December 2015Complete phy sical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)
Obtain vital signs measurement (blood pressure, pulse, respi[INVESTIGATOR_1487], and temperature)
Obtain 12 -lead ECG ( performed supi[INVESTIGATOR_050] )
Obtain height and w eight
Obtainurine samplesfor the following laboratory  analyses:
Urinalysisand urine chemistry
Obtain blood sample sfor the following laboratory anal yses:
Serum pregnancy  test (females of childbearing potential only ). If the test is positive, the 
subject will not be enrolled
.
Chemistry  profile: alkaline phosphatase, AST, ALT, total bilirubin, direct and indirect 
bilirubin, total protein, albumin, bicarbonate, BUN, calcium, chloride, creatinine, 
glucose, phosphorus, magnesium, potassium, sodium, and uric acid. 
Hematology profile: complete blood count (CBC) with differential and platelet count
Coagulation assessments : International Normalized Ratio ( INR), prothrombin time (PT), 
and activated partial thromboplastin time (APTT)
CD4+ cell count 
Plasma HIV -1 RNA (COBAS®TaqMan®HIV RNA Test, v2.0) 
Whole blood sample for HIV proviral genot ype analysis of archived resistance (if a 
historical genoty pe is not available )
Plasma HCV RNA (COBAS®TaqMan®HCV Quantitative Test, v2.0)
HCV genoty pe and subt ype, and IL28B genot ypetesting 
Serology for:
■HIV antibody  
■HBV core antibody  (HBcAb), surface antibody  (HBsAb), surface antigen (HBsAg), 
e-antibody(HBeAg), e -antibody (HBeAb), and HBV DNA
■HCV antibody
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page51 18 December 2015Obtain estimated glomerular filtration rate according to the Cockcroft- Gault formula (see 
Section4.2for details)
Obtain details of adverse events related to screening procedures
Review concomitant medications
Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to the 
clinic within 42days after the Screening visit for the Day  [ADDRESS_763806] all serious adverse events (SAEs), as well as any adverse events (AE) 
related to protocol -mandated procedures on the adverse events e lectronic case report form 
(eCRF).  All other untoward medical occurrences observed until dosing of study  drugs, including 
exacerbation or changes in medical history  are to be captured on the medica l history eCRF.  See 
Section7, Adverse Events and Toxicity  Management, for additional details .
6.2.2. Day [ADDRESS_763807] within 24 hours after the Day  1 visit.
ReviewAEs and changes in concomit ant medications
Complete phy sical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)
Obtain vital signs, including weight
Obtain urine samplesfor the following laboratory  analyses: 
Urinalysis and urine chemistry  
Urine pregnancy  test (females of childbearing potential only ). If the urine pregnancy  test 
is positive at Day  1, study drugs will not be dispensed. The positive result will be 
confirmed with a serum pregnancy  test. If the serum pregnancy  test is posi tive, the 
subject will not be able to participate.  
Renal tubular function assessments (collected fasted, no food or drink, except water, at 
least 8hours prior to blood collection) : retinol binding protein ,beta-2 microglobulin, 
urine albumin , and urine protein
Urine sample storage for possible additional clinical testing
FTC/RPV/TAF 
Protocol GS-US-366-1992 
[COMPANY_009] Sciences, Inc. 
• Obtain blood samples for the following laboratory analyses: 
-Chemistly profile 
- Hematology profile 
-Coagulation assessments Final 
Original 
-Metabolic assessments (collected fasted, no food or drink, except water, at least 8 hours 
prior to blood collection): glucose and lipid panel (total cholesterol, HDL, direct LDL, 
and triglycerides). 
• If the subject has not fasted prior to the visit, the visit may proceed, but the subject 
must retum within 72 hours in a fasted state to draw blood for the metabolic 
assessments. 
-CD4+ cell count 
-PlasmaHIV-1 RNA 
-Plasma HCV RNA 
-Serum bone safety assessments: (collected fasted, no food or drink, except water, at 
least 8 hours prior to blood collection) parathyroid hormone (PTH) and serum 25-0H 
Vitamin D 
• If the subject has not fasted prior to the visit, the visit may proceed, but the subject 
must retw.n within 72 hours in a fasted state to draw blood for these assessments. 
-Platelet and coagulation ftmction assessments may include: Soluble glycoprotein VI 
(sGPVI), P-selectin , soluble CD40 ligand, and D-dimer 
-Inflammation assessments may include: cystatin-C, IL 6, hs CRP, sCD14, sCD163, 
sTNF-Rl, and Lp-PLA2 
-Plasma storage samples for virology, safety, and/or PK testing 
-Sennn storage sample for possible additiona l clinical testing 
-[COMPANY_003] 
• Obtain estimated glomemla r filu·ation rate according to the Cockcroft-Gault f01mula (see 
Section 4.2 for details) 
CONFIDENTIAL Page 52 18 December 2015 
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page53 18 December 2015Complete questionnaires: s ubject is to read questionnaire b y her/himself and write/mark 
answers directl y onto the questionnaire s.
Adherence for HIV (VAS)
HIV Treatment Satisfaction Questionnaire –Statusversion(HIVTSQs)
Medical Outcomes Short Form -36 (SF-36)
Functional Assessment of Chronic Illness Therapy-Fatigue scale (FACIT- F)
Chronic L iver Disease Questionnaire (CLDQ -HCV)
Work Productivity  and Activity  Impairment Questionnaire: Hepatitis C, v2.0 (WPAI : 
Hepatitis C)
6.3. Randomization
Obtain subject number and randomize the subject via the IWRS. The subject number 
assignment and randomization may  be performed up to [ADDRESS_763808] eligibility  has 
been confirmed.
Dispense HIV study drugs . Subjects should initiate dosing of HIV study drugsafterDay1
visitassessments. I nitiation of treatment with the study drugs must take place within 24 hours 
after the Day 1 visit.
Subjects should also be counseled regarding the importance of adherence and taking their 
study drug daily with food at approximately  the same time each day .
6.4. Treatment Assessments
6.4.1. HIV and HCV Treatment Visits (Weeks 4, 6, 8, 12, 16, and 20)
The following assessments are to be completed at the end of Weeks4, 8, 12, 16, and 20, unless 
otherwise specified .The Week 6 visit is a laboratory  visit only  –please see Section 6.4.1.1for 
details.
All study visits are to be scheduled relative to the Day 1 visit date. Studyvisits are to be 
completed within ± 2 days of the protocol -specified visit date based on the Day  1 visit through 
Week 20. 
ReviewAEs and changes 
in concomitant medications
Perform s ymptom-directed phy sical examination as needed 
Obtain vital signs
, including weight
FTC/RPV/TAF 
Protocol GS-US-366-1992 
[COMPANY_009] Sciences, Inc. 
• Obtain urine samples for the following laboratoty analyses: 
-Urinalysis and urine c.hemistiy Final 
Original 
-Urine pregnancy test (females of childbearing potential only); positive urine pregnancy 
tests will be confmned with a sennn test. If the se1um test is positive, the subject will be 
discontinued. 
- Renal tubular function assessments (Weeks 4, 8, 12, and 20 only) 
-Urine sample stor age for possible additional clinical testing 
• Obtain blood samples for the following laboratoty analyses: 
-Chemistly profile 
-Hematology profile 
-Coagulation assessments 
-Metabolic assessments (Weeks 8 and 20 only) 
- CD4+ cell count 
-PlasmaHIV-1 RNA 
- Plasma HCV RNA (Weeks 8, 12, 16, and 20 only) 
-Samples for population PK (Weeks 4, 8, 12, 16, and 20) 
• Two (2) blood samples will be collected: 1) the predose sample should be drawn prior 
to observed study dmg dosing; 2) the postdose sample should be drawn between 15 
millS and 4 hours postdose. 
- Semm bone safety assessments (Weeks 4, 8, 12, and 20 only) 
-Platelet and coagulation function assessments (Weeks 4, 8, 12, and 20 only) 
-Inflammation assessments (Weeks 4, 8, 12, and 20 only) 
-Plasma storage samples for virology, safety, and/or PK testing 
-Se1um storage sample for possible additional clinical testing 
-[COMPANY_003] 
CONFIDENTIAL Page 54 18 December 2015 
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page55 18 December 2015Obtain estimated glomerular filtration rate according to the Cockc roft-Gault formula (see 
Section4.2for details)
Complete questionnaires (Weeks 8 and 20 only) : subject is to read questionnaire b y 
her/himself and write/mark answers directl y onto the questionnaire s.
VASfor HIV adherence
HIVTSQc–Change version 
SF-36
FACIT-F
CLDQ-HCV
WPAI: Hepatitis C
Subjects who meet the criteria for virologic rebound should be managed according to 
Management of HIV Virologic Failure (Section6.9)
Document study  drugsdispensation and accountability  for all study  drugs dispensed. Cou nsel 
all subjects regarding the importance of adherence and maintaining consistency  to study drug 
administration.
HIV study drugs are dispensed at every visit (with the exception of Week 6 
laboratory visit) .
HCV treatment will commence at Week 8, after determination of HIV suppression 
(<50copi[INVESTIGATOR_014]/mL) based on the Week 6 HIV-1 RNA value and tolerability  of HIV study  
drugs. Once confirmed, dispense HCV study drug (LDV/SOF) at Week s8, 12, and 16 
only.
[IP_ADDRESS]. Week 6 (Laboratory  Visit Only )
The Week 6 visit is a laboratory  visit only , to confirm HIV suppression prior to initiation of 
HCV treatment. 
The following will be performed and documented at the Week 6 visit:
Obtain blood sample s for plasma HIV -1 RNA testing
Plasma storage sample for s afety and virology  testing
FTC/RPV/TAF
Protocol GS -US-366-[ADDRESS_763809]-HCV Treatment Assessments ( Post-HCV 
Treatment Week s4 and 12) 
The following evaluations are to be completed at the end of 4 and 12 weeks after completion of 
HCV treatment (Post -HCV Treatment Weeks 4 and 12 visits, respectively ) and should be timed 
from the date of last administration of the HCV treatme nt. The Post -HCV Treatment Week4 
visit is to be completed ± [ADDRESS_763810] -HCV Treatment Week 12 visit isto be completed 
within ± 4days; however, u nless notified by  [CONTACT_10869], the Post -HCV Treatment Week [ADDRESS_763811] -HCV Treatment Week 12 visit.
The following assessments are to be completed :
ReviewAEs and changes in concomitant medications
Complete phy sical examination (Post-HCV Treatment Week 12 only) (urogenital/anorectal 
exams will be performed at the discretion of th e Investigator)
Perform s ymptom-directed phy sical examination as needed 
Obtain vital signs, including weight
Obtain urine samples for the following laboratory  analyses: 
Urinalysis and urine chemistry  
Urine pregnancy  test (females of childbearing potential only ); positive urine pregnancy  
tests will be confirmed with a serum test. If the serum test is positive, the subject will be 
discontinued.
Renal tubular function assessments (Post- HCV Treatment Week 12only)
Urine sample storage for possible additional clinical testing
Obtain blood sample s for the following laboratory anal yses:
Chemistry profile 
Hematology  profile
Coagulation assessments 
Metabolic assessments (Post-HCV Treatment Week 12 only)
CD4+ cell count
FTC/RPV/TAF 
Protocol GS-US-366-1992 
[COMPANY_009] Sciences, Inc. 
-Plasma HIV -1 RNA 
-Plasma HCV RNA 
-Semm bone safety assessments (Post-HCV Treatment Week 12 only) Final 
Original 
-Platelet and coagulatio n function assessments (Post-HCV Treatment Week 12 only) 
-Inflammation assessments (Post-HCV Treatment Week 12 only) 
-Plasma storage samples for virology, safety, and/or PK testing 
-Sennn storage sample for possible additional clinical testing 
-[COMPANY_003] 
• Obtain estimated glomemlar filtration rate according to the Cockcroft-Gault f01mula (see 
Section 4.2 for details) 
• Complete questionnaires (Post-HCV Treatment Week 12 only): subject is to read 
questionnaire by [CONTACT_39420]/himself and write/mark answers directly onto the questionnaires. 
-VAS for HIV adherence 
- HIVTSQc- Change version 
-SF-36 
-FACIT-F 
-CLDQ-HCV 
-WP AI: Hepatitis C 
• Subjects who meet the criteria for virologic rebound should be managed according to 
Management of HIV Virologic Failure (Section 6.9) 
• Document study chugs dispensatio n and accmmtabil ity for all HIV study drugs dispensed. 
Counsel all subjects regarding the importance of adherence and maintaining consistency to 
HIV study dmg administration. 
CONFIDENTIAL Page 57 18 December 2015 
FTC/RPV/TAF
Protocol GS -US-366-[ADDRESS_763812]-treatment Assessments
6.5.1. Early Study Drug Dis continuation (ESDD) Visit
Early study drug discontinuation during Part 1 (Day  1through W eek 8):
If the subject discontinues HIV study  drugdosing in Part 1, the subject will be discontinued from 
the study and will not continue to Part [ADDRESS_763813] will be asked to return to the 
clinic within 72 hours of stoppi[INVESTIGATOR_580864], followed b y the 30-Day 
Follow-Up visit. 
Early study drug discontinuation during Part 2 (after initiation of HCV treatment ):
If the subject discon tinues HCV study  drug dosing onlyprior to completing the 12 -week HCV 
treatment, the following will occur:
Be asked to return to the clinic within 72 hours of stoppi[INVESTIGATOR_580865]. 
Remain in the study to return for follow -up visits [ADDRESS_763814] dose of 
LDV/SOF, as described in Section 6.4.2.
Continue to receive HIV study  drugs (see ESDD procedures below).
If the subject discontinues HIV study  drug dosing only, the 
following will occur:
Be asked to return to the clinic within 72 hours of stoppi[INVESTIGATOR_580866]. 
HIV regimen may  be changed , after discussion with the Medical Monitor. The new HIV 
regimen should be designed to allow continued dosing of LDV/SOF. LDV/SOF should be 
continued unless an HIV regimen cannot be constructed that would allow coadministration 
with the new HIV regimen. 
Remain in the study  to complete the 12 -week HCV treatment (see Section 6.4.1) and follow -
up visits [ADDRESS_763815] dose of LDV/SOF, as described in Sec tion6.4.2.
If the subject discontinues both HI V and HCV study  drug dosing, the following will occur:
Be asked to return to the clinic within 72 hours of stoppi[INVESTIGATOR_580867]. 
Remain in the study  to return for follow- up visits [ADDRESS_763816] dose of 
LDV/SOF, as described in Section 6.4.2.
FTC/RPV/TAF 
Protocol GS-US-366-1992 
[COMPANY_009] Sciences, Inc. Final 
Original 
At the ESDD Visit, any evaluation s showing abnormal results indicating that there is a 
possible or probable causal relationship with the study drugs, should be repeated weekly 
(or as often as deemed prudent by [CONTACT_737]) until the abnormality is resolved, 
returns to baseline, or is otherwise explained. 
The following evaluations are to be completed at the ESDD Visit: 
• Review of AEs and changes in concomitant medications 
• Complete physical examination (urogenitaVanorectal exams will be perf01med at the 
discretion of the Investigator) 
• Obtain vital signs, including weight 
• Obtain 12-lead ECG (perfom1ed supi[INVESTIGATOR_050]) 
• Obtain urine samples for the following laboratory analyses: 
- Urinalysis and urine chemistry 
- Urine pregnancy test (females of childbearing potential only); positive urine pregnancy 
tests will be confnmed with a se1um test. 
-Urine sample storage for possible additional clinical testing 
• Obtain blood samples for the following laboratory analyses: 
-Chelnistly profile 
-Hematology profile 
- CD4+ cell count 
-PlasmaHIV-1 RNA 
-Plasma HCV RNA 
-Plasma storage samples for virology, safety, and/or PK testing 
PD 
• Obtain estimated glomemlar filn·ation rate according to the Cockcroft-Gault f01mula (see 
Section 4.2 for details) 
CONFIDENTIAL Page 59 18 December 2015 
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page60 18 December 2015Complete questionnaires: s ubject is to read questionnaire b y her/himself and write /mark 
answers directl y onto the questionnaire s.
VASfor HIV adherence
HIVTSQc–Change version
SF-36
FACIT-F
CLDQ-HCV
WPAI: Hepatitis C
HIV-1 genotype/phenotype resistance testing for subjects with unconfirmed virologic 
rebound with HIV -1 RNA value ≥ 400 copi[INVESTIGATOR_014]/mL .
Perform s tudydrug accountability :
For subjects that 
discontinue during Part 1 of the study , perform stud y drug 
accountability  on HIV study  drugs.
For subjects that discontinue during Part 2 of the study , perform stud y drug 
accountability  for HIV and HCV study  drugs. 
■If the subject discontinues HCV study  drug and is stay ing on HIV study  drug, 
dispense HIV stud y drug until the last study  visit. 
■If the subject discontinues HIV study  drug, HCV study  drug will be dispensed at the 
scheduled visits a
s described in Section 6.4.[ADDRESS_763817] -HCV Trea tment Week 12 visit will be 
required to return to the clinic 30 day safter the completion of study  for the 30
-Day Follow-Up 
visit.
Subjects who permanently discontinue HIVstudy drug in Part 1 of the study  will be asked to 
return to the clinic after the completion of the ESDD visit for a 30 -Day Follow-Up visit.
A±6 days window may  be usedto schedule this visit . The following evaluations are to be 
completed at th is visit:
Review of AEs and changes in concomitant medications
Perform s ymptom-directed phy sical examination 
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page61 18 December 2015Obtain vital signs measurement , including weight
Obtain urine samplesfor the following laboratory  analyses:
Urinalysis and urine chemistry
Urine pregnancy test (females o f childbearing potential only );positive urine pregnancy  
tests will be confirmed with a serum test. 
Obtain blood sample sfor the following laboratory anal yses:
Chemistry  profile
Hematology  profile
CD4+ cell count
Plasma HI V-1RNA
Plasma HCV RNA
At the 30-Day Follow-Up Visit, any  evaluations showing abnormal results indicating that there is 
a reasonable possibility  of a causal relationship with the study  drug will be repeated weekly  
(oras often as d eemed prudent by  [CONTACT_737]) until the abnormality  is resolved, returns to 
baseline, or is otherwise explained.
6.6. Assessments for Premature Discontinuation from Study
If a subject discontinues study  dosing (for example, as a result of an AE), every  attempt should 
be made to keep the subject in the study  and continue to perform the required study -related 
follow-up and procedures ( refer to Appendix 2). If this is not possible or acceptable to the 
subject or investigator, the subject may  be withdrawn from 
the study and asked to return for the 
ESDD Visit followed by  [CONTACT_941] 30-Day Follow-UpVisit.
6.7. Criteria for Discontinuation of Study Treatment
Study medication may  be discontinued in the following instances:
Intercurrent illness that would, in the judgment of the Investigator, affect assessments of 
clinical status to a significant degree.
Unacceptable toxicity , as defined in the toxicity  management section of the protocol, or 
toxicity that, in the judgment of the Investigator, compromises the ability  to continu e 
study-specific procedures or is considered to not be in the subject’s best interest
Lack of efficacy  (virologic failure)
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page62 18 December 2015Subject request to discontinue for an y reason
Subject noncompliance
Pregnancy  during the study ; refer to Appendix 5
Discontinuation of the study  at the request of [COMPANY_009] Sciences, a regulatory agency  or an 
institutional review board or independent ethics committee (I RB/IEC)
6.8. Other Assessments
6.8.1. Blood and Urine Storage
Aportion of the blood drawn and urine collected at all visits (except Screening, Week 6, 30-Day 
Follow-Up, or Unscheduled ) will be frozen and stored. From subjects who provide additional 
consent, a portion of the blood draw at Day 1, Weeks 4, 8, 20, Post-HCV Treatment Week 12, 
and ESDD visit will be frozen and stored. These stored samples may  be used by  [CONTACT_580882], HIV -1 infection and its 
associated conditions, or clinical laboratory  testing to provide additional safety  data. No human 
genetic testing will be pe rformed without express consent of the stud y subjects. At the 
conclusion of this study , these samples may  be retained in storage for [COMPANY_009] for a period of up to 
15 years.
6.8.2. Bone Safety and Inflammation
For all subjects, blood will be collected for selected assessments ofbone safety, including serum 
25-OHVitamin D and PTH. Assessments for inflammation may  include: cystatin-C, IL 6, hs 
CRP, sCD14, sCD163, 
sTNF-R1, and Lp -PLA2. Collections will be made at Day  1, Weeks 4, 8, 
12, 20, and Post -HCV Treatment Week 12.
6.8.3. Markers of Platelet Function and Coagulation
For all subjects, blood will be collected for selected assessments of platelet function and 
coagulation that 
may include:soluble gl ycoprotein VI (sGPVI), P -selectin, soluble CD40 ligand
and D
-dimer. Collections will be made at Day  1, Weeks 4, 8, 12, 
20, and Post -HCV Treatment 
Week 12.
6.8.4. Markers of Renal Tubular Function
For all subjects, urine will be collected for selected assessments of renal tubular function that 
mayincluderetinol binding protein ,beta-[ADDRESS_763818]-HCV Treatment Week 12.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page63 18 December [ZIP_CODE].9. HIV Virologic Failure
Subjects who experience virologic rebound (VR), as defined below, will be considered to have 
virologic failure.
Subjects will be considered to have virologic rebound if at any visit has an HIV -1 RNA value 
50copi[INVESTIGATOR_014]/mL confirmed at the next scheduled or unscheduled visit (2 to 4 weeks later).
6.9.1. Management of HIV Virologic Rebound
The management of vir ologic rebound during Part 1 and Part 2 are different; subjects that have 
confirmed virologic failure during Part [ADDRESS_763819] virologic failure in Part 2 will be managed as described below.
Management of HIV -1 RNA ≥ 50copi[INVESTIGATOR_014]/mL  during Part 1 (Day  1 through Week 8)
All HIV-1 RNA values ≥ 50 copi[INVESTIGATOR_014]/mL should be discussed with the M edical Monitor. 
If the viral load at any visitis ≥ 50 copi[INVESTIGATOR_014]/mL , HIV-[ADDRESS_763820] with HIV -1 RNA
≥ 50copi[INVESTIGATOR_014]/mL .
Upon confirmation of HIV -1 RNA ≥
50 copi[INVESTIGATOR_014]/mL, potential causes of virologic failure 
should be documented :
Adherence 
Concomitant medication
Comorbidities (eg, active substance abuse, depression, other intercurrent illnesses)
If virologic rebound is confirmed at the scheduled or unscheduled visit and the HIV- 1 RNA 
value is ≥ 400 copi[INVESTIGATOR_014]/mL, the blood samples from that visit will be used for HIV-1 
genotype/phenotype testing.
If virologic failure is confirmed during Part 1 (regardless of detection of HIV drug 
resistance), the subject should be discontinued from HIV study drug and have the ESDD an d 
30 Day Follow-Up visit.
If the viral load at the Week 6 visit is ≥ 50 copi[INVESTIGATOR_014]/mL (and this is nota confirmation of 
virologic failure value) ,the HIV-[ADDRESS_763821] be completed prior to the Week 8 visit (which subsequently  means that the Week 8 visit 
will be delay ed). The subject should not start Part 2 (nor should the subject start L DV/SOF 
therapy) until the repeat HIV
-1RNA value is available .  If the repeatHIV-1 RNA confirms 
virologic rebound ( ≥ 50 copi[INVESTIGATOR_014]/mL ), then the subject will be discontinued from HI V study 
drugs as above.  If the repeatHIV-1RNA is < 50 copi[INVESTIGATOR_014]/mL , then the subject may  proceed to 
Part 2 and ma intain the same visit schedule. Initiation of L DV/SOF therapy  must occur 
within 2to 4 weeksof the original visit window of the Week 8 visit. 
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page64 18 December 2015Management of HIV -1 RNA ≥ 50copi[INVESTIGATOR_014]/mL  during Part 2 (at or after Week 8)
If the viral load at any visitis ≥ 50 copi[INVESTIGATOR_014]/mL , HIV-[ADDRESS_763822] with HIV -1 RNA
≥ 50copi[INVESTIGATOR_014]/mL .
Upon confirmation of HIV -1 RNA ≥
50 copi[INVESTIGATOR_014]/mL, potential causes of virologic failure 
shouldbe documented. Assessment should include:
Adherence 
Concomitant medication
Comorbidities (eg, active substance abuse, depression, other intercurrent illnesses)
All subjects with confirmed virologic failure should be discussed with the M edicalMonitor.
If virologic rebound is confirmed at the scheduled or unscheduled visit and the HIV -1 RNA 
value is ≥ 400 copi[INVESTIGATOR_014]/mL, the blood samples from that visit will be used for HIV-1 
genotype/phenotype testing.
If genotypic/phenot ypic resistance to study drug is do cumented, HIV study  drugs 
(E/C/F/TAF or F/R/TAF) should be discontinued. 
If the HIV study drugs (E/C/F/TAF or F/R/TAF) are discontinued, a new HIV regimen 
should be constructed, after discussion with the M edical Monitor. The new HIV regimen 
should be desi gned to allow continued dosing of LDV/SOF. LDV/SOF should be continued 
unless an HIV regimen cannot be constructed that would allow coadministration with the 
new HIV regimen.
If no resistance is detected from genot ype/phenot ype testing, the 
subject may  remain on HI V 
study drugsand anHIV-1 RNA should be repeated ( [ADDRESS_763823] with viral load
≥ 50copi[INVESTIGATOR_014]/mL ). Investigators should carefully  evaluate the benefits and risks of remaining on 
HIV study drugfor each individual subject and document this assessment in the source 
documents . Investigators who opt to discontinue HIV study drugs for an individual subject must 
discuss with the Medical Monito r priorto study drugdiscontinuation .
Please refer to Figure6-1for the management of subjects who meet the criteria for virologic 
rebound.
FTC/RPV/TAF
Protocol GS -US-366-[ADDRESS_763824] will remain on their current HIV regimen.
b.If virologic rebound is confirmed, and the HIV -1 RNA is ≥ 400 copi[INVESTIGATOR_014]/mL, the HIV -1 genotype and phenotype (reverse 
transcriptase , integrase, and protease) will be analyzed.
c.Based on the results of the genotype/phenotype assays, the subject will remain on HIVstudy drugs or study drugs will be 
discontinued. If genotypi[INVESTIGATOR_007]/phenotypi[INVESTIGATOR_580868], a new ARV regimen may be configured at the discretion of the Investigator.
d.If no resistance detected, HIV -1 RNA will be repeated (2 to 4 weeks later). Investigator reviews HIV study drug 
continuation/discontinuation options and discuss with Medical Monitor prior to study drug discontinuation .
e.A new ARV regimen will be configured, after discussion with the Medical Monitor.  The new HIV regimen should be 
designed to allow conti nued dosing of LDV/SOF. LDV/SOF should be continued unless an HIV regimen cannot be 
constructed that would allow coadministration with the new HIV regimen .
6.9.2. Subjects with ≥ 400 copi[INVESTIGATOR_014]/mL of HIV -[ADDRESS_763825] Study Visit
Subjects with HI V-1 RNA < 50 copi[INVESTIGATOR_014]/m L could subsequently  experience unconfirmed blips of 
HIV-1 RNA ≥ 400 copi[INVESTIGATOR_014]/mL . Such subjects will be anal yzed for resistance if the unconfirmed 
rebound happens at thePost-HCV Treatment Week 12visit, or last visit while receiving HIV 
study drugs (or with in 72hours of discontinuation of study  treatment).

FTC/RPV/TAF
Protocol GS -US-366-[ADDRESS_763826] oppi[INVESTIGATOR_580869] -based treatment stoppi[INVESTIGATOR_327102]:
Confirmed > 1 log 10increase from on treatmen t nadir
HCV RNA ≥ LLOQ through [ADDRESS_763827] occur no later than 2 weeks after 
an initial observation indicating virologic failure during the HCV on treatment phase.  
All subjects who te rminate LDV/SOF treatment early  will complete the ESDD visit (see 
Section6.5.1) and post-HCV treatment follow-up visits at [ADDRESS_763828] dose of 
LDV/SOF (see Section 
6.4.2).
6.11. End of Study
End of study  is defined as completion of the 
Post-HCV Treatment Week [ADDRESS_763829] has completed/terminated their participation in the study , long-term care for the 
subject will remain the responsibility  of their primary  treating ph ysician.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page67 18 December [ZIP_CODE]. ADVERSE EVENTS AND TO XICITY MANAGEMENT
7.1. Definition sof Adverse Events , Adverse Reactions, and Serious Adverse 
Events
7.1.1. Adverse Events
An adverse event (AE) is any  untoward medical occurrence in a clinical study subject 
administered a medicinal product,which does not necessarily  have a causal relationship with th e
treatment. An AE can therefore be an y unfavorable and/or unintended sign, sy mptom, or disease 
temporally  associated with the use of a medicinal product, whether or not considered re lated to 
the medic inal product. AEs may also include pre -or post-treatment complications that occur as a 
result of 
protocol specifiedprocedures, overdose ,drug abuse/misuse reports , or occupational 
exposure.Preexisting events that increase in severity or change in nature during or as a 
consequence of participation in the clinical study  will also be considered AEs.
An AE does not include the following:
Medical or surgical procedures such assurgery, endoscopy ,tooth extraction, andtransfusion.
The condition that ledto the procedure may  be an adverse event and must be reported.
Pre-existing diseases, conditions, or laboratory  abnormalities present or detected beforethe 
screening visit that donot worsen
Situations where an untoward medical occurrence has not occurred (e.g .,hospi[INVESTIGATOR_10800] , socialand/or convenience admissions)
Overdose without clinical sequelae ( see Section 7.7.1)
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol- associated procedure is not an 
AE. It is considered to be pre -existing and should be documented on the medical history  
CRF.
7.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at an y dose, results in the following :
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
In-patient hospi[INVESTIGATOR_580870]/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page68 18 December 2015Persistent or significant disability /incapacit y
A congenital anomal y/birth defect
A medically important eventor reaction: such events may  not be immediately  
life-threatening or result in death or hospi[INVESTIGATOR_10802]. Medical and 
scientific judgment mustbe exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of m edically i
mportant e vents include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_1838]; and development of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a m edically i
mportant e vent and subject to expedited reporting 
requirements.
7.1.3. Clinical Laborator y Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , and urinalysis) that 
require medical or surgical intervention or lead to IMP interruption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (eg, electrocardiogra m, x-rays, vital signs) that are 
associated with signs and/or symptoms must be recorded as an AE or SAE if they  meet the 
definition of an AE or SAE as described in Sections 7.1.1and 7.1.2. If the laboratory  
abnormality is part of a sy ndrome, record the s yndrome or diagnosis (eg, anemia), not the 
laboratory  result (ie, decreased hemoglobin).
For specific information on handling of clinical laboratory  abnormalities in this study , please 
refer to Sectio n 7.5
.
7.2. Assessment of Adverse Events and Serious Adverse E vents
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality and severity , and for final review and confirmation of accuracy  of event
information 
and assessments.
7.2.1. Assessment of Causality for Study Drugs and Pr ocedures
The investigator or qualified subinvestigator is responsible for assessing t he relationship to IMP
therapy using clinical judgment and the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the IMP. ForSAEs, an 
alternative causality must be provided (eg, pre -existing condition, underl ying disease, 
intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that the event may  have been caused by [CONTACT_580883].
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page69 18 December 2015It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of adverse event reporting. 
The relationship to study  procedures (eg, invasive procedures such as venipuncture or biops y) 
should be assessed using the following considerations:
No: Evidence existsthat the adverse event has an etiology  other than the study  procedure.
Yes:The adverse event occurred as a result of protocol procedures, (eg,venipuncture)
7.2.2. Assessment of Severity
Severity should be recorded and graded according to the GSI Grading Scale for Severit y of 
Adverse Events and Laboratory  Abnormalities ( Appendix 4). For adverse events associated with 
laboratory  abnormalities, the event should be graded on the basis of the clinical severity in the 
context of the underly ing conditions; this may  or may not be in agreement with the grading of 
the laboratory abnormality .
7.3. Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to Gilea d
Requireme nts for collection prior to study  drug initiation:
After informed consent, but prior to initiation of study  medication, the following t ypes of events 
should be reported on the eCRF: all SAEs and adverse events related to protocol
-mandated 
procedures.
Adverse Events
Following initiation of study  medication, collect a ll AEs, regardless of cause or relationship, 
until [ADDRESS_763830] consents to 
participate in the stud y (ie, signing the informed consent) and throughout the duration of the 
study, including the protocol -required post treatment follow -up period, must be reported to the 
eCRF database and [COMPANY_009] Drug Safet y and Public Health (DSPH) as instructed. This also 
includes an y SAEs resulting from protocol- associated procedures performed after informed 
consent is signed.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page70 18 December 2015Investigators are not obligated to activel y seek SAEs after the protocol defined follow up period; 
however, if the investigator learns of an y SAEs that occur after stud y participation has concluded 
and the event is deemed relevant to the use of IMP, he/she should promptly  document and report 
the event to [COMPANY_009] DSPH.
All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the 
eCRF completion guideline.
Electronic Serious Adverse Event (eSAE) Reporting Process
Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to [COMPANY_009] DSPH within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.
If for any reason it is not possible to record the SAE information electronically , ie, the eCRF 
database is unable to be a ccessed,record the SAE on the paper serious adverse event 
reporting form and submit within 24 hours as described above.
GSI Drug Safet y and Public Health (DSPH): Fax: +[PHONE_12052]
E-mail: [EMAIL_11049]
As soon as it is possible to do so, anySAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.
If an SAE has been reported via a paper form because the eCRF database has been locked, no 
further action is necessary
.
For fatal or life-threatening events, copi[INVESTIGATOR_3103], autops y reports, and other 
documents are also to be submitted by  e-mail or fax when requested and applicable. 
Transmission of such documents should occur without personal subject identification , 
maintaining the traceability  of a document to the subject identifiers.
Additional information may  be requested to ensure the timel y completion of accurate 
safetyreports.
Any medications necessary  for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s eCRF and the event description section of the SAE form .
All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the
eCRF completion guideline.
7.4. [COMPANY_009] Reporting Requirements
Dependingon relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regulations (CFR), the EU Clinical Trials Directive (2001/20/EC) and relevant updates, 
and other country -specific legislation or regulations, [COMPANY_009] may  berequired to expedite to 
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page71 18 December 2015worldwide regulatory  agencies reports of SAEs, serious adverse drug reactions (SADRs) ,or 
suspected 
unexpected serious adverse reactions (S[LOCATION_003]Rs). In accordance with the EU Clinical 
Trials Directive (2001/20/EC), [COMPANY_009] or a specified de signee will notify  worldwide regulatory  
agenciesand the relevant IECin concerned Member States of applicable S[LOCATION_003]Rs as outlined in 
current regulations.
Assessment of e xpectedness forSAEs will be determined by  [CONTACT_122035] . 
All investigators will receive a safet y letter notifying them of relevant S[LOCATION_003]R reports associated 
with any study IMP. The investigator should notify the IRB or IEC of S[LOCATION_003]R reports as soon as 
is practical, where this is required b y local regulatory agencies, and in accordance with the local 
institutional policy .
7.5. Toxicity Management 
All clinical and clinicall y significant labor atory toxicities relating to HIV ARV agents will be 
managed according to uniform guidelines detailed in Appendix 3.
Management for toxicity  should be differentiated between ARV and HCV medications.
Grade [ADDRESS_763831] discontinuation, unless such a delay  is not consistent with good medical practice.
Clinical events and clinically  significant laboratory  abnormalities will be graded according to 
the 
Table for GSI Grading Scale for Severity  of Adverse Events and Laboratory  
Abnormalities (Appendix 4).
When restarting investigational medicinal product following resolution of the adverse event, 
the investigational medicinal product should be restarted at full dose afterdiscussion with the 
Medical Monitor.
Any recurrence of the investigational medicinal product-related Grade
[ADDRESS_763832].
Any questions regarding toxicity  management should be directed to the Medical Monitor
7.5.1. Grades [ADDRESS_763833] at the discretion of the Investigator.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page72 18 December [ZIP_CODE].5.2. Grade 3 Laboratory Abnormality or Clinical Event
For Grade [ADDRESS_763834].
For a Grade [ADDRESS_763835] should be withheld until the toxicity  returns to Grade2.
If a laboratory  abnormality  recurs to Grade3 following rechallenge with investigational 
medicinal product and is considered related to investigational medicinal product, then 
investigational medicinal product should be permanently  discontinued and the subject 
managed according to local practice. Recurrence of laboratory  abnormalities considered 
unrelated to investigational medicinal product may not require permane nt discontinuation.
7.5.3. Grade 4 Laboratory Abnormality or Clinical Event
For a Grade [ADDRESS_763836]. A clinically  significant Grade 4 laboratory  abnormalit y that is not confirmed b y 
repeat testing should be managed according to the algorithm for the new toxicity  grade.
Investigational medicinal product may  be continued without dose interr uption for a clinically  
non-significant Grade 4 laboratory  abnormality  (eg, Grade 4 creatinine kinase (CK) after 
strenuous exercise or trigly ceride elevation that is nonfasting or that can be medically  
managed) or a clinical event considered unrelated to i nvestigational medicinal product
7.5.4. Management of Potential Nephrotoxicity
Estimated glomerular filtration rate, according to the Cockcroft -Gault (eGFR CG)formula for
creatinine clearance, will be followed post -baseline during the study . All subjects with estimated 
eGFRCG< 30 mL/min must have serum creatinine measured again within 3 calendar day s of 
receipt of results. At the time of this repeat serum creatinine assessment, Cystatin C will also be 
measured and the eGFR by  [CONTACT_9289]-EPI (cystatin C) will be calculat edand compared with the 
baseline measurement. Any  subjects who have an estimated eGFR CG< 30 mL/min that also 
experience > 20% reduction in eGFR by  [CONTACT_9289]-EPI (cystatin C) from baseline or who have other 
clinical and/or laboratory evidence of acute renal fai
lure will be discussed with the 
MedicalMonitor and may  discontinue from study  drugs.
For subjects with eGFR CG<30mL/min who are not discontinued based on toxicity management 
procedures above and considered to have stable renal function per Principal Investigator [INVESTIGATOR_580871], it is not mandatory  to repeat eGFR assessments within 3 days.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page73 18 December 2015CKD-EPI (cystatin C) formula adjusted for age and sex:
eGFR (mL/min/1.73 m2) = 133 ×min(Scys/0.8, 1)−0.499× max(Scys/0.8, 1)1.328×0.996Age
[×0.932 if 
female],
where Scy s is serum cy statin C (mg/L), min (Scy s/0.8,1) indicates the minimum of Scys/κor 1, 
and max (Scy s/0.8,1) indicates the maximum of Scy s/κor 1.
All subjects with a change from baseline serum creatinine of ≥ 0.4 mg/dL  must have serum
creatinine repeated, with a concurrent urinal ysis and urine chemistry , within two weeks of
receipt of results. If a subject has a confirmed change from baseline serum creatinine of
≥ 0.4 mg/dL, the Medical Monitor should be notified and a consultation with a nephrologist 
should be obtained.
7.6. Stoppi[INVESTIGATOR_580872]/SOF unless the 
investigator believes that immediate action is warranted to ensure the continued safet y of the 
subject.
Administration of study  drugmay be discontinued in the event of a clinical or laboratory  event. 
There is no option for dose reduction of LDV/SOF. If LDV/SOF FDC is stopped due to tox icity, 
it must not be restarted. The ESDD visit should be completed after discontinuation of L DV/SOF. 
The Post-HCV Treatment Week [ADDRESS_763837] stop HCV study  treatment :
Elevation of ALT and/or AST > 5x Day 1 or nadir, confirmed by  [CONTACT_199607]
Abnormal elevation of ALT > 3 x Day 1 and total bilirubin > [ADDRESS_763838], confirmed by  
[CONTACT_199607]
Elevation of ALT > [ADDRESS_763839] ing
Any Grade3 or greater rash associated with constitutional sy mptoms
Any Grade4 adverse event or laboratory  abnormality  assessed (and confirmed by  [CONTACT_580884]) as related to L DV/SOF
7.7. Special Situations Reports
7.7.1. Definitions of Special Situat ions
Special situation reports includ e all 
reports of medication error, abuse, misuse, overdose , reports 
of adverse events associated with product complaints ,and pregnancy  reports regardless of an 
associated AE.  
FTC/RPV/TAF
Protocol GS -US-366-[ADDRESS_763840] labelling (as it applies to the daily  dose of the subje ct in 
question). In cases of a discrepancy  in drug accountability , overdose will be established only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy  except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as 
complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.  
7.7.2. Instructions for Reporting Special Situations
[IP_ADDRESS]. Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study  subjects that are identified after 
initiation of study  medication and throughout the study , including the pos t study drug follow -
up 
period, to the [COMPANY_009] DSPH using the pregnancy  report form within [ADDRESS_763841] (ie, partner pregnancies).
Refer to S ection7.3and the eCRF completion guidelines for full instructions on the mechanism 
of pregnancy  reporting.
The pregnancy  itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  without medical reasons.
Any premature termination of pregnancy  (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported with in 24hours as an 
SAE. The underl ying medical reason for this procedure should be recorded as the AEterm.
A spontaneous abortion is alway s considered to be an SAE and will be reported as described in 
Sections7.1.2and7.3. Furthermore, an y SAE occurring as an adverse pregnancy outcome post 
study must be reported to [COMPANY_009] DSPH.
FTC/RPV/TAF
Protocol GS -US-366-[ADDRESS_763842] should receive appropriate monitoring and care until the conclusion of the 
pregnancy . The outcome (of both female subject pregnancies and male subject’s partner 
pregnancies) should be reported to [COMPANY_009] DSPH using the pregnancy  outcome report form. If 
the end of the pre gnancy occurs after the study  has been completed, the outcome should be 
reported directl y to [COMPANY_009] DSPH. [COMPANY_009] DSPH contact [CONTACT_10856]: 
GSI Drug Safet y and Public Health (DSPH): Fax: +[PHONE_12052]
E-mail: [EMAIL_11049]
Refer to Appendix 5for Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements
.
[IP_ADDRESS]. Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to [COMPANY_009] DSPH within [ADDRESS_763843] of situations that involve study  IMPand/or [COMPANY_009] concomitant 
medications, but do not apply to non-[COMPANY_009] concomitant medications. 
Special situations involving non-[COMPANY_009] concomitant medications donot need to be reported on 
the special situations report form; however, for special situations that result in AEs due to a 
non-[COMPANY_009] concomitant medication, the AE should be reported on the AE form. 
Any inappropriate use of concomitant medications prohibited by  [CONTACT_10857] “misuse,” but may  be more appropriately  documented as a protocol deviation.
Refer to Section 7.3and the eCRF completion guidelines for full in structions on the mechanism 
of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE report form. Details of the sy mptoms and 
signs, clinical management, and outcome will be reported, when available .
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page76 18 December [ZIP_CODE]. STATISTICAL  CONSIDER ATIONS
8.1. Analysis Objectives and Endpoints
8.1.1. Analysis Objectives
The primary  objective of this study  is as follows:
To evaluate ef ficacy of LDV/SOF as measured b y the proportion of subjects achieving HCV
RNA below the lower limit of quantification (LLOQ) [ADDRESS_763844] dose of 
LDV/SOF ( SVR 12).
The secondary  objectives of this study  are:
To determine the proportion of subjects achieving HCV RNA below LLOQ [ADDRESS_763845] dose of LDV/SOF ( SVR 4);
To evaluate maintenance of HIV -1 RNA suppression after switc hing to E/C/F/TAF or 
F/R/TAF 24 weeks from the start of the F/TAF- based regimen ; 
To evaluate the safet y and tolerability  of switching to E/C/F/TAF or F/R /TAF from the 
current ARV therap y in virologicall y-suppressed, HIV -
1/HCV co-infected subjects;
To evaluate the safety and tolerability  of12 weeks of treatment for HCV with L DV/SOF in 
virologicall y-suppressed, HIV -1/HCV co-infected subjects who switched to E/C/F/TAF or 
F
/R/TAF.
8.1.2. Primary Endpoint
The primary  efficacy endpoint is SVR12 (HCV RNA < LLOQ 12 weeks after completion of 
LDV/SOF treatment ).
8.1.3. Secondary Endpoint
Secondary  efficacy endpoints are: 
SVR4 (HCV RNA < LLOQ 4 weeks after completion of LDV/SOF treatment ).
The proportion of subjects with HI V-1 RNA ≥ 50 copi[INVESTIGATOR_014]/mL  
(virologic failure) 24 weeks 
after start of the F/TAF -based regimen using modified FDA snapshot algorithm
Note:Most often,[ADDRESS_763846]-HCVTreatment Week 4 
visit
Secondary  safety endpoint is:
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page77 18 December 2015Grades 1 through 4 adverse events after switch to E/C/F/TAF or F/R/TAF throughout the 
study and during coadministration with LDV/SOF t reatment.
8.1.4. Other Endpoints of Interest
No other endpoints of interest will be considered.
8.2. Analysis Conventions
8.2.1. Analysis Sets
[IP_ADDRESS]. Efficacy
HIV Full Analy sis Set: The primary  analysis set for HIV efficacy analysis will be the HIVfull
analysis set (HIV FAS) and is defined as all subjects randomized and who received at least one 
dose of F/TAF-based regimen . 
HCV Full Anal ysis Set: The primary  analysis set for HCV 
efficacy analysis will be the HCV full 
analysis set (HCV FAS) and is defined as allsubjectswho received at least one dose of
LDV/SOF.
Subjects will be grouped acco rding to the treatment they were randomized to.
[IP_ADDRESS]. Safety
HIV Safety Analysis Set: The primary  analysis set forHIVsafety analyses will be the HIV 
safety analysis set and is defined as all subjects randomized to the study  and who received at 
leastone dose of F/TAF-based regimen. 
HCV Safet y Analysis Set: The primary  analysis set for HCV safety  analyses with 
coadministration with the F/TAF -based regimen in Part 2 will be the HCV safet y analysis set and 
is defined as all subjects who received at leastone dose of LDV/SOF.
All data collected during treatment will be included in the safet y summaries.Subjects will be 
grouped according to the treatment they  actually received.
[IP_ADDRESS]. Pharmacokinetics
The PK anal ysis set will include all subjects who were randomi zed and have received at least one 
dose of either the F/TAF -based regimen (at Week 4) or coadministration of the F/TAF -based 
regimen and LDV/SOF, and for whom concentration data of an y analyte of interest are available. 
The PK anal ysis set will be used for listing PK concentration data and summaries .
FTC/RPV/TAF
Protocol GS -US-366-[ADDRESS_763847] descriptive methods
using the safet y analysis set. Demographic and baseline measurements will b e summarized by  
[CONTACT_1570] ( E/C/F/TAF ; F/
R/TAF) and overall. 
Summaries will include sex, race/ethnicit y,age, height, weight and bo dy-mass index.
Baseline data will include a summary  of risk factors for HIV -
1 infection and HCV infection, and 
enrollment distribution.
For categorical demographic and baseline characteristics, a Cochran-Mantel-Haenszel ( CMH) 
test will be used to compare treatment groups. For continuous demographic and baseline 
characteristics, a Wilcoxon rank sum test will be used to compare the treatment groups.
8.4. Efficacy Analysis
8.4.1. Primary Analysis
The primary  efficacy endpoint is SVR12 (HCV RNA < LLOQ 12 weeks after discontinuation of 
therapy). The primary analysis will be performed after all enrolled subjects have been followed 
through post -HCVtreatment Week 12 or discontinued from study .
In the primary  efficacy analysis, the SVR12 rate will be compared to the performance goal of 
88% by [CONTACT_256653]- sided exact one -sample binomial test at the 0.[ADDRESS_763848] increasing SVR rates in recent years; and 
the general appeal of using a fixed clinically  relevant threshold as a measure of treatment benefit 
of LDV/SOF.
The null (H 0) and alternative (H 1) hypotheses used to a ssess superiorit y of LDV/SOF relative to
the performance goal of 88% are:
H0: SVR12= 88%
H1: SVR12 ≠ 88 %
The primary  efficacy analysis will also include the construction of an associated two- sided exact 
95% CI.
Furthermore, SVR12 will also be summarized by [CONTACT_580885] (F/TAF- based 
regimen).
8.4.2. Secondary Analyses
The methods to assess proportion of HIV -1 RNA ≥50 copi[INVESTIGATOR_014]/mL  
(virologic failure) 24 weeks 
after start of the F/TAF -based regimen using a modified FDA snapshot a lgorithm will be 
provided in detail in the Statistical Analy sis Plan.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page79 18 December 2015The changes from baseline in CD4+ count at Week [ADDRESS_763849]-HCV Treatment Week 12 will be 
summarized using descriptive statistics.
The analysis of SVR4 will be summarized using similar methods as for the primary  endpoint.
8.5. Safety Analysis
All safety data collected on or after the date F/TAF-based ARV regimen was first dispensed up 
to the date of last dose of study drug(s) (either F/ TAF-based regimen alone or in combination 
with LDV/SOF) plus 30 day swill be summarized overall,according 
to the study  drug(s)
received. 
Additionally , safety data collection on or after the first dose of LDV/SOF until the last dose of 
LDV/SOF plus 30 day s (ie,during coadministration of HIV/HC V study drugs), will also be 
summarized.
Data for pretreatment and post-last-dose-plus-30-dayswill be included in data listings. 
8.5.1. Extent of Exposure
A subject’s extent of exposure to each study  drugwill be generated from the corresponding study  
drugadministration data. Duration of exposure to each study drug will be expressed as the 
number of weeks between the first and last dose 
foreachstudy drug, inclusive, regardless of 
temporary  interruptions in study drugadministration.
Dosing information for individual subjects will be listed.
8.5.2. Adverse Events
Clinical and laboratory  adverse events (AEs) will be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA). Sy stem Organ Class (SOC), High -Level Group Term 
(HLGT), High -Level Term (HL T), Preferred Term (PT),and Lower -Level Term (LLT) will be 
attached to the clinical database.
HIV treatment
-emergent AEs are events that meet one of the following criteria up to 30 days 
after the permanent discontinuation of HIV study drug(s):
AEs with onset dates on or after the first dose date of HIV study drug(s) and no later than 
30days after permanent discontinuation of HI V study drug(s), or,
AEs that result in permanent study  drug discontinuation of HIV study drug(s).
The number and percentage of subjects with treatment -emergent AEs(by[CONTACT_580886]) will be 
summarized as described in Section 8.5. A similar definition will be used to define HCV 
treatment -emergent AEs during coadministration of HIV/HCV study drugs.Additional 
summaries will include summaries for AE s by [CONTACT_479], Investigator’s assess ment of relationship to 
studydrug, and effect on study  drug dosing.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page80 18 December 2015All treatment -emergent and non-treatment emergent AEs will be included in a data listing.
8.5.3. Laboratory Evaluations
Selected laboratory  datawill be summarized us ing only observed data. Absolute values and 
changesfrom baseline at all scheduled time points will be summarized.
Graded laboratory  abnormalities will be defined using the GSI Grading Scale for severity  of 
Adverse Events and Laboratory  Abnormalities ( Appendix 4).
Incidence of treatment -emergent laboratory  abnormalities, defined as values that increase at least 
one toxicity  grade from baseline at an y time post baseline up to the date of last dose of HIV 
study drug(s)plus 30 days, will be summarized as described in Section 8.5
. Similarly, 
treatment -emergent abnormalities during coadministration of HIV/HCV studydrugs will also be 
summarized. If baseline data are missing, then any graded abnormality  (ie, at least a Grade 1) 
will be considered treatment emergent. Themaximum toxici ty grade will be summarized by  
[CONTACT_10862].
Laboratory  abnormalities that occur before the first dose of HIV study drug(s)or after the subject 
hasbeen discontinued from HIVstudy drug(s)plus 30 day s will be included in a data listing .
8.5.4. Other Safety Evaluations
Weight will be summarized by  [CONTACT_765]. 
Safety ECGs will be listed and summarized for subjects in the Safet y Analysis Set. The number 
and percent of subjects with abnormal safet y ECG will be summarized by  [CONTACT_765].
8.6. Pharmacokinetic Analysis
Population PK assessments may  be conducted for some of the relevant analy tes: TAF, TFV, 
RPV, FTC, EVG, COBI, LDV, SOF ,or GS-331007. Population PK assessment s will be 
summarized in a separate report .
8.7. Biomarker Analysis
The renal, vascular and inflammatory  markers (see Sections 6.8.2 –6.8.4for details) will be 
summarized by  [CONTACT_72082]. The difference in change 
from baseline in these biomarkers between thetreatment groups (E/C/F/TAF and F/R/TAF) will 
be tested using Wilcoxon rank sum test .
8.8. Sample Size
A sample size of 240subjects will provide at least 85 % power to detect an improvement of at 
least 
6percentage points in SVR12 rate from the performance g oal of 88% by  [CONTACT_2329] a two- sided 
exactone
-sample binomial test at significance level of 0.05.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page81 18 December [ZIP_CODE]. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Toky o,Venice, Hong Kong, and 
SouthAfrica), International Conference on Harmonisation (I CH) guidelines, or with the laws and 
regulations of the country in which the research is conducted, whichever affords the greater 
protection to the study  subject. These stan dards are consistent with the European Union Clinical 
Trials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.
The investigator will ensure adherence to the basic principles of Good Clinical Practice, as 
outlined in 21 CFR312, subpart D, “Responsibilities of Sponsors and Investigators,” 21 CFR, 
part50, and 21 CFR, part 56, ”Institutional Review Board” .
The investigator and all applicable sub -investigators will comply  with 21CFR, Part 54, 
”Financial Disclosure b y Clinical Investigators ”,providing documentation of their financial 
interest or arrangements with [COMPANY_009], or proprietary interests in the investigational drug under 
study. This documentation must be provided prior to the investigator’s (and any  
sub-investigator’s) participation in the study . The investigator and sub -investigator agree to 
notify [COMPANY_009] of an y change in reportable interests during the stud y and for [ADDRESS_763850] (IRB)/Independent Ethics Committee (IEC) 
Review and 
Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompany ing material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study  used to obtain 
informed consent) to an IRB/IEC. The investigator will not begin an y study subject activities 
until approval from the IRB/IEC has been documented and provided as a letter to the 
investigator.
Before implementation, the investigator will submit to and receive documented approval from 
theIRB/IECany modifications made to the protocol or any accompan ying material to be 
provided to the subject after initial IRB/IEC approval, with the exception of those necessary  to 
reduce immediate risk to study  subjects.
9.1.3. Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study  and before undertaking an y study-related procedures. The 
FTC/RPV/TAF
Protocol GS -US-366-[ADDRESS_763851] current IRB-or IEC-approved consent form for documenting 
written informed consent. Each informed consent (or assent as applicable) will be appropriatel y 
signed and dated b y the subject or the subject’s legally authorized representative and the person 
conducting the consent discussion, and also by  [CONTACT_537114] b y IRB/IEC or
local requirements.
9.1.4. Confidentiality
The Investigator must assure that subjects’ anon ymity will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only  subject initials, date of birth, another 
unique identifier (as allowed by [CONTACT_1769]) and an identification code will be recorded on an y 
form or biological sample submitted to the Sponsor ,or laboratory . Laboratory  specimens must 
be labeled in such a way  as to protect subject id entity while allowing the results to be recorded to 
the proper subject. Refer to specific laboratory  instructions NOTE:The Investigator must keep a 
screening log showing codes, names, and addresses for all subjects screened and for all subjects 
enrolled i n the trial. Subject data will be processed in accordance with all applicable regulations .
The investigator agrees that all information received from [COMPANY_009], including but not limited to the 
investigator brochure, this protocol, eCRF, the IMP, and any  other study information, remain the 
sole and exclusive property  of [COMPANY_009] during the conduct of the study  and thereafter. This 
information is not to be disclosed to any  third party  (except employ ees or agents directl y 
involved in the conduct of the study  or asrequired by  [CONTACT_2371]) without prior written consent from 
[COMPANY_009]. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure b y any employee or agent of the stud y site to any  third party  or otherwise into the 
public domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the stud y 
to be fully  documented and the study data to be subsequently  verified. These documents should 
be classified into at least the following two categories: (1)investigator’s study  file, and 
(2)subject clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, eCRF and query  forms, 
IRB/IEC and governmental approval with correspondence, informed co nsent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:
Subject identi fication (name, date of birth, gender);
Documentation that subject meets eligibility  criteria, ie, history , physical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);
Documentation of the reason(s) a consented subjec t is not enrolled
Participation in study  (including study  number);
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page83 18 December 2015Study discussed and date of informed consent;
Dates of all visits;
Documentation that protocol specific procedures were performed;
Results of efficacy  parameters, as required b y the protocol;
Start and end date (including dose regimen) of IMP, including dates of dispensing and return;
Record of all adverse events and other safety parameters (start and end date, and including 
causality and severity );
Concomitant medication (including start an d end date, dose if relevant; dose changes);
Date of stud y completion and reason for earl y discontinuation, if it occurs.
All clinical study  documents must be retained b y the investigator until at least [ADDRESS_763852] approval of a marketing application in 
an ICH region (ie, [LOCATION_002], Europe, or Japan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no application is filed or if the application is not 
approved for such indication, until [ADDRESS_763853] been received.  Subsequent to data entry , a study monitor will perform source 
data verification within the electronic d ata capture ( EDC)system.Original entries as well as any  
changes to data fields will be stored in the audit trail of the sy stem.  Prior to database lock (or 
any interim time points as described in the clinical data management plan), the investigator will
use his/her log in credentials to confirm that the forms have been reviewed, and that the entries 
FTC/RPV/TAF
Protocol GS -US-366-[ADDRESS_763854] or updating the original entry , and providing the 
reason for the update (eg, data entry  error).At the conclusion of the trial, [COMPANY_009] will provide the 
site with a read-onl y archive cop y of the data entered by [CONTACT_10867]. This archive must be stored in 
accordance with the records retention requirements outlined in Section 9.1.5.
9.1.7. Investigational Medicinal Product Accountability and Return
[COMPANY_009] recommends that used and unused IMP supplies be returned to the shippi[INVESTIGATOR_10803]. The stud y monitor will provide instructions for return. If 
return is not possible, the study monitor will evaluate each s tudy center’s IMPdisposal 
procedures and provide appropriate instruction for destruction of unused IMPsupplies. I f the site 
has an appropriate standard operating procedure (SOP) for drug destruction as determined b y 
[COMPANY_009] Qualit y Assurance (QA) , the site may destroy used (empt yor partially  empty) and unused 
IMPsupplies in accordance with th atsite’s approved SOP. A copy  of the site’s approved 
SOP 
will be obtained for central files. 
If IMPis destroyed on site, the investigator must maintain accurate r ecords for all IMP
destroyed. Records must show the identification and quantity  of each unit destroy ed, the method 
of destruction, and the person who disposed of the IMP. Upon study  completion, copi[INVESTIGATOR_10804]. Another copy  will be returned to [COMPANY_009].
The study  monitor will review IMP supplies and associated records at periodic intervals .
9.1.8. Inspections
The investigator will make available all source documents and other records for this trial to 
[COMPANY_009]
’s appointed study monitors , to IRB/IEC, or to regulatory  authority or health authorit y 
inspectors.
9.1.9. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations described in this protocol.
9.2.
Sponsor Responsibilities
9.2.1. Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study  subjects, may  be 
made only  by [CONTACT_10866]. The investigator must submit all protocol modifications to the IRB/IEC in 
accordance with local requirements and receive documented IRB/IEC approval before 
modifications can be implemented.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page85 18 December [ZIP_CODE].2.2. Study Report and Publications
A clinical study  report (CSR) will be prepared and provided to the regulatory  agencies.[COMPANY_009] 
will ensure that the repor t meets the standards set out in the I CH Guideline for Structure and 
Content of Clinical Study Reports (I CHE3). Note that an abbreviated report may  be prepared in 
certain cases. 
Investigators in this study  may communicate, orally  present, or publish in s cientific journals or 
other scholarl y media only after the following conditions have been met: the results of the stud y 
in their entiret y have been publicly disclosed b y or with the consent of [COMPANY_009] in an abstract, 
manuscript, or presentation form or the study has been completed at all study  sites for at least 
2years
The investigator will submit to [COMPANY_009] any  proposed publication or presentation alongwith the 
respective scientific journal or presentation forum at least 30 day s before submission of the 
publication or presentation. 
No such communication, presentation, or publication will include [COMPANY_009]’s confidential 
information (see Section 9.1.4
).
The investigator will comply  with [COMPANY_009]’s request to delete references to its confidential 
information (oth er than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary .
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, e.g. attendance at I nvestigator's Meetings.  If required under the applicable statutory  
and regulatory  requirements, [COMPANY_009] will capture and disclose to Federa l and State agencies any  
expenses paid or reimbursed for such services, including an y clinical trial payments, meal, travel 
expenses or reimbursements, consulting fees, and any  other transfer of value.
9.3.2. Access to Information for Monitoring
In accordance with 
regulations and guidelines, the study  monitor must have direct access to the 
investigator’s source documentation in order to verify  the accuracy of the data recorded in the 
CRF/eCRF.
The monitor is responsible for routine review of the CRF /eCRFat regular intervals throughout 
the study to verify adherence to the protocol and the completeness, consistency , and accuracy  of 
the data being entered on them. The monitor should have access to an y subject records needed to 
verify the entries on the CRF /eCRF. The investigator agrees to cooperate with the monitor to 
ensure that an y problems detected through any  type of monitoring (central, on site) are resolved.
FTC/RPV/TAF
Protocol GS -US-366-[ADDRESS_763855] of an y inspection or audit.
9.3.4. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at any time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory  authority(ies), IRBs, and IECs. In terminating the study , [COMPANY_009] and the investigator 
will assure that adequate consideration is given to the protection of the subjects’ interests.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page87 18 December 201510. REFERENCES
Backus LI, Boothro yd DB, Phillips BR, Belperio P, Halloran J, Mole L A. A sustained virologic 
response reduces risk of all -cause mortality  in patients with hepatitis C. Clin 
Gastroenterol Hepatol 2011;9 (6):509 -16 e1.
Bhagani S, Sulkowski MS, Cooper C, Kwo PY, Kowdley  K, Mertens M, et al. 
Ledipasvir/Sofosbuvir is Safe and Effective for the Treatment of Patients with 
Genotype 1 Chronic HCV Infection in Both HCV  Mono -and HCV/HIV Co -
infected Patients [Abstract: 386]. European AIDS Clinical Society  (EACS); 2015 
21-24 October; Barcelona, Spain. 
Campsmith ML , Rhodes PH, Hall HI, Green TA. Undiagnosed HIV prevalence among adults 
and adolescents in the [LOCATION_002] at the end of 2006. J Ac quir Immune Defic 
Syndr 2010;53 (5):619- 24.
Carrat F, Bani -Sadr F, Pol S, Rosenthal E, L unel-Fabiani F, Benzekri A, et al. Pegy lated 
interferon alfa -2b vs standard interferon alfa -2b, plus ribavirin, for chronic 
hepatitis C in HI V-
infected patients: a rand omized controlled trial. JAMA 
2004;292 (23):2839-48.
Chesney M. Factors affecting adherence to antiretroviral therap y. Clin Infect Dis. 2000;30 
(Suppl 2):S -171-S6.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 
1976;16:31 -41.
Custodio J, Doy le E, Pang PS, Das M, H. C, Ma G, et al. Lack of Drug Interactions between 
Boosted and Unboosted Tenofovir Alafenamide -based Antiretroviral Single 
Tablet Regimens (Emtricitabine/Rilpi[INVESTIGATOR_12979]/Tenofovir Alafenamide and 
Elvitegravir /Cobicistat/Emtricitabine/Tenofovir Alafenamide) and the anti
-HCV 
Single Tablet Regimen Ledipasvir/Sofosbuvir [Abstract 727]. I nfectious Diseases 
Society of America (IDSA); 2015 7-11 October; San Diego, CA. 
Deng LP, Gui XE, Zhang YX, Gao SC, Yang RR. Impa ct of human immunodeficiency  virus 
infection on the course of hepatitis C virus infection: a meta- analysis. World J 
Gastroenterol 2009;15 (8):[ADDRESS_763856] JW, McQuillan GM, et al. Chronic 
Hepatitis C Virus Infection in the [LOCATION_002], National Health and Nutrition 
Examination Survey  2003 to 2010. Ann I ntern Med 2014;160:293 -300.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page88 18 December 2015Department for Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral 
Agents in HIV -1-Infected Adults and Adolescents. Developed b y the DHHS 
Panel on Antiretroviral Guidelines for Adults and Adolescents –A Working 
Group of the Office of AIDS Research Advisory  Council (OARAC). Downloaded 
from http://aidsinfo.nih.gov/guidelines on 5/11/2015. L ast Updated 08 Apri l, 
2015.
Gay CL, Mayo AJ, Mfalila CK, Chu H, Barry  AC, Kuruc JD, et al. Efficacy of NNRTI -based 
antiretroviral therap y initiated during acute HIV infection. AIDS 2011;25 (7):941 -
9.
[COMPANY_009] Sciences Canada Inc. SOVALDI® (Sofosbuvir) Tablets [ADDRESS_763857] M onograph.  
Mississauga, ON. December 2013:
[COMPANY_009] Sciences Inc. SOVALDI® (sofosbuvir) tablets, for oral use. US Prescribing Information.  
Foster City , CA. December 2013:
[COMPANY_009] Sciences Inc. HARVONI® (ledipasvir and sofosbuvir) tablets, for oral use. US 
Prescribing Information.  Foster City , CA. Revised November 2015:
[COMPANY_009] Sciences Inc. HARVONI®(ledipasvir and sofosbuvir) tablets, for oral use. US 
Prescribing Information.  Foster City , CA October 2014:
[COMPANY_009] Sciences Limited. SOVALDI [ADDRESS_763858] 
Characteristics.  County  Cork Ireland. January 2014.  2014:
Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human 
immunodeficiency  virus infection on the course of hepatitis C virus infection: a 
meta-analysis. Clin Infect Dis 2001;33 (4):562 -9.
HCV Guidelines. Recommendations for Testing, Managing, and Treating Hepatitis C.  2015.
Laguno M, Murillas J, Blanco J L, Martinez E, Miquel R, Sanchez -Tapi[INVESTIGATOR_41570], et al. 
Peginterferon alfa -2b plus ribavirin compa red with interferon alfa -2b plus 
ribavirin for treatment of HIV/HCV co -infected patients. AI DS 2004;18 (13):F27 -
36.
Lavanchy D. Evolving epi[INVESTIGATOR_142058] C virus. Clin Microbiol Infect 2011;17 (2):107-
15.
Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of 
mortality from viral hepatitis in the [LOCATION_002] between 1999 and 2007. Ann 
Intern Med 2012;156 (4):271 -8.
Mahajan R, Xing J, L iu SJ, Ly KN, Moorman AC, Rupp L , et al. Mortality  Among Persons in 
Care With Hepatitis C Virus Infection: The Chronic Hepatitis Cohort Study  
(CHeCS), 2006- 2010. Clin I nfect Dis 2014.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page89 18 December 2015Mills A, Arribas JR, Andrade -Villanueva J, DiPerri G, Van Lunzen J, Koenig E, et al. Switching 
from tenofovir disoproxil fumarate to tenofovir alafena mide in antiretroviral 
regimens for virologically suppressed adults with HIV- 1 infection: a randomised, 
active-controlled, multicentre, open- label, phase 3, non- inferiority study 
[Supplementary  Webappendix]. L ancet 2015.
Mocroft A, Vella S, Benfield TL , Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of 
mortality across Europe in patients infected with HIV- 1. EuroSIDA Study  Group. 
Lancet 1998;352 (9142):1725-30.
Myers RP, Liu M, Shaheen AA. The burden of hepatitis C virus infection is growing: a Canadian 
population -based study  of hospi[INVESTIGATOR_368396] 1994 to 2004. Can J 
Gastroenterol 2008;22 (4):381 -7.
Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, et al. Ledipasvir and 
Sofosbuvir for HCV in Patients Coinfected with HIV- 1. N Engl J Med 2015.
Nakano T, Lau GM, Sugiyama M, Mizokami M. An updated analysis of hepatitis C virus 
genotypes and subt ypes based on the complete coding region. Liver Int 2012;32 
(2):339-45.
Palella FJ, Delaney  KM, Moorman AC, L oveless MO, Fuhrer J, Satten GA, et al. Declining 
Morbidity  and Mortalit y Among Patients With Advanced Human 
Immunodeficiency  Virus Infection. N Eng J Med 1998;338 (13):853-60.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of 
antiretroviral agents in HIV-1-infected adults and adolescents. Department of 
Health and Human Services. 1 –239. Available at  
http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf . Accessed 
August 22.  2012.
Salmon-Ceron D, Lewden C, Morlat P, Bevilacqua S, Jougla E, B onnet F, et al. L iver disease as 
a major cause of death among HIV infected patients: role of hepatitis C and B 
viruses and alcohol. J Hepatol 2005;42 (6):799-
805.
Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, et al. Tenofovir alafenamide versus 
tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and 
emtricitabine, for initial treatment of HIV -1 infection: two randomised, double -
blind, phase 3, non -inferiority  trials. Lancet 2015.
Selik RM, Mokotoff ED, Branson B, Owen SM, Whitmore S, Hall HI . Morbidity  and Mortalit y 
Weekly Report (MMWR). Revised Surveillance Case Definition for HIV 
Infection -[LOCATION_002] 2014. Centers for Disease Control and Prevention,  2014.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page90 18 December 2015Smith BD, Morgan ML, Beckett GA, Falck -Ytter Y, Holtzman D, Teo CG, et al. 
Recommendations for the Identification of Chronic Hepatitis C Virus Infection 
Among Persons Born During 1945 –1965. Centers for Disease Control and 
Prevention MMWR  August, 2012.
Staples CT, Jr., Rimland D, Dudas D. Hepatitis C in the HIV (human immu nodeficiency  virus) 
Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study  (HAVACS): the 
effect of coinfection on survival. Clin Infect Dis 1999;29 (1):150-
4.
Sterne J, Hernán M, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long -term effectivene ss 
of potent antiretroviral therapy in preventing AIDS and death: a prospective 
cohort study . Lancet 2005;366 (9483):378-84.
Stone VE JJ, Tolson J, Pi[INVESTIGATOR_44768] T. Potential impact of once dail y regimens on adherence to HAART 
[abstract]. . 40th Annual Meeting of the Infectious Disease Societ y of America; 
[ADDRESS_763859] 24-27; Chicago. pp. p.129, Abstract 486.
The Joint United Nations Programme on HIV/AIDS (UNAIDS). Regional Fact Sheet 2012. 
North America, Western and Central Europe.  2012.
Thomas DL. The challenge of he patitis C in the HIV -infected person. Annu Rev Med 
2008;59:473 -85.
Torriani FJ, Rodriguez -Torres M, Rockstroh JK, Lissen E, Gonzalez -Garcia J, L azzarin A, et al. 
Peginterferon Alfa -2a plus ribavirin for chronic hepatitis C virus infection in 
HIV-infected p atients. N Engl J Med 2004;351 (5):438 -50.
World Health Organigation (WHO). World Health Organization, UNAIDS, UNI CEF. Global 
HIV/AIDS Response: Epi[INVESTIGATOR_580873]. Progress Report 2011.  2011.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page91 18 December 201511. APPENDIC ES
Appendix 1.Investigator Signature [CONTACT_10882] 2.Study Procedures Table
Appendix 3.Management of Clinical and Laboratory A dverse Events (HIV ARV Agents only)
Appendix 4.GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Appendix 5.Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements
Appendix 6.CDC Classification Systems, AIDS -Indicator Conditions
FTC/RPV rr AF 
Protocol GS-US-366-[ADDRESS_763860] 
FOSTER CITY, CA [ZIP_CODE] 
STUDY ACKNOWL EDGEMENT 
A Phase 3b Randomized , Open-label , Controlled Study of the Efficacy, Safety and 
Tolerability of 12 Weeks ofLedipasvir /Sofosbuvir (LDV/SOF) Treatment for HIV/HCV 
Co-infected Subjects who Switch to Elvitegravir /Cobicistat /Emtricitabine /Tenofovir 
Alafenamide (E/CJF/TAF) or Emtricitabine/Rilpi[INVESTIGATOR_580874] (F/R/TAF) 
prior to LDV/SOF HCV Treatment , the HIV/HCV Co-STARs study (Co-infection 
treatment with Single Tablet Antiviral Regimens) 
GS-US-366-1992 Original Protocol, 18 December 2015 
~~;sa~;~~~ i has been approved by [CONTACT_204984] p P'D <io,nabrre...dnc-'"'""n" 
Richard Haubrich, MD 
Richard Haubrich (Printed) 
Medical Monitor 
[ADDRESS_763861] this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I will provide all study personnel under my supervision copi[INVESTIGATOR_10805] , Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigato r Name (Printed) Signature 
[CONTACT_279395] 92 18 December2015 
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page93 18 December 2015Appendix 2. Study Procedures Tabl e
ScreeningaDay 1bEnd of Weekc
Part 1
On Treatm entEnd of Weekc–Part [ADDRESS_763862]-HCV Treatm ent
4 6 8 12 16 20 4 12
Written Informed Consent X
Medical History X
Liver Cirrhosis Determination X
Concomitant Medications X X X X X X X X X X X
Adverse Events X X X X X X X X X X X
Complete Physical Examination X X X X
Symptom -DirectedPhysical ExaminationfX X X X X X X
Vital Signs & Weight X X X X X X X X X X X
Height X
12-Lead ECG (performed supi[INVESTIGATOR_050]) X X
Urinalysis &Urine Chemistry X X X X X X X X X X X
Urine Storage Sample X X X X X X X X X
Urine Pregnancy TestgX X X X X X X X X X
Serum Pregnancy TestgX
Chemistry ProfilehX X X X X X X X X X X
Hematology ProfileiX X X X X X X X X X X
Coagulation AssessmentsjX X X X X X X X X
Metabolic AssessmentskX X X X
CD4+ Cell Count X X X X X X X X X X X
FTC/RPV/TAF 
Protocol GS-US-366-1992 
[COMPANY_009] Sciences, Inc. 
Plasma HIV -1 RNA 
HIV -1 Provu·al Genotype1 
HlV -1 Genotype/Phenotypem 
Plasma HCV RNA 
HCV Genotype & Subtype 
HCV IL28B Genotype 
HIV, HBV & HCV Serologie sn 
Evaluation s of Bone & Renal Safety, 
Inflammation and Platelet and 
Coagulation Ftmction° 
Plasma Storage SampleP 
Senun Storage Sample!' rpo I I 
Estimated GFRCGr 
Population PK5 
Health Related Questiormaires1 
Randomiza tion 
Study Drug Dispensation and 
Accountabilityu Screening• Day1b 
X X 
X 
X X 
X 
X X 
X 
X 
X 
X 
X X 
X 
X 
X 
a Evaluation s to be completed within 42 days prior to the Day 1 visit End ofWeE'kc 
Part 1 
On TrE-atment 
4 6 
X X 
X 
X X 
X 
X 
X 
X 
X End of Week<- Part [ADDRESS_763863]-HCV Treatment 
8 12 16 20 4 12 
X X X X X X 
X X X X X X 
X X X X 
X X X X X X 
X X X X X X 
X X X 
X X X X X X 
X X X X 
X X X 
X X X X X X 30-Day 
Follow-Upd 
X 
X Final 
Original 
Esnn• 
X 
X 
X 
X 
X 
X 
X 
X 
X 
xv 
b Subjects will be dispensed HIV study dmos only at the Day 1 visit; initiation ofHIV treatment with the study dmgs must take place within 24 hours after the Day 1 visit. 
c All study visits are to be scheduled relative to the Day 1 visit date. Visit windows are± [ADDRESS_763864]-HCV Treatment We.ek 4 visit, and 
± [ADDRESS_763865]-HCV Treatment Week 12. 
CONFIDENTIAL Page 94 18 December 2015 
FTC/RPV IT AF 
Protocol GS-US-366-1992 
[COMPANY_009] Sciences, Inc. 
d For the purpose of scheduling a 30-Day Follow-Up Visit, a± [ADDRESS_763866]. 
h Chemistry profile: alkaline phosphatase, AST, ALT, total bilirubin, direct and indirect bilirubin, total protein, albumin, bicarbonate, BUN, calcium, chloride, creatinine, 
glucose, phosphorus, magnesium, potassium, sodium, and uric acid. At visits in which metabolic assessments are to be performed, analyses of glucose will be done as part of 
the fasting metabolic assessments and not as part of the chemistry profile 
CBC with differential and platelet count 
J Coagulation assessments: International Normalized Ratio (INR), prothrombin time (PT), and activated partial thromboplastin time (APTT) 
k Metabolic assessments (collected fasted, no food or drink, except water, at least 8 hours prior to blood collection): glucose and lipid panel (total cholesterol, HDL, direct LDL, 
and triglycerides ) 
If a historical genotype report is not available, whole blood sample for proviral genotype analysis of archived resistance 
m HIV-1 genotype/phenotype resistance testing for subjects with unconfirmed virologic rebound with HIV-1 RNA value 2' 400 copi[INVESTIGATOR_014]/mL 
n Serology testing includes HIV and HCV antibody, and HBV core antibody (HBcAb), surface antibody (HBsAb), surface antigen (HBsAg), e-antibody (HBeAg), e-antibody 
(HBeAb), andHBVDNA. 
o Blood for bone safety, parathyroid (PTH) and serum OH-25 vitamin D; Inflammation may include cystatin-C, IL-6, hs-CRP, sCD14, sCD163, sTNF-lR, and Lp-PLA2; 
Platelet and coagulation function may include soluble glycoprotein VI (sGPVI), P-selectin, soluble CD40 ligand, and D-dimer will be collected. Urine for renal safety, 
including retinol binding protein, beta-2-microglobulin, urine albumin, and urine protein will be collected. Samples will be collected fasted. If the subject has not fasted prior 
to the visit, the visit may proceed, but the subject must return within 72 hours in a fasted state. 
p Plasma storage samples for safety, virology, and/or PK testing. Serum storage samples for possible additional clinical testing. 
q [COMPANY_003] 
r EstrmateoGFR: accoriling to the COckcrott-liaii.It lormula'for creatmme clearance (see Secuoo4~2 tOr"detmis) 
s Two (2) blood samples will be collected: 1) the predose sample should be drawn prior to observed study drug dosing; 2) the postdose sample should be drawn between 
15 mins and 4 hours postdose 
Health related questionnaires: adherence for HIV (VAS), HIVTSQs- Status version (at Day 1 only), HIVTSQc -Change version (at all other visits), SF-36, FA CIT -F, 
CLDQ-HCV, and WPAI: Hepatitis C. 
u Part 1: HIV study drugs are dispensed after all Day 1 assessments are completed and randomization occurred, and through the duration of the study. Part 2: After 
determination ofHIV suppression( < 50 copi[INVESTIGATOR_014]/mL) based on the Week 6 HIV-1 RNA value and tolerability ofHIV study drugs, LDV/SOF will be dispensed at Weeks 8, 12, 
and [ADDRESS_763867]-HCV Treatment Week 12: drug accountability only; study drug will not be dispensed at this visit. 
v If subjects discontinue during Part 1, only drug accountability will be performed; study drug will not be dispensed at this visit. In Part 2, if subject discontinues LDV/SOF but 
still continues with HIV study drug, HIV study drug will be dispensed until the last study visit. If subject discontinues HIV study drug but still continues with LDV/SOF, 
LDV/SOF will be dispensed. If subject discontinues both HIV and HCV study drugs, only drug accountability will be performed; no dispensation will occur at this visit. 
CONFIDENTIAL Page 95 18 December 2015 
FTCIRPV/TAF 
Protocol GS-US-366-1992 Final 
[COMPANY_009] Sciences, Inc. Original 
Appendix 3. Management of Clinical and Laboratory Adverse Events (HIV ARV Agents only) 
Grade 1 
L_ ______ G_r_a_d_e-2------~~ Ll _______ G_r_a_d_e_3 ______ _JI Ll ----------G--r-a-d e--4----------~ 
~ ~ 
l\fay continue Repeatlab to 
dosing at the confirm toxicity 
discretion of the grade 
investigator 
If confirmed and possibly and/or probably related to 
investigational medicinal products: 
1. Withhold investigational medicinal products until s Grade [ADDRESS_763868] 
weekly until a return 
to baseline or is 
othenvise explained 
If Grade 3 or 4 recurrence that is considered unrelated to 
investigational medicinal products, continue all investigational 
medicinal products at the same dose at the discretion ofthe 
investigator 
CONFIDENTIAL Page 96 18 December 2015 
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page97 18 December 2015Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Antiviral Toxicity Grading Scale Version: 01 April 2015
HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Hemoglobin
HIV POSITIVE
Adult and Pediatric 57 Days8.5to10.0g/dL 
85 to 100 g/L7.5to 8.5g/dL 
75to85g/L6.5 to 7.5g/dL 
65 to 75g/L6.5g/dL
65g/L
HIV NEGATIVE
Adult and Pediatric 57 Days 10.0to10.9g/dL
100to109g/L
OR
Any decrease from Baseline
2.5 to 3.5g/dL
25 to 35g/L9.0 to 10.0g/dL
90 to 100g/L
OR
Any decrease from Baseline
3.5 to 4.5g/dL
35 to 45g/L7.0 to 9.0g/dL
70 to 90g/L
OR
Any decrease from Baseline
4.5g/dL
45g/L7.0g/dL
70g/L
Infant, 36 –56 Days
(HIV POSITIVE OR
NEGATIVE )8.5 to 9.4 g/dL
85 to 94g/L7.0 to 8.5g/dL
70 to 85g/L6.0 to 7.0 g/dL
60 to < 70 g/L6.0 g/dL
< 60 g/L
Infant, 22 –35 Days
(HIV POSITIVE OR
NEGATIVE )9.5 to 10.5 g/dL
95 to 105 g/L8.0 to 9.5g/dL
80 to 95g/L7.0 to 8.0g/dL
70 to 80g/L7.0g/dL
70g/L
Infant, 1–21 Days
(HIV POSITIVE OR
NEGATIVE )12.0 to 13.0 g/dL
120 to 130 g/L10.0 to 12.0g/dL
100 to 120g/L9.0 to 10.0g/dL
90 to 100g/L9.0g/dL
90g/L
Absolute Neutrophil Count 
(ANC)
Adult and Pediatric, 
≥ 7 Months #1000to1300/mm3750to1000/mm3500to750/mm3500/mm3
1.00to 1.30GI/L 0.75to 1.00 GI/L 0.50to0.75 GI/L 0.50 GI/L
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page98 18 December 2015HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Absolute CD4+ Count
HIV NEGATIVE ONLY
Adult and Pediatric 
>13Years300to400/mm3
300to400/μL200to300/mm3
200to 300/μL100to200/mm3
100to200/μL100/mm3
100/μL
Absolute Lymphocyte Count
HIV NEGATIVE ONLY
Adult and Pediatric 
13Years600 to 650/mm3
0.60 to 0.65 GI/L500 to 600/mm3
0.50 to 0.60 GI/L350 to 500/mm3
0.35 to 0.50 GI/L350/mm3
0.35 GI/L
Platelets 100,000 to < 125,000/mm3
100to125 GI/L50,000 to 100,000/mm3
50to 100 GI/L25,000 to 50,000/mm3
25 to 50 GI/L25,000/mm3
25GI/L
WBCs 2000/mm3to 2500/mm31,500 to  2,000/mm31000 to 1,500/mm31000/mm3
2.00GI/Lto 2.50GI/L 1.50to 2.00GI/L 1.00 to 1.50GI/L 1.00 GI/L
Hypofibrinogenemia 100to200mg/dL 75 to 100mg/dL 50to 75mg/dL 50mg/dL
1.00to2.00g/L 0.75to 1.00g/L 0.50 to 0.75g/L 0.50g/L
Hyperfibrinogenemia ULN to 600 mg/dL 600mg/dL — —
ULN  to 6.0 g/L 6.0g/L — —
Fibrin Split Product 20 to 40μg/mL 40to 50μg/mL 50to 60μg/mL 60μg/mL
20 to 40mg/L 40 to 50mg/L 50 to 60mg/L 60mg/L
Prothrombin Time (PT) 1.00 to 1.25 ULN 1.25 to 1.50 ULN 1.50 to 3.00 ULN 3.00 ULN 
International Normalized Ratio 
of prothrombin time (INR)1.[ADDRESS_763869] >1.[ADDRESS_763870] >2.[ADDRESS_763871] >3.[ADDRESS_763872]
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page99 18 December 2015HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Activated Partial
Thromboplastin Time (APTT)1.00to 1.66ULN 1.66to 2.33ULN 2.33to 3.00ULN 3.00 ULN
Methemoglobin 5.0to10.0% 10.0to15.0% 15.0to20.0% 20.0%
#An overlap between the Grade 1 scale and the Lab’s normal range for absolute neutrophils may result for pediatric subjects.  Please follow the [COMPANY_009] convention of grading 
any result within the LLN and ULN a 0.  
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page100 18 December 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyponatremia 130 to <LLNmEq/L 125 to130mEq/L 121 to125mEq/L 121 mEq/L
130 to<LLNmmol/L 125 to130mmol/L 121 to125mmol/L 121 mmol/L
Hypernatremia >ULN  to 150 mEq/L 150 to 154 mEq/L 154 to 159 mEq/L 159 mEq/L
>ULN  to 150 mmol/L 150 to 154 mmol/L 154 to 159 mmol/L 159 mmol/L
Hypokalemia 
Adult and Pediatric
1 Year3.0 to  <LLNmEq/L 2.5 to3.0mEq/L 2.0 to2.5mEq/L 2.0 mEq/L
3.0 to<LLNmmol/L 2.5 to3.0mmol/L 2.0 to2.5mmol/L 2.0 mmol/L
Infant<1 Year 3.0 to 3.4 mEq/L
3.0 to 3.4 mmol/L2.5 to3.0mEq/L                
2.5 to <3.0 mmolL2.0 to2.5mEq/L                 
2.0 t o <2.5 mmolL2.0 mEq/L                          
<2.0 mmolL
Hyperkalemia 
Adult and Pediatric
1 Year5.6 to 6.0 mEq/L
5.6 to 6.0 mmol/L6.0 to 6.5 mEq/L
6.0 to 6.5 mmol/L6.5 to 7.0 mEq/L
6.5 to 7.0 mmol/L7.0 mEq/L
7.0 mmol/L
Infant<1 Year >ULN to 6.0 mEq/L           
>ULN to 6.0 mmol/L> 6.0 to 6.5 mEq/L
> 6.0 to 6.5 mmol/L6.5 to 7.0 mEq/L             
6.5 to 7.0 mmol/L7.0 mEq/L                   
7.0 mmol/L
Hypoglycemia
Adult and Pediatric
1Month55 to 64mg/dL
3.03 to 3.58 mmol/L40 to55mg/dL
2.20 to3.03mmol/L30 to40mg/dL
1.64 to2.20mmol/L30 mg/dL
1.64 mmol/L
Infant,1Month 50 to 54mg/dL
2.8 to 3.0 mmol/L40 to 50mg/dL
2.2 to 2.8mmol/L30 to 40mg/dL
1.7 to 2.2mmol/L30 mg/dL
1.7 mmol/L
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page101 18 December 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyperglycemia, Nonfasting 116to 160mg/dL 160 to 250 mg/dL 250 to 500 mg/dL 500 mg/dL
6.42 to 8.91 mmol/L 8.91 to 13.90 mmol/L 13.90 to 27.79 mmol/L 27.79 mmol/L
Hyperglycemia, Fasting 110 to 125 mg/dL
6.08 to 6.96 mmol/L>125 to 250 mg/dL
>6.96 to 13.90 mmol/L>250 to 500 mg/dL
>13.90 to 27.79 mmol/L>500 mg/dL
>27.79 mmol/L
Hypocalcemia 
(corrected for albumin if 
appropriate* )
Adult and Pediatric
2 Years7.8 <LLN mg/dL
1.94 to <LLNmmol/L7.0 to7.8 mg/dL
1.74 to1.94 mmol/L6.1 to7.0mg/dL
1.51 to1.74 mmol/L6.1mg/dL
1.51mmol/L
Pediatric ≥7 days -2 Years 7.8 to 8.4 mg/dL                               
1.94 to 2.10 mmol/L7.0 to <7.8 mg/dL              
1.74 to <1.94 mmolL6.1 to  <7.0 mg/dL                         
1.51 to < 1.74 mmolL< 6.1 mg/dL                           
< 1.51 mmol/L
Infant,7Days 6.5to 7.5 mg/dL
1.61 to 1.88  mmol/L6.0 to 6.5 mg/dL
1.49 to < 1.61 mmol/L5.5 to 6.0 mg/dL
1.36 to < 1.49 mmol/L 5.5 mg/dL
< 1.36 mmol/L
Hypercalcemia (corrected 
for albumin if appropriate* )
Adult and Pediatric 
7Days>ULNto 11.5 mg/dL 11.5 to 12.5 mg/dL 12.5 to 13.5 mg/dL 13.5 mg/dL
>ULN to 2.88 mmol/L 2.88 to 3.13 mmol/L 3.13 to 3.38 mmol/L 3.38 mmol/L
Infant,7Days 11.5 to 12.4 mg/dL
2.86 to 3.10  mmol/L12.4 to 12.9 mg/dL
> 3.10 to 3.23  mmol/L12.9 to 13.5 mg/dL
> 3.23 to 3.38  mmol/L13.5 mg/dL
> 3.38 mmol/L
Hypocalcemia (ionized) 3.0 mg/dL to LLN 2.5 to < 3.0 mg/dL 2.0 to2.5 mg/dL 2.0 mg/dL
0.74 mmol/L to LLN 0.62 to0.74 mmol/L 0.49 to0.62 mmol/L 0.49 mmol/L
Hypercalcemia (ionized) ULN to 6.0 mg/dL 6.0 to 6.5 mg/dL 6.5 to 7.0 mg/dL 7.0 mg/dL
ULN to 1.50 mmol/L 1.50 to 1.63 mmol/L 1.63 to 1.75 mmol/L 1.75 mmol/L
Hypomagnesemia 1.40 to<LLN mg/dL
1.2 to <LLN mEq/L1.04 to1.40 mg/dL
0.9 to   1.2 mEq/L0.67 to1.04 mg/dL
0.6 to 0.9 mEq/L0.67 mg/dL
0.6 mEq/L
0.58 to<LLNmmol/L 0.43 to0.58 mmol/L 0.28 to0.43 mmol/L 0.28 mmol/L
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page102 18 December 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypophosphatemia
Adult and Pediatric
14Years2.0 to < LLN mg/dL
0.63  to LLN mmol/L1.5 to2.0 mg/dL
0.47 to0.63 mmol/L1.0 to1.5 mg/dL
0.31 to0.47 mmol/L1.0 mg/dL
0.31 mmol/L
Pediatric 1 Year– 14 Years 3.0 to <LLN mg/dL
0.96 to <LLNmmol/L2.5 to 3.0 mg/dL
0.80 to < 0.96mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
Pediatric 1Year 3.5 to <LLN mg/dL
1.12 to <LLNmmol/L2.5 to 3.5mg/dL
0.80 to < 1.12mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
Hyperbilirubinemia 
Adult and Pediatric 
>14Days1.0 to 1.5 ULN 1.5 to 2.5 ULN 2.5 to 5.0 ULN 5.0 ULN 
Infant, 14Days
(non-hemolytic)NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 to 30.0 mg/dL
> 428 to 513 μmol/L30.0 mg/dL
> 513 μmol/L
Infant, 14Days
(hemolytic)NA NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 mg/dL
> 428 μmol/L
Blood Urea Nitrogen 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
Hyperuricemia >ULNto 10.0 mg/dL 10.0 to 12.0 mg/dL 12.0 to 15.0 mg/dL 15.0 mg/dL
>ULNto 597 μmol/L 597 to 716 μmol/L 716 to 895 μmol/L 895 μmol/L
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page103 18 December 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypouricemia               
Adult and Pediatric           
≥ 1 year   
Infant  < 1 Year1.5 mg/dL to LLN
87 μmol/L to LLN1.0 to1.5 mg/dL
57 to87 μmol/L0.5 to1.0 mg/dL
27 to57 μmol/L0.5 mg/dL
27 μmol/L
N/A 1.0 mg/dl to <LLN -
57 μmol to <LLN0.5 to1.0 mg/dL
27 to57 μmol/L0.5 mg/dL
27 μmol/L
Creatinine** 1.50to 2.00 mg/dL
133to 177μmol/L2.00to 3.00 mg/dL
177to 265 μmol/L3.00 to 6.00 mg/dL 
265to 530μmol/L6.00 mg/dL
53 0μmol/L
Bicarbonate
Adult and Pediatric 
≥ 4 Years16.0 mEq/L to LLN 11.0 to16.0 mEq/L 8.0 to11.0 mEq/L 8.0 mEq/L
16.0 mmol/L to LLN 11.0 to16.0 mmol/L 8.0 to11.0 mmol/L 8.0 mmol/L
Pediatric < 4 Years NA 11.0 mEq/Lto <LLN 8.0 to11.0 mEq/L 8.0 mEq/L
11.0 mmol/L to <LLN 8.0 to11.0 mmol/L 8.0 mmol/L
Triglycerides
(Fasting)NA 500 to 750 mg/dL
5.64–8.47 mmol/L750 to 1200 mg/dL
8.47–13.55 mmol/L1200 mg/dL
13.55 mmol/L
LDL (Fasting)
Adult130 to 160 mg/dL >160 to 190 mg/dL > 190 mg/dL NA
3.35 to 4.15 mmol/L >4.15 to 4.92 mmol/L >4.92 mmol/L
LDL (Fasting)
Pediatric >2 to <18 years110 to 130 mg/dL >130 to 190 mg/dL > 190 mg/dL NA
2.84 to 3.37 mmol/L >3.37 to  4.92 mmol/L >4.92 mmol/L
Hypercholesterolemia
(Fasting)200 to 239 mg/dL 239 to 300 mg/dL 300 mg/dL NA
5.16 to 6.19 mmol/L 6.19 to 7.77 mmol/L 7.77 mmol/L
Pediatric 18 Years 170 to 199 mg/dL
4.39 to 5.15 mmol/L199 to 300 mg/dL
5.15 to 7.77 mmol/L300 mg/dL
7.77 mmol/LNA
Creatine Kinase 3.0 to6.0 ULN 6.0 to10.0 ULN 10.0 to20.0 ULN 20.0 ULN
* Calc ium should be cor rected for albumin if albumin is < 4.0 g/dL
**An overlap between the Grade 1 scale and the Lab’snormal range for creatinine may result for Male subjects >[ADDRESS_763873] a 0.  
FTC/RPV/TAF
Protocol GS -US-366-[ADDRESS_763874] (SGOT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
ALT (SGPT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
GGT 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
Alkaline Phosphatase 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
Total Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Pancreatic Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Lipase 1.0 to 1.5 ULN 1.5 to 3.0 ULN 3.0 to 5.0 ULN 5.0 ULN
Albumin
Pediatrics <16 years
≥ 16 years- 2.0 to LLNg/dL
20 to LLNg/L2.0 g/dL
20 g/LNA
3.0 g/dL to LLN
30 g/L to LLN2.0 to 3.0 g/dL
20 to 30 g/L2.0 g/dL
20 g/LNA
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page105 18 December 2015URINALYSIS
Grade 1 Grade 2 Grade 3 Grade 4
Hematuria (Dipstick) 1 2 3-4+ NA
Hematuria (Quantitative) 
See Note below
                              Females >ULN -10RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
                              Males 6-10 RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
Proteinuria (Dipstick) 1 2–3 4 NA
Proteinuria, 24 Hour Collection
Adult and Pediatric 
10 Years200 to999mg/24h >999to1999mg/24 h >1999to3500 mg/24 h 3500 mg/24 h
Pediatric 3 Mo to 
<10Years201 to499mg/m2/24h >499to799mg/m2/24 h >799to1000 mg/m2/24 h 1000 mg/ m2/24 h
Glycosuria (Dipstick) 1+ 2-3 4 NA
Notes: 
Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by [CONTACT_10870], however for other laboratories, toxicity grades will only be assigned to 
Dipstick Hematuria.
With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigne d Grade 0.
If theseverity of a clinical AE could fall under either one of two grades (eg, the severity of an AE could be either Grade 2 or Gra de 3), select the higher of the two grades for 
the AE.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page106 18 December 2015CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Cardiac A rrhythmia (general)
(By [CONTACT_10871])Asymptomatic AND No 
intervention indicatedAsymptomatic AND Non -
urgent medical intervention 
indicatedSymptomatic, non -life-
threatening AND Non -
urgent medical intervention 
indicated Life-threatening arrhythmia 
OR Urgent intervention 
indicated
Cardiac-ischemia/I nfarction NA NA Symptomatic ischemia 
(stable angina) OR Testing 
consistent with ischemia Unstable angina OR Acute 
myocardial infarction
Hemorrhage (significant acute 
blood loss)NA Symptomatic AND No 
transfusion indicatedSymptomatic AND 
Transfusion of 2units 
packed RBCs (for children 
10cc/kg) indicated Life-threatening hypotension 
OR Transfusion of 2units 
packed RBCs indicated (for 
children 10cc/kg) indicated
Hypertension (wit h repeat 
testing at sa me visit)140–159mmHg systolic 
OR 
90–99 mmHg diastolic159–179 mmHg systolic 
OR 
99–109 mmHg diastolic179mmHg systolic 
OR 
109mmHg diastolicLife-threatening consequences 
(eg, malignant hypertension) 
OR Hospi[INVESTIGATOR_059] (other than 
ER visit) indicated
Pediatric 17Years (with 
repeat testing at same visit)NA 91st–94th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)≥95th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)Life-threatenin g consequences 
(eg, malignant hypertension) 
OR Hospi[INVESTIGATOR_374] 
(other than emergency room 
visit)
Hypotension NA Symptomatic, corrected w ith 
oral fluid replacementSymptomatic, IV fluids 
indicatedShock requiring use of 
vasopressors or mechanical
assistance to maintain blood 
pressure
Pericardial E ffusion Asymptomatic, small 
effusion requiring no 
interventionAsymptomatic, moderate or 
larger effusi on requiring no 
interventionEffusion with non -life-
threatening physiologic 
consequences OR Effusion 
with nonurgent intervention 
indicatedLife-threatening consequences 
(eg, tamponade) OR Urgent 
intervention indicated
Prolonged PR Interval PR interval 
0.21 to 0.25 secPR interval
0.25 secType II 2nd degree AV 
block OR Ventricular pause 
3.0 secComplete AV block 
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page107 18 December 2015CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Pediatric [ADDRESS_763875] degree AV block
(PR > normal for age and 
rate)Type I 2nd degree AV block Type II 2nd degree AV 
block Complete AV block
Prolonged QTc Asymptomatic, QTc interval 
0.45 to 0.47 sec OR Increase 
interval 0.03 sec above 
baselineAsymptomatic, QTc interval 
0.48 to 0.49 sec OR Increase 
in interval 0.03 to 0.05 sec 
above baselineAsymptomatic, QTc interval 
0.50sec OR Increase in 
interval 0.06sec above 
baselineLife-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Pediatric 16Years Asymptomatic, QTc interval 
0.450 to 0.464 sec Asymptomatic, QTc interval 
0.465 to 0.479 sec Asymptomatic, QTc interval 
0.480 sec Life-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Thrombosis/E mbolism NA Deep vein thrombosis AND 
No intervention indicated ( eg, 
anticoagulation, lysis filter, 
invasive procedure) Deep vein thrombosis AND
Intervention indicated ( eg, 
anticoagulation, lysis filter, 
invasive procedure) Embolic event ( eg, pulmonary 
embolism, life -threatening 
thrombus) 
Vasovagal Epi[INVESTIGATOR_1865] (associated 
with a procedure of any kind)Present without loss of 
consciousness Present with transient loss of 
consciousnessNA NA
Ventricular Dysfunction 
(congestive heart failure, 
CHF)NA Asymptomatic diagnostic 
finding AND intervention 
indicatedNew onset with symptoms 
OR Worsening symptomatic 
CHFLife-threatening CHF
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page108 18 December 2015RESPI[INVESTIGATOR_10806] 1 Grade 2 Grade 3 Grade 4
Bronchospasm (acute) FEV1 or peak flow  reduced to 
70% to 80%FEV1 or peak flow  50% to 69% FEV1 or peak flow  25% to 
49% Cyanosis OR FEV1 or peak flow  
25% OR Intubation
Dyspnea or Respi[INVESTIGATOR_10807] & functional 
activities Dyspnea on exertion causing 
greater than minimal interference 
with usual social & functional 
activities Dyspnea at rest causing 
inability to perform usual 
social & functional activities Respi[INVESTIGATOR_10808] 14 Years Wheezing OR minimal 
increase in respi[INVESTIGATOR_10809] 
90% to 95%Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
OR Pulse oximetry 90%Respi[INVESTIGATOR_422258]/VISUAL
Grade 1 Grade 2 Grade 3 Grade 4
Uveitis Asymptomatic but detectable 
on examSymptomatic anterior uveitis OR 
Medical intervention indicatedPosterior or pan -uveitis OR 
Operative intervention 
indicatedDisabling visual loss in affected 
eye(s) 
Visual Changes (from 
baseline)Visual changes causing no or 
minimal interference with 
usual social & functional 
activitiesVisual changes causing greater 
than minimal interference with 
usual social & functional 
activitiesVisual changes causing 
inability to perform usual 
social & functional activitiesDisabling visual loss in affected 
eye(s)
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page109 18 December 2015SKIN
Grade 1 Grade 2 Grade 3 Grade 4
Alopecia Thinning detectable by 
[CONTACT_10872] (for disabled 
adults)Thinning or patchy hair loss 
detectable by [CONTACT_10873] – Rash Localized macular rash Diffuse macular, 
maculopapular, or 
morbilliform rash OR Target 
lesions Diffuse macular, 
maculopapular, or morbilliform 
rash with vesicles or limited 
number of bullae OR 
Superficial ulcerations of 
mucous membrane limited to 
one siteExtensive or generalized 
bullous lesions OR 
Stevens-Johnson syndrome 
OR Ulceration of mucous 
membrane involving two 
or more distinct mucosal 
sites OR Toxic epi[INVESTIGATOR_7387] (TEN)
Hyperpi[INVESTIGATOR_10810] (itching –no skin 
lesions) 
(See also Injection Site 
Reactions: Pruritis associated 
with injection)Itching causing no or 
minimal interference with 
usual social & functional 
activitiesItching causing greater than 
minimal interference with 
usual social & functional 
activitiesItching causing inability to 
perform usual social & 
functional activities NA
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page110 18 December 2015GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Anorexia Loss of appetite without 
decreased oral intakeLoss of appetite associated with 
decreased oral intake w ithout 
significant weight loss Loss of appetite associated 
with significant weight loss Life-threatening consequences 
OR Aggressive intervention 
indicated [ eg,tube feeding or 
total parenteral nutrition]
Ascites Asymptomatic Symptomatic AND Intervention 
indicated ( eg, diuretics or 
therapeutic paracentesis)Symptomatic despi[INVESTIGATOR_10811]-threatening consequences
Cholecystitis NA Symptomatic AND Medical 
intervention indicatedRadiologic, endoscopic, or 
operative intervention 
indicatedLife-threatening consequences 
(eg, sepsis or perforation) 
Constipation NA Persistent constipation requiring 
regular use of dietary 
modifications, laxatives, or 
enemas Obstipation with manual 
evacuation indicatedLife-threatening consequences 
(eg, obstruction)
Diarrhea 
Adult and Pediatric 
1 YearTransient or intermittent 
epi[INVESTIGATOR_10812] 3stools 
over baseline/24 hrPersistent epi[INVESTIGATOR_10813] 
4–6 stools over baseline per 
24hrs. Bloody diarrhea OR Increase 
of 7stools per 24 -hour 
period OR IV fluid 
replacement indicatedLife-threatening consequences 
(eg, hypotensive shock)
Pediatric 1 Year Liquid stools (more 
unformed than usual) but 
usual number of stoolsLiquid stools with increased 
number of stools OR Mild 
dehydrationLiquid stools with moderate 
dehydrationLiquid stools resulting in 
severe dehydration with 
aggressive rehydration 
indicated OR Hypotensive 
shock
Dysphagia-Odynophagia Symptomatic but able to eat 
usual dietSymptoms causing altered 
dietary intake without medical 
intervention indicatedSymptoms causing severely 
altered dietary intake with 
medical intervention indicatedLife-threatening reduction in 
oral intake
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page111 18 December 2015GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Mucositis/S tomatitis 
(clinical exam)
See also Pr octitis, 
Dysphagia-OdynophagiaErythema of the mucosa Patchy pseudomembranes or 
ulcerations Confluent pseudomembranes 
or ulcerations OR Mucosal 
bleeding with minor traumaTissue necrosis OR Diffuse 
spontaneous mucosal bleeding 
OR Life-threatening 
consequences ( eg, aspi[INVESTIGATOR_1516], 
choking)
Nausea Transient ( 24hours) or 
intermittent nausea with no 
or minimal interference with 
oral intakePersistent nausea resulting in 
decreased oral intake for 24 –48 
hoursPersistent nausea resulting in 
minimal oral intake for  48 
hours OR Aggressive 
rehydration indicated (eg, 
IVfluids)Life-threatening consequences 
(eg, hypotensive shock)
Pancreatitis NA Symptomatic AND 
Hospi[INVESTIGATOR_10814] 
(other than ER visit)Symptomatic AND 
Hospi[INVESTIGATOR_374] 
(other than ER visit)Life-threatening consequences 
(eg, sepsis, circulatory failure, 
hemorrhage )
Proctitis (functional -
symptomatic)
Also see Mucositis/ 
Stomatitis for Clinical 
ExamRectal discomfor t AND No 
intervention indicatedSymptoms causing greater than 
minimal interference with usual 
social & functional activities OR 
Medical intervention indicated Symptoms causing inability to 
perform usual social/
functional activities OR 
Operative intervention 
indicated Life-threatening consequences 
(eg, perforation)
Vomiting Transient or intermittent 
vomiting with no or 
minimal interference with 
oral intakeFrequent epi[INVESTIGATOR_10815]-threatening consequences 
(eg, hypotensive shock)
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page112 18 December 2015NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Alteration in Personality -
Behavior or in M ood (eg, 
agitation, anxiety, 
depression, mania, 
psychosis)Alteration causing no or 
minimal interference with 
usual social & functional 
activities Alteration causing greater than 
minimal interference with 
usual social & functional 
activities Alteration causin g inability to 
perform usual social & 
functional activities Behavior potentially harmful 
to self or others ( eg, 
suicidal/homicidal ideation or 
attempt, acute psychosis) OR 
Causing inability to perform 
basic self -care functions
Altered Mental Status 
For Dementia, see Cognitive 
and Behavioral/Attentional 
Disturbance (including 
dementia and ADD)Changes causing no or 
minimal interference with 
usual social & functional 
activitiesMild lethargy or somnolence 
causing greater than minimal 
interference with usual social 
& functional activitiesConfusion, memory 
impairment, lethargy, or 
somnolence causing inability 
to perform usual social & 
functional activitiesDelirium OR obtundation, OR 
coma
Ataxia Asymptomatic ataxia 
detectable on exam OR 
Minimal ataxia causing no 
or minimal interference with 
usual social & functional 
activitiesSymptomatic ataxia causing 
greater than minimal 
interference with usual social 
& functional activitiesSymptomatic ataxia causing 
inability to perform usual 
social & functional ac tivities Disabling ataxia causing 
inability to perform basic self -
care functions
Cognitive a nd 
Behavioral/Attentional 
Disturbance (including 
dementia and Attention 
Deficit Disorder) Disability causing no or 
minimal interference with 
usual social & funct ional 
activities OR Specialized 
resources not indicatedDisability causing greater than 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources on part -time basis 
indicatedDisability causing inability to 
perform usual socia l & 
functional activities OR 
Specialized resources on a 
full-time basis indicatedDisability causing inability to 
perform basic self -care 
functions OR 
Institutionalization indicated
CNS Ischemia
(acute)NA NA Transient ischemic attack Cerebral vascular accident 
(CVA, stroke) with 
neurological deficit 
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page113 18 December 2015NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Developmental delay –
Pediatric 16 YearsMild developmental delay, 
either motor or cognitive, as 
determined by [CONTACT_7424] a developmental 
screening tool appropriate 
for the setting Moderate developmental 
delay, either motor or 
cognitive, as determined by 
[CONTACT_7425] a 
developmental screening tool 
appropriate for the setting Severe developmental delay, 
either motor or cognitive, as 
determined by [CONTACT_7424] a developmental 
screening tool appropriate for 
the setting Developmental regression, 
either motor or cognitive, as 
determined b y comparison 
with a developmental 
screening tool appropriate for 
the setting
Headache Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference with 
usual social & functional 
activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesSymptoms causing inability to 
perform basic self -care 
functions OR Hospi[INVESTIGATOR_373] (other than ER visit) 
OR Headache with significant 
impairment of alertness or
other neurologic function 
Insomnia NA Difficulty sleepi[INVESTIGATOR_10816]/functional activitiesDifficulty sleepi[INVESTIGATOR_10817] & functional activitiesDisabling insomnia causing 
inability to perform basic self -
care functions
Neuromuscular Weakness 
(including myopathy & 
neuropathy) Asymptomatic with 
decreased strength on exam 
OR Minimal muscle weak -
ness causing no or minimal 
interference with usual 
social & functional activitiesMuscle weakness causing 
greater than minimal 
interference with usual social 
& functional activitiesMuscle weakness causing 
inability to perform usual 
social & functional activities Disabling muscle weakness 
causing inability to perform 
basic self -care functions OR 
Respi[INVESTIGATOR_10818] 
(including paresthesia and 
painful neuropathy)Asymptomatic with sensory 
alteration on exam or 
minimal paresthesia causing 
no or minimal interference 
with usual social &
functional activities Sensory alteration or 
paresthesia causing greater 
than minimal interference with 
usual social & functional 
activities Sensory alteration or 
paresthesia causing inability to 
perform usual social & 
functional activitiesDisabling sen sory alteration or 
paresthesia causing inability to 
perform basic self -care 
functions
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page114 18 December 2015NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Seizure: (new onset) NA 1 seizure 2–4 seizures Seizures of any kind that are 
prolonged, repetitive ( eg, 
status epi[INVESTIGATOR_7397]), or difficult 
to control ( eg, refractory 
epi[INVESTIGATOR_002])
Seizure: (pre- existing) 
For Worsening of Existing 
Epi[INVESTIGATOR_10819]-
existing seizures (non -
repetitive) without change in 
seizure character OR 
infrequent breakthrough 
seizures while on stable meds 
in a previously controlled 
seizure disorderChange in seizure character 
from baseline either in 
duration or quality ( eg, 
severity or focality) Seizures of any kind that are 
prolonged, repetitive ( eg, 
status epi[INVESTIGATOR_7397]), or difficult 
to control ( eg, refractory 
epi[INVESTIGATOR_002])
Seizure 
–Pediatric 18 YearsSeizure, generalized onset 
with or without second ary 
generalization, lasting 
< 5minutes with < 24hours 
post ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 5 –20 
minutes with 
< [ADDRESS_763876] ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 
> 20 minutes Seizure, generalized onset 
with or witho ut secondary 
generalization, requiring 
intubation and sedation
Syncope (not associated 
with a procedure)NA Present NA NA
Vertigo Vertigo causing no or 
minimal interference with 
usual social & functional 
activitiesVertigo causing greater than 
minimal interference with 
usual social & functional 
activities Vertigo causing inability to 
perform usual social & 
functional activitiesDisabling vertigo causing 
inability to perform basic self -
care functions
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page115 18 December 2015MUSCULOSKELETAL
Grade 1 Grade 2 Grade 3 Grade 4
Arthralgia
See also ArthritisJoint pain causing no or 
minimal interference with 
usual social & functional 
activitiesJoint pain causing greater than 
minimal interference with usual 
social & functional activitiesJoint pain causing inability 
to perform usual social & 
functional activitiesDisabling joint pain causing 
inability to perform basic self -
care functions
Arthritis
See also ArthralgiaStiffness or joint sw elling 
causing no or minimal 
interference with usual 
social & functional activitiesStiffness or joint sw elling causing 
greater than minimal interference 
with usual social & functional 
activitiesStiffness or joint sw elling 
causing inability to perform 
usual social & functional 
activitiesDisabling joint stiffness or 
swelling causing inability to 
perform ba sic self-care 
functions
Bone Mineral Loss BMD t-score or z- score
–2.5 to –1.0 BMD t-score or z- score–2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Pediatric 21Years BMD z-score 
–2.5 to –1.0BMD z-score < –2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Myalgia
(non-injection site)Muscle pain causing no or 
minimal interference with 
usual social & functional 
activitiesMuscle pain causing greater than 
minimal interference with usual 
social & functional activitiesMuscle pain causing 
inability to perform usual 
social & functional activitiesDisabling muscle pain causing 
inability to perform basic self -
care functions
Osteonecrosis NA Asymptomatic with radiographic 
findings AND No operative 
intervention indicatedSymptomatic bone pain with 
radiographic findings OR 
Operative intervention 
indicatedDisabling bone pain with 
radiographic findings causing 
inability to perform basic self -
care functions
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page116 18 December 2015SYSTEMIC
Grade 1 Grade 2 Grade 3 Grade 4
Acute Systemic Allergic 
Reaction Localized urticaria 
(wheals) with no medical 
intervention indicatedLocalized urticaria with medical 
intervention indicated OR Mild 
angioedema with no medical 
intervention indicatedGeneralize d urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild 
bronchospasmAcute anaphylaxis OR Life -
threatening bronchospasm OR 
laryngeal edema
Chills Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activities Symptoms causing inability to 
perform usual social & 
functional activitiesNA
Fatigue
MalaiseSymptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesIncapacitating fatigue/ malaise 
symptoms causing inability to 
perform basic self -care 
functions
Fever (nonaxillary) 37.7C to 38.6C
99.8F to 101.5F38.7C to 39.3C
101.6F to 102.8F39.4C to 40.5C
102.9F to 104.9F40.5C 
104.9F
Pain-Indicate Body Site
See also Injection Site 
Pain, Headache, 
Arthralgia, and MyalgiaPain causing no or 
minimal interference with 
usual social & functional 
activitiesPain causing greater than minimal 
interference with usual social & 
functional activitiesPain causing inability to 
perform usual social & 
functional activitiesDisabling pain causing 
inability to perform basic self -
care functions OR 
Hospi[INVESTIGATOR_059] (other than ER 
visit) indicated
Unintentional Weight 
LossNA 5% to 9% loss in body weight from 
baseline10% to 19% loss in body 
weight from baseline20% loss in body weight 
from baseline OR  Aggressive 
intervention indicated [ eg, 
tube feeding or total parenteral 
nutrition]
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page117 18 December 2015INJECTION SITE REACTION
Grade 1 Grade 2 Grade 3 Grade 4
Injection Site P ain (pain 
without touching)
Or Tenderness (pain when 
area is touched) Pain/tenderness causing no 
or minimal limitation of use 
of limbPain/tenderness limiting use of 
limb OR Pain/tenderness 
causing greater than minimal 
interference with usual social 
& functional activitiesPain/tenderness causing 
inability to perform usual 
social & functional activitiesPain/tenderness causing inability 
to perform basi c self-care 
function OR Hospi[INVESTIGATOR_059] 
(other than ER visit) indicated 
for management of 
pain/tenderness
Injection Site Reaction 
(Localized), 15YearsErythema OR Induration
of 55cm to 99cm (or 
2581cm2)Erythema OR Induration OR 
Edema 9cm any diameter 
(or 81cm2)Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR DrainageNecrosis (invo lving dermis and 
deeper tissue)
Pediatric 15Years Erythem a OR Induration 
OR Edema present but 
2.5cm diameterErythema OR Induration 
OR Edema > 2.5cm 
diameter but < 50% surface 
area of the extrem ity 
segment ( eg, upper 
arm/thigh)Erythem a OR Induration 
OR Edema involving 
50% surface area of the 
extremity segment ( eg, 
upper arm/thigh) OR 
Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR 
DrainageNecrosis (involving dermis and 
deeper tissue)
Pruritis Associated with 
Injection 
See also Skin: Pruritis 
(itching—no skin lesions)Itching localized to injection 
site AND Relieved 
spontaneously or w ith 
48h treatment Itching beyond the injection 
site but not generalized OR 
Itching localized to injection 
site requiring 48h treatment Generalized itching causing 
inability to perform usual 
social & functional activitiesNA
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page118 18 December 2015ENDOCRINE/METABOLIC
Grade 1 Grade 2 Grade 3 Grade 4
Lipodystrophy ( eg, back 
of neck, breasts, 
abdomen)Detectable by [CONTACT_10874] 
(for young children and 
disabled adults)Detectable on physical exam by 
[CONTACT_10875][INVESTIGATOR_10820]-threatening consequences 
(eg, ketoacidosis, 
hyperosmolar non -ketotic 
coma) 
Gynecomastia Detectable by [CONTACT_10874] 
(for young children and 
disabled adults)Detectable on physical exam by 
[CONTACT_10876] & functional activities OR 
Thyroid suppression therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despi[INVESTIGATOR_10821]-threatening consequences 
(eg, thyroid storm)
Hypothyroidism Asymptomatic Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid replacement therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despi[INVESTIGATOR_10821]-threatening consequences 
(eg, myxedema coma)
Lipoatrophy ( eg, fat loss 
from the face, extremities , 
buttocks)Detectable by [CONTACT_10874] 
(for young children and 
disabled adults)Detectable on physical exam by 
[CONTACT_580887]/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page119 18 December 2015GENITOURINARY
Grade 1 Grade 2 Grade 3 Grade 4
Intermenstrual Bleeding 
(IMB)Spotting observed by [CONTACT_10878] -
threatening hypotension OR 
Operative intervention 
indicated
Urinary T ract 
obstruction ( eg, stone)NA Signs or symptoms of urinary 
tract obstruction without 
hydronephrosis or renal 
dysfunctionSigns or symptoms of urinary 
tract obstruction with 
hydronephrosis or renal 
dysfunctionObstruction causing life -
threatening consequences
INFECTION
Grade 1 Grade 2 Grade 3 Grade 4
Infection (any other 
than HIV infection)Localized, no systemic anti μbial 
treatment indicated AND 
Symptoms causing no or 
minimal interference with usual 
social & functional activitiesSystemic anti μbial treatment 
indicated OR Symptoms 
causing greater than minimal 
interference with usual social 
& functional activitiesSystemic antiμ bial treatment 
indicated AND Symptoms 
causing inability to perform 
usual social & functional 
activities OR Operative 
intervention (other than simple 
incision and drainage) indicatedLife-threatening 
consequences ( eg, septic 
shock)
Basic Self-care Functions: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
Usual Social & Functional Activities: Adaptive tasks and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, use of transportation, pursuing a hobby, etc.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page120 18 December 2015Appendix 5. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1)Definitions
a.Definition of Childbearing Potential
For the purposes of this study , a female born subject is considered of childbearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming post -menopausal, unless 
permanentl y sterile or with medically documented ovarian failure.  
Women are considered to be in a postmenopausal sta te when they  are >
54years of age with 
cessation of previously  occurring menses for > [ADDRESS_763877] is considered fertile after t he initiation of 
puberty unless permanently  sterile by [CONTACT_210192].
2)Contraception Requirements for Female Subjects
a.Study Drug Effects on Pregnancy and Hormonal Contraception
Data from clinical pharmacokinetic interaction studies of E/C/F/TAF have demonstrated that 
E/C/F/TAFreduces the exposure of ethiny l estradiol in hormonal contraceptives. No clinically  
significant interactions between the components of F/R/TAF and LDV/SOF and hormonal 
contraception are known. Female s ubjects who choose hormonal contraception will be required 
to select a second backup method as defined below. 
Non-clinical toxicity  studies of LDF/SO F, F/R/TAF, and E/C/F/TAF have demonstrated no 
adverse effect on fertility or embry o-fetal development.  H owever, there is insufficient clinical 
data available on use of these products in pregnant women. Please refer to the latest version of 
the IB (F/R/TAF) and package inserts ( E/C/F/TAF and LDV/SOF ) for additional information.
b.Contraceptive Methods allowed f or Female Subjects of Childbearing Potential
The inclusion of female subjects of childbearing potential requires using at least an acceptable 
effectivecontraceptive measure.  Women must also not rely  solely on hormone -containing 
contraceptives (except for intrauterine devices [ IUDs]that may release hormones) as a form of 
birth control during the study .  Women may  continue oral, injectable, transdermal, or other 
hormonally  based contraceptives that are designed to inhibit ovulation, if desired, but thesewill 
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page121 18 December 2015not be acceptable as a sole form of contraception; an additional form of acceptable effective 
contraception (methods below) must be chosen even if hormonal ovulation -inhibiting 
contraception is continued. 
Women of childbearing potential must have a negative serum pregnancy  test at Screening and a 
negative pregnancy  test on the Day  [ADDRESS_763878] 
will be performed at the end of relevant s ystemic exposure.  I n the event of a delay ed menstrual 
period (over one month between menstruations), a pregnancy test must be performed to rule out 
pregnancy .  This is even true for women of childbearing potential with infrequent or irregular 
periods.  
Women of child bearing potential in this study  must agree to use the following forms of 
contraception from Screening until [ADDRESS_763879] dose of stud y drug.
Complete abstinence from intercourse of reproductive potential.  Abstinence is an acceptable 
method of contraceptio n only when it is in line with the subject’s preferred and usual 
lifestyle.
Or
Consistent and correct use of 1 of the following methods of birth control listed below. 
Intrauterine device (IUD) with a failure rate of < 1% per year. Hormonal IUDs meeting 
this criterion are acceptable as a sole method .
Tubal sterilization
Essure micro- insert system (provided confirmation of success 3 months after procedure)
Vasectom y in the male partner (provided that the partner is the sole sexual partner and 
had confirmatio n of surgical success 3 months after procedure)
Combined barrier methods:
■Diaphragm with spermicide and a male condom without spermicide
Or
■Cervical cap with spermicide and m ale condom without spermicide
Women who choose to continue on their hormonal co ntraceptive method (eg, combined oral 
contraceptives, injectable, transdermal, and intravaginal contraceptives) are asked to also 
choose one of the above methods to supplement the hormonally  based method given the 
effectof E/C/F/TAF   on ethinyl estradiol . These women may, however, use their hormonal 
contraceptive method and choose a single barrier method to supplement their hormonal 
contraceptive method (preferabl ythemale condom). 
Female subjects must also refrain from egg donation and in vitro fertili zation during treatment 
and until at least [ADDRESS_763880] dose of study  drug.
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page122 18 December [ZIP_CODE]) Contraception Requirements for Male Subjects
During the study  and for [ADDRESS_763881] dose of study  drug, male subjects with female 
partners of childbearing potential should use condoms without spermicide when engaging in 
intercourse of reproductive potential.
4) Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (eg, calendar, ovulation, 
symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides onl y, and 
lactational amenorrhea method (LAM).  Female condom and male condom should not be used 
together.
5) Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the investigator if they  become pregnant at any  time during 
the study, or if they  become pregnant within [ADDRESS_763882] dose of study  drugs. Instructions for reporting pregnancy  and pregnancy  outcome 
are outlined in Section [IP_ADDRESS].
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page123 18 December 2015Appendix 6. CDC Classification Systems, AIDS -Indicator Conditions
Bacterial infections, multiple or recurrent
Candidiasis of bronchi, trachea, or lungs
Candidiasis of esophagus
Cervical cancer, invasive
Coccidioidomy cosis, disseminated or extrapulmonary
Cryptococcosis, extrapulmonary
Cryptosporidiosis, chronic intestinal (>1 month's duration)
Cytomegalovirus disease (other than liver, spleen, or no des)
Cytomegalovirus retinitis (with loss of vision)
Encephalopath y attributed to HIV
Herpes simplex: chronic ulcers (>1 month's duration) or bronchitis, pneumonitis, or 
esophagitis
Histoplasmosis, disseminated or extrapulmonary
Isosporiasis, chronic intestinal (>1 month duration)
Kaposi sarcoma
Lymphoma, Burkitt (or equivalent term)
Lymphoma, immunoblastic (or equivalent term)
Lymphoma, primary , of brain
Mycobacterium avium complex or Mycobacterium kansasii , disseminated or extrapulmonary
Mycobacterium tub erculosis of any site, pulmonary , disseminated, or extrapulmonary
Mycobacterium , other species or unidentified species, disseminated or extrapulmonary
Pneumocystis jirovecii (previously  known as " Pneumocystis carinii ") pneumonia
Pneumonia, recurrent
FTC/RPV/TAF
Protocol GS -US-366-1992 Final
[COMPANY_009] Sciences, Inc. Original
CONFIDENTIAL Page124 18 December 2015Progressive multifocal leukoencephalopathy
Salmonella septicemia, recurrent
Toxoplasmosis of brain
Wasting sy ndrome attributed to HIV Infection
CDC Revised S urveillance Case Definition for HIV I nfection – 2014 {Selik et al 2014}